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Introduction: Ovarian cancer, with over a 90% reoccurrence within 18 months of treatment, 
and approximately a 30% mortality rate after 5 years, is the leading cause of death in cases of 
gynaecological malignancies. Acquired resistance, and toxic side effects by clinically used 
agents are major challenges associated with current treatments, indicating the need for new 
approaches in ovarian cancer treatment.  Increased tumour cell proliferation associated with 
upregulation of cannabinoid (CB) receptors has been observed in ovarian cancer. As 
cannabinoids reported to bind to CB receptors, and can potentially modulate their 
downstream signalling, this raises the possibility of cannabinoids as potential anticancer drugs 
for ovarian cancer treatment. Amongst the cannabinoids, non-psychoactive CBD and CBG 
have been shown to have anticancer activities towards prostate and colon cancer cells 
through multiple mechanisms of action. However, CBD and CBG have yet to be investigated 
in relation to ovarian cancer therapy either in vitro or in vivo. 
Aim: The aims of this study were to evaluate the potential cytotoxic effects of CBD and CBG 
in human ovarian cancer cells, their ability to potentiate existing clinically used agents for 
ovarian cancer, and to perform initial mode of action studies in vitro. 
Methods: In this study, the cytotoxic effects of CBD and CBG were evaluated in several 
ovarian cancer cell lines, and in non-cancer cells. Chemosensitivity assays were performed to 
determine the relative potency, selectivity and combination effects of the cannabinoids CBD 
and CBG. Effects on the cell cycle, cell death by apoptosis and ROS levels in ovarian cancer 
cells when treated with CBD or CBG were evaluated. The expression of the cannabinoid 
receptors CB1, CB2 and GPR55 in ovarian cancer cells, and their possible contribution to CBD 
and CBG cytotoxicity was also assessed.  
Results: CBD and CBG induced dose- dependent and time-dependent cytotoxic effects on the 
ovarian cancer cells tested with activity at micromolar concentrations towards the A2780 and 
A2780/CP70 cancer cells whilst displaying less activity against the non-cancer cells. CBD was 
the more potent of the two cannabinoids. However, the difference observed was not 
significant compared to CBG.  CBD and CBG in combination with the established 
chemotherapeutic drug carboplatin showed synergistic effects in the cancer cells but 
importantly, CBD and CBG did not synergise with carboplatin in the non-cancer ARPE19 cells. 
Preliminary data suggested that the cytotoxicity of CBD and CBG is dependent, in part at least, 
on the cannabinoid receptor GPR55 whilst CB2 cannabinoid receptor status did not affect the 
cytotoxicity of the cannabinoids in ovarian cancer cells. GPR55 expression analysis in ovarian 
cancer tissues showed that the target is expressed at the mRNA level in ovarian cancer patient 
samples. 
Conclusions: Both CBD and CBG showed preferential cytotoxicity against the ovarian cancer 
cells analysed compared to the non-cancer cells; however, this was less than for carboplatin. 
Importantly, in contrast to carboplatin, CBD and CBG showed similar activity towards cisplatin 
sensitive and cisplatin resistant cells indicating distinctive mechanisms of action to platinum 
drugs. Preferential cytotoxicity towards cancer cells in vitro and ability to potentiate 
carboplatin and overcome cisplatin resistance identify CBD and CBG as promising candidates 
that warrant further investigation, both in terms of detailed mechanism of action studies and 
also in vivo studies to assess whether this promising activity translates into an in vivo setting 
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CHAPTER 1 : Introduction 
1.1  Cancer  
Cancer is a leading cause of death across the world, characterised by uncontrolled division of 
previously normal cells. The uncontrolled division leads to the accumulation of mutations in 
the cellular genome. These mutations further leads to the alterations in physiological 
mechanisms of the cells. The alterations in physiological mechanisms of the cells are 
responsible for avoiding the programmed cell death, which dictates the accumulation of 
cellular masses leads to the tumour growth. The ability to invade into surrounding tissue 
spaces is the characteristic feature of  malignant cancer cells which distinguish cancer from 
normal benign tumours (Weinberg, 2013). 
1.2 Hallmarks of cancer 
 Hanahan and Weinberg, in 2000, described the alterations acquired in the mechanisms of 
the cancer cells as ‘hallmarks’ (Figure 1-1). The six major hallmarks are i) sustaining growth 
signalling ii) insensitivity to growth inhibitors, iii) Resisting cell death (evasion of apoptosis), 
iv) inducing angiogenesis, v) enabling immortality by limitless replicative potential, and vi)  
activating tissue invasion and metastasis. These hallmarks are essential for cancer cell survival 
and division (Hanahan and Weinberg, 2000). In 2011, Hanahan and Weinberg extended the 
hallmarks by adding four further characteristics. The authors classified the deregulation of 
cellular energetics, and the avoidance of immune destruction as ‘emerging hallmarks’ 
whereas the tumour promoting inflammation, and genome instability and mutation as the 
enabling traits of cancer  (Hanahan and Weinberg, 2011). 
 Self- sufficiency of growth signals 
Mitogenic growth signals (GS) are essential for the proliferation of normal cells. In normal 
cells, the stimulatory growth factors bind to the growth receptors- containing intracellular 
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tyrosine kinase domains. The GS thus initiates cellular signalling pathways, which regulates 
the progression of cell cycle, and cellular growth. The GS are regulated by the neighbouring 
cells (paracrine signalling) or by the actions of complex network of enzymes (proteases, 
sulfatases etc.) in the extracellular matrix (systemic signalling). Cancer cells however, able to 
acquire self- sufficiency of growth signals by multiple alternative ways: Autocrine cell 
proliferative stimulation is involves in the production of growth ligands by cancer cells.  
Cancer cells may also stimulate surrounding normal cells to produce growth factors. Cancer 
cells also elevates expression of the receptor proteins, which makes them hyper responsive 
to growth-factor ligands. Structural alterations of the receptor molecules (deregulating the 
tyrosine kinase and associated receptor proteins at the cancer cell surface) also makes cancer 
cells more responsive to growth-factor ligands which facilitates cell division (Hanahan and 
Weinberg, 2011). 
 Insensitivity to growth inhibitors 
There are number of tumour supressing genes that operate in various ways to control cell 
proliferation. Among them, retinoblastoma associated (RB) proteins and tumour p53 protein 
(TP53), are commonly known tumour suppressor gene family proteins which regulates cell 
proliferation by activating senescence and apoptotic programs. Cancer cells promote cell 
cycle progression by acquired resistance to the growth inhibitors. This is achieved  by 
promoting the mutations in tumour suppressor genes which leads to the blocking of anti- 
proliferative signalling pathways  (Hanahan and Weinberg, 2011). 
 Resisting cell death 
 The rapid proliferation of cancer cells causes physiological stresses including DNA damage. In 
a normal cell, physiological stress can induce apoptosis, a programmed cell death. However, 
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cancer cells evade apoptosis by altering the signalling circuitry responsible for apoptosis. 
Cancer cells approach multiple strategies to avoid cell death; the most notable is the loss of 
p53 tumour suppressor function. In case of DNA damage, TP53 induces apoptosis by 
upregulating pro-apoptotic factors such as Noxa and Puma BH3- only proteins. Cancer cells 
avoid this by losing the TP53 function. Alternatively, cancer cells achieve similar ends by 
increasing the expression of anti-apoptotic regulators (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011). 
 Inducing angiogenesis 
Angiogenesis is the process of post-natal neovasculature, which is required for tumour 
sustenance. In rapidly proliferating tumour cells, angiogenesis is vital to maintain the supply 
of nutrients and oxygen. In normal cells, angiogenesis is largely quiescent. In adults, 
angiogenesis is transiently turned on to facilitate the demands of the physiological processes 
such as wound healing and female reproductive cycles. In contrast, in the tumour, ‘angiogenic 
switch’ is usually on to facilitate the formation new vessels that helps progression of tumour. 
The tumour microenvironment (hypoxia) and oncogenes upregulates the expression of 
Vascular endothelial growth factor A (VEGF-A) which contributes to angiogenesis (Hanahan 
and Weinberg, 2011). 
 Enabling replicative immortality 
Normal cells are able to pass only a limited number of cell divisions. After a finite number of 
divisions, cells enter into either senescence (an irreversible non-proliferative viable state) or 
crisis (cell death). This phenomenon is called the Hayflick limit (Luft, 2015).This is due to the 
loss of telomeres DNA (function to protect chromosomal ends) after each cell cycle(Donate 
and Blasco, 2011). Cancer cells, however, are able to overcome the Hayflick limit by 
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upregulating a telomerase reverse transcript enzyme that allow cancer cells to maintain 
telomerase DNA at a length sufficient to avoid the triggering senescence or apoptosis. This 
enables cancer cells to attain immortality (Hanahan and Weinberg, 2011). 
 Activating tissue invasion and metastasis 
Cancer cells activate tissue invasion by promoting the degradation of the extracellular matrix, 
altering the genes encoding cell to cell and cell to ECM adhesion molecules. The best example 
is, E-cadherin, a prominent cell adhesion molecule involves in the formation of adherens 
junctions with adjacent epithelial cells. Cancer cells activate invasions by down regulating E-
cadherin. Cancer cells, however, upregulate the adhesion molecules involved in cell migration 
during embryogenesis and cell inflammation. N-cadherin is an adhesion molecule expressed 
for migration of neurons and mesenchymal cells during organogenesis. Cancer cells 
upregulate N-cadherin, which helps in tumour metastasis (Hanahan and Weinberg, 2011). 
Pro-inflammatory substances enhances the activity of survival factors and growth factors, 
which further induces in tumour invasion and metastasis. (Hanahan & Weinberg 2011). 
 Reprogramming of cellular energy metabolism 
Non-cancer cells metabolise glucose to pyruvate via glycolysis in the cytosol, and pyruvate 
undergo oxidative phosphorylation in mitochondria in aerobic conditions. Anaerobic or 
hypoxic conditions favour glycolysis where relatively a little pyruvate is produced. Cancer cells 
are able to reprogram their glucose metabolism, and thus their energy production in tumour 
microenvironment. The cancer cells are able to alter the glycolysis even in the presence of 
oxygen. This phenomenon is called ‘aerobic glycolysis’ or ‘Warburg effect’ (Liberti and 
Locasale, 2016). Cancer cells compensate for the ATPs produced in oxidative phosphorylation 
by upregulating glucose transporters, GLUT1, which can increases glucose uptake into 
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cytoplasm. The increased glucose in cytoplasm of cancer cells was efficiently metabolised by 
the upregulation of multiple enzymes in glycolytic pathway (Jones and Thompson, 2009, 
Hanahan and Weinberg, 2011). 
 Evading Immune Destruction 
The immune system is responsible for identifying and eradicating potentially mutant cells 
from the tissues. Cancer cells, however, are able to bypass this immune surveillance to form 
tumour. Tumour cells are able to achieve this by disabling active immune components. Yang 
et al, and Shelds et al reported that cancer cells release immune suppressive factors like TGF-
β to disable CTLs and NK cells (Shields et al., 2010, Yang et al., 2010, Hanahan and Weinberg, 
2011).  
 Tumour- promoting inflammation 
Cancer cells have been shown to evade immune responses by promoting inflammation. 
Tumour cells have shown to supress the cytosolic lymphocytes by upregulating the 
inflammatory cells like regulatory T cells and myeloid – derived suppresser cells (Mougiakakos 
et al., 2010, Hanahan and Weinberg, 2011). The relation between inflammation and tumour 
progression has been widely studied since 2000. The upregulation of inflammation by tumour 
cells shown to contribute multiple hallmark capabilities by supplying bioactive molecules like 
growth factors, anti- apoptotic factors, extracellular modifying enzymes, and proangiogenic 




  Genome instability and mutation 
The alterations in the genome by inactivation of tumour suppressor genes enable tumour 
cells to acquire most of the hallmarks mentioned earlier.  The acquisition of mutant genotypes 
is achieved with series successive clonal expansions.  
The above characteristics individually or collectively contribute to the survival and unlimited 
division of cancer cells. 
 
 




1.3 Ovarian cancer 
Ovarian cancer, with its high rate of mortality, is one of the most clinically significant 
gynaecological cancers.  In the UK from 2013 to 2016, there were on average 20 women 
diagnosed with ovarian cancer every day, and 11 registered fatalities (Cancer Research UK, 
2015). The low morbidity, asymptomatic nature or displayed symptoms including bloating, 
abdominal pain or loss of appetite, which is similar to gastrointestinal, genitourinary and 
gynaecological disorders, allows ovarian cancer to go undetected; this contributes to the high 
fatality ratio (Colombo et al., 2006). There is more than a 90% reoccurrence within 18 months 
of diagnosis with approximately a 30% mortality rate after 5 years of treatment; this makes 
ovarian cancer a leading cause of death in cases of gynaecological malignancies (Schmid and 
Oehler, 2014)  
The initial research on ovarian cancer could not find the primary site of tumour origin due to 
the lack of glandular epithelial cells in the ovarian system. Glandular epithelial cells are 
believed to be the common precursor for most the cancers, however later research found 
that ovarian cancers could have originated from three potential sites including ovarian 
coelomic epithelial cells, the fallopian tubes and the peritoneal cavity lined by mesothelium 
(Bast et al., 2009).  
Besides the lack of distinct symptoms, the heterogeneous nature of ovarian cancer makes it 
difficult to treat. Cellular grade, proliferative index and histotypes are the factors that 
contribute to the heterogeneity of ovarian cancer. However, the adaptation of such changes 
by ovarian cancer cells yet to be determined (Bast et al., 2009). 
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 Risk factors and pathogenesis  
Epidemiology studies show that the risk of ovarian cancer is correlated with the number of 
ovulatory cycles a woman has in her lifetime. The incessant ovulation results in over 
expression of p53, successive bouts of apoptosis and oxidative damage of DNA in ovarian 
surface epithelium (OSE) at ovulation site induce trauma and genome instability which further 
contributes to the carcinogenesis (Ho., 2003). The factors responsible for reduction in 
ovulatory cycles such as pregnancy and usage of contraceptive pills are being associated with 
protective effect against ovarian cancer (Sundar et al., 2015). Genetic mutations are also 
increases the risk of causing ovarian cancer in women. The risk of ovarian cancer for women 
aged over 70, with BRCA1 mutation, and BRCA2 mutations are as much as 63% and 27% 
respectively (Sundar et al., 2015). 
The wide differentiation in the histology correlates with the molecular and clinical behaviour 
of the ovarian cancer types (Sundar et al., 2015). Based on the factors mentioned earlier, 
ovarian cancer can be broadly classified into two categories; Type 1 and Type 2.  Type 1 
tumours include low-grade serous (LGSC), endometrioid (EC), mucinous (MC), and clear cell 
(CCC). Type 1 tumours are behave to be indolent with distinct morphological and molecular 
features, often confined to the ovaries. Type 1 ovarian cancers are tend to grow slow, and 
detected in early stages by ultrasonography, and show a relatively  stable genome without 
TP53 mutations (Koshiyama et al., 2014).  
 Type 2 tumours include High- grade Serous (HGSC) and undifferentiated ovarian carcinoma, 
and are tend to be more aggressive and spreads beyond ovaries. Genetically unstable nature 
makes the tumours to be detected only in advanced stages.  Most of Type 2 tumours have 
TP53 mutations and more than half of them exhibit BRCA1/2 mutations. However, Type 1 
28 
 
tumours are more challenging to treat due to their adamant clinical response to 
chemotherapy drugs (Sundar et al., 2015, Koshiyama et al., 2014) 
1.3.1.1 Role of Oestrogen and Hormone Replacement Therapy in ovarian cancer 
Ovaries are the main source of oestrogen in premenopausal women as Estrone (E1) and 
Estradiol (E2) are produced in follicular theca of ovarian cells. Oestrogen receptors (αand β) 
are highly expressed in OSE also indicates that ovaries are vital targets. Studies suggested that 
EOC is an oestrogen dependant as it could affect the tumour progression by involving 
proliferation, invasion and mobility of cells (Figure 1-2). The inhibition of EOC proliferation in 
the presence of tamoxifen (antioestrogen) supported the earlier statement.  
 
Figure 1-2.  Oestrogen induced growth factors results tumour progression in ovarian cancer  (Cunat et al., 2004) 
Ovarian cancer is commonly diagnosed in either advanced or delayed menopausal women. 
Most of the women expected to spend one third of their life in post-menopausal stage due 
to increase in the life expectancy. Oestrogen based Hormonal Replacement Therapy (HRT) is 
often used by women to relieve from the persistent symptoms (vasomotor flashes and 
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sweats) associated with menopause state and age-related diseases including osteoporosis, 
dementia, and myocardial infraction (Ho., 2003). However, the studies shown that HRT 
increases the risk of epithelial ovarian cancer in postmenopausal women (Colombo et al., 
2006, Cunat et al., 2004). 
 Screening techniques   
As mentioned earlier, non- specific symptoms are the major challenge in the early detection 
of ovarian cancer. In a survey conducted in the UK, more than 36% of women who were 
subsequently diagnosed with ovarian cancer, had consulted general practitioners with the 
non-specific symptoms for more than three times before the diagnosis (Error! Reference 
source not found.). According to the National Institute for Health and Care Excellence (NICE) 
recommendations, patients with the symptoms related to ovarian cancer should be initially 
tested for cancer antigen (serum CA125) levels. If the CA125 levels are ≥ 35 IU/mL the patients 
are recommended to undergo ultrasonography; it is used to detect malignant tumours in the 





Figure 1-3 Symptoms and diagnosis of ovarian cancer. Adapted from (Sundar et al., 2015) 
CA125 is a membrane-bound glycoprotein, which shows increased in levels during benign 
processes due to inflammation. It is widely used as a biomarker for the detection of ovarian 
cancer. However, the increase in the levels of CA125 is not ovarian cancer-specific; it is often 
associated with menstruation and endometriosis. Another drawback is that only 50% of stage 
1 and 75%- 80% of advanced ovarian cancers show increased levels of CA125 (Rauh-Hain et 
al., 2011, Moss et al., 2013, Sundar et al., 2015). 
Ultrasonography is another current screening technique involves in the detection of 
morphological changes that may contribute to the malignancy by the detailed imaging of the 
ovaries.  Morphologic index- based criteria, Risk of Malignancy index (RMI), is used to analyse 
ultrasound images, which helps to differentiate benign masses from ovarian cancer. However, 
there are no universal guidelines for morphological index analysis. The sensitivity and 
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specificity of Ultrasonography screening towards ovarian cancer is 89% and 70% respectively 
(Rauh-Hain et al., 2011, Natarajan et al., 2018). 
Recent studies have shown that new possible biomarkers HE4 or OVA1, in conjunction with 
CA125 can improve the screening of ovarian cancer. Both biomarkers are still under clinical 
studies. Plasma circulating tumour DNA is another promising screening technique. It is a 
complex genomic technology; designed to detect specific mutations in DNA in the plasma 
released from ovarian cancer cells. The ability to identify the small loads of ovarian tumours 
is the significant advantage (Forshew et al., 2012, Sundar et al., 2015).  
 Ovarian cancer histology 
Ovarian cancers are mainly classified in to two types- epithelial ovarian cancer and non-
epithelial ovarian cancer based on precursor histotypes (Figure 1-4).  (Barlette, 2000, Bast et 
al., 2009) 
 
Figure 1-4. The classification of subtypes of ovarian carcinoma based on histologic subtypes. Adopted from 
(Banerjee and Kaye., 2013) 
1.3.3.1 Epithelial Ovarian Cancer (EOC) 
Ovaries are surrounded by epithelial cells that are involved in the exchange of molecules 
between the ovaries and the peritoneal cavity, and are involved in the rupture and repair of 
an ovarian surface during ovulation. The morphologically indistinctive and histologically 
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simple nature of the epithelial cells are the barriers in understanding the transformation of 
the normal cells into tumours. EOC account for over 90% of the cases of all ovarian cancers  
(Gubbels et al., 2010). 
Epithelial Ovarian Cancer (EOC) can be further classified into five distinctive histologic 
subtypes. High- grade Serous (HGSC), endometrioid (EC), mucinous (MC), Low-grade serous 
(LGSC) and clear cell (CCC) ovarian cancers (Error! Reference source not found.). All EOC were 
believed to originate from the ovarian surface epithelium (OSE) however, and recent findings 
suggest distinct sites of origin for different EOC histotypes. HGSC have shown to be originated 
from the fallopian tube. Endometroid, mucinous and clear cell ovarian cancers originates from 
endometroid, endocervix and endovaginal cells respectively. LGSC Origins are unclear and still 
believed to originate from OSE (Mackenzie et al., 2015, Bast et al., 2009).  
HGSC are most common type of ovarian cancer (70%), which occur in advanced stages of 
ovarian cancer and metastases. HGSC exhibit p53 (70%), BRCA1/2 (35- 40%), WT1 and p16 
mutations (Rescigno et al., 2013). LGSC accounts for less than 5% of all cases of ovarian 
cancers. LGSC acquire mutations in BRAF, NRAS and KRAS. However, but show stable p53 and 
BRCA1/2.  Mucinous cancer represents 3 – 4% of all cases of OC. They are usually larger and 
confined to the ovaries. Mutations in KRAS and HER2 enables the progression of 
tumorigenesis in mucinous cancer. Endometriod cancer (10%) frequently occur at 
perimenopausal age in women. EC often have ARIDA1, PIK3CA and PTEN mutations.  Clear 
cell cancers (10%) often diagnosed in patients at earlier stages of OC.  Similar to EC, CCC 




All EOC subtypes distinctly differ from each other with many clinicopathological features 
including the degree of responses to chemotherapy, different patterns in metastasis and 
survival mechanisms (Banerjee and Kaye., 2013). 
1.3.3.2 Non-Epithelial Ovarian Cancer (NOC) 
The non-epithelial OC can be further divided into germ cell and sex-cord stromal ovarian 
cancer. Non-epithelial OC  are very rare and are found in approximately six women per million 
women per year. Germ cell OC generally occurs in young and adolescent women with high 
incidents at 15-19 years age whereas sex-cord stromal carcinoma is more like epithelial OC 
occurs in elderly women. The risk profile and cancer biology of non- epithelial OC is not fully 
understood due to rare occurrence (Barlette, 2000). 
 Hallmarks of Ovarian cancer 
For different cancers, or cancer subtypes, particular genetic mutations are more common 
than others. As such, the oncogenic drivers responsible for the acquisition of the individual 
hallmarks and enabling characteristics of cancer can differ for different cancers. In this 
subsection, key oncogenic drivers responsible for acquisition of different hallmarks in ovarian 
cancer are discussed. Among the hallamarks, genome instability, inflammation and 
angiogenesis in OC has been widely investigated due to their clinical significance. 
1.3.4.1 Genome instability and mutations in OC 
Genome instability plays a vital role in the development and progression of ovarian cancer. 
35- 40% women with HGSC carry germline BRCA 1/2 mutations and over 70% patients acquire 
p53 mutations. DNA damage induced by UV radaitions, inappropriate activation of proto-
oncogene, hypoxia, and mitogenic are common cause of the gene mutation. EOC exhibit the 
p53 mutations at the locus 17p13.1. P53 involves in growth arrest, in response to DNA 
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damage by regulating G1/S transition, and allows the repair. If the damage is irreversible, p53 
activates apoptosis by regulating both proapoptotic and anti-apoptotic proteins of BCl-2 
family (Ozaki and Nakagawara, 2011, Zhang. et al., 2016). Studies have shown that p53 
mutated cancer types show higher resistance to platinum-based chemotherapy.  The chemo 
resistance nature of High-grade ovarian cancer is because 97% of HGSC acquire p53 mutation. 
Small molecules capable of restoring p53 function can be a potential therapeutic approach in 
HGSC treatment (Hientz. et al., 2017). BRCA 1/2 play important role in homologous 
recombination repair. BRCA acts a checkpoint in response to DNA damage. BRCA 1 involves 
in the survey of double standard breaks (DSB) whereas BRCA 2 involves in the repair of DSB 
by enabling the RAD51 complex to attach at the repair site (Neff. et al., 2017). Germline 
mutation of either BRCA1 or BRCA 2 increases the susceptibility to ovarian cancer due to loss 
of self-protection of cells in response to DNA damage  (Neff. et al., 2017).  EOC with 
homologous recombination deficiency (BRCA 1/2 mutations) rely on PARP for DNA repair. 
PARP is an enzyme involves in the repair of single standard DNA breaks by base excision repair 
whereas BRCA 1/2 proteins involve in repair of double standard DNA breaks through 
homologous recombination repair pathway. Since most of the ovarian cancer types exhibit 
BRCA mutations, PARP inhibitors can cause accumulation of DNA damage in BRCA defected 
ovarian cancers (Monk and Anastasia., 2016) Hence, synthetic PARP inhibitors are a potential 
targeted approach for the OC with BRCA mutations (Petrillo et al., 2016). PTEN genes 
mutations also contribute to the ovarian carcinogenesis. The mutations in PTEN gene results 
in alterations in PI3K/AKT pathway, which results in survival of cancer cells by evasion of 
apoptosis (Saad. et al., 2010). Besides BRCA, p53, and PTEN mutations, ovarian cancer often 
exhibit BRAF, RAS, ARIDA1 mutations (Banerjee and Kaye., 2013, Rescigno et al., 2013) 
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1.3.4.2 Promoting inflammation in OC 
The correlation between severe inflammation and OC progression is well understood over the 
years. Upregulation of several pro-inflammatory mediators and cytokines, which are 
produced by TNF-α, and interleukins (IL-6 and IL-8) were observed in EOC (Macciò and 
Madeddu., 2012, Petrillo et al., 2016).  Several pro-inflammatory mediators are released 
during the ovulation process, and repair process followed by the release of ovum. The 
incessant ovulation results in exposure of OSE to inflammatory environment, which may leads 
to the carcinogenesis (Figure 1-5) (Macciò and Madeddu., 2012). COX enzymes are 
responsible in maintaining the inflammatory status in ovarian cancer. Particularly COX-2 is 
highly expressed in non-mucinous ovarian cancer cancer. Therefore targeting COX enzymes 






Figure 1-5. The role of inflammation in the development of ovarian cancer (Macciò and Madeddu., 2012) 
1.3.4.3 Evading immune destruction 
Ovarian cancer creates tumour microenvironment with immunosuppressive factors to evade 
immune system. Studies has shown that mutation in PTEN and BRCA2 leads to loss of T cells, 
which contributes to immunodeficiency in ovarian cancer (Jeong et al., 2015).  The 
upregulation of immunosuppressive cytokines such as TGF-β and IL-10, PD-L1 (Programmed 
Death- Ligand1), and VEGF was observed in peritoneal cavity of ovarian cancer patients. 
Targeting the immunosuppressive factors could be a potential pharmacological strategy to 
restore immune system competence in OC (Latha. et al., 2014, Petrillo et al., 2016). 
1.3.4.4 Angiogenesis and metastases in OC 
OC induces angiogenesis by upregulating the angiogenetic stimulator VEGF.  Studies have 
shown an increase VEGF expression in ovarian tumour tissue, cystic and ascites fluids, and 
serum of EOC patients. Mutated p53 in ovarian cancer upregulates hypoxia induced factor-1  
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(HIF-1). The upregulated HIF-1 increases the expression of VEGF. Studies also showed that 
mutations in KRAs and HRAS genes in ovarian cancer also responsible for over expression of 
VEGF (Brown et al., 2000, Lengyel., 2010)  
The ovarian cancer initiates the invasion and metastases by detaching from primary site of 
origin and form multi- cellular aggregates. The cellular aggregates travel through peritoneal 
cavity by ascites. Membrane protein type 1 and 2 are proteolytic enzymes, which enable the 
detachment of OC cells from site of origin. Omentum, right diaphragm and small bowel 
mesentery of peritoneum are the most common secondary sites of ovarian metastasis. 
Integrins and CD44 produced by OC cells helps in binding of OC cells to mesothelium 
basement membrane of metastatic site. Fas ligands secreted by OC tumour enables the 
invasion into mesothelial cells. Once OC cells invade through mesothelial cells, they binds to 
collagen-I of the sub-mesothelial membrane, which enables the tumour to invade 
extracellular matrix (Lengyel., 2010).  Targeting VEGF, Fas ligands, and collagen 1 by using 





Figure 1-6 Relevance of cancer hallmarks in biology to epithelial ovarian cancer histotypes (Petrillo et al., 2016) 
 
 Surgical stages of ovarian cancer 
Ovarian cancer is a surgically staged disease; the stages of ovarian carcinoma are classified 
based on the extent of metastasis by a tumour examined surgically. Stage I is confined to one 
or both the ovaries, stage II affects organs in the pelvic region, in stage III metastasis occurs 
beyond the pelvic region into the upper abdomen cavity, and stage IV involves the spread of 
tumour cells outside the peritoneal cavity which generally affects the liver and lungs. 
Metastases can occur through blood vessels to the parenchyma of the liver or lung, through 
the lymphatic system to nodes at the renal hilus or by merely shredding tumour cells into the 
peritoneal cavity. The absence of an anatomical barrier in the peritoneal cavity allows the 




 Patients diagnosed with early stage (stage I) ovarian cancer is generally treated surgically 
with bilateral oophorectomy, hysterectomy and lymph node dissections. Chemotherapy is 
usually used for stages II, III and IV (Gubbels et al., 2010). Stages II and III of ovarian cancer 
are typically treated with platinum-based chemotherapy, for those diagnosed in advanced 
stages cytoreductive surgery followed by platinum- paclitaxel-based chemotherapy is 
suggested (Colombo et al., 2006). Carboplatin and paclitaxel are currently used as primary 
adjuvant therapy for over 95% women diagnosed with ovarian cancer (Boyd and Muggia., 
2018). 
Carboplatin is an alkylating agent involves in DNA damage. It covalently binds DNA to create 
adducts that forms both intra and inter crosslinks (Romero and Bast., 2012). Carboplatin was 
developed in 1980s to overcome the toxicities of cisplatin (Boyd and Muggia., 2018). 
Paclitaxel stabilises microtubules independent of energy (GTP independent) which results in 
unusual microtubule stability. This results in accumulation of disorganised microtubule array, 
which leads to G2/M cell cycle arrest (2010). Carboplatin (5-6 AUC) is administered to patients 
by intravenous (IV) fusion for 30- 60 minutes followed by IV infusion of 175-185 mg/m2 
paclitaxel over 3 hours (Bukowska et al., 2016). 
The initial response of primary chemotherapy is very positive, but relapse can commonly 
occur within 2 years with the development of resistance. The platinum- resistant and 
recurrent patients have been treated by various agents including paclitaxel, docetaxel, 
topotecan and doxorubicin but none of them has proven to show more than 20% efficacy yet. 
A recombinant monoclonal antibody, Bevacizumab, is currently used along with carboplatin 
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and paclitaxel for stage III/IV relapsed cancer patients with platinum resistance. (Llauradó et 
al., 2014, Bukowska et al., 2016).  
 Chemotherapy challenges 
Many chemotherapeutic drugs are used to treat ovarian cancer, but none of them has been 
found to be completely effective and safe because of de novo and acquired chemo resistance 
combined with the expression of immunosuppressive factors. The possible mechanisms for 
acquired resistance involved in the alteration of membrane transport, target enzymes and 
target molecules, enhanced DNA repair system and failure to apoptosis (Luqmani, 2005). The 
toxicity of established drugs is also one of the major problems in cancer chemotherapy. In 
case of ovarian cancer treatment, carboplatin/ paclitaxel has shown better effects compared 
to previously used chemotherapeutic combination cisplatin/ paclitaxel, but it did not solve 
the reoccurrence issue  (Ozols, 2006). Besides the fact that carboplatin reduced ototoxicity 
and nephrotoxicity associated with cisplatin it increased the risk of haematological toxicities 
(Boyd and Muggia., 2018). The high fatality in advanced stages of ovarian cancer after 
reoccurrence is due to a small number of tumour cells, which survived during chemotherapy; 
remain dominant in the peritoneal cavity and grow progressively which may lead to further 
metastasis and the death of the patient despite the treatment (Ozols, 2006). Another 
challenge with carboplatin/ paclitaxel chemotherapy is significant induction of toxicities 
which include neuropathy, alopecia (hair loss) and myelosuppression(Ozols, 2006, Bast et al., 
2009). 
 Current research in ovarian cancer treatment 
 Ovarian cancers have shown multidrug resistance; besides significant toxicities involved with 
current drugs indicates the importance of new approaches for the treatment of ovarian 
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cancer. Some of the potential new chemotherapeutic drugs, which are in under clinical 
research are listed below: 
 Olaparib (Lynparza) is a PARP inhibitor; it has shown antitumour activity in high-grade serous 
ovarian cancer cells independent of BRCA mutations. FDA approved Olaparib as oral medicine 
for recurrent ovarian cancers (Ledermann et al., 2012, FDA, 2017). 
Bevacizumab commercially known as Avastin is a recombinant monoclonal antibody Ig1. It 
targets VGEF- A (Vascular endothelial growth factor). It has previously indicated anticancer 
effects on lung, colon and glioblastoma. Recently FDA approved it as a front-line 
chemotherapeutic drug for ovarian cancer. Bevacizumab is used in combination with 
paclitaxel and carboplatin for early stages of ovarian cancer. Bevacizumab as a single 
chemotherapeutic agent for the treatment of stage III and IV ovarian cancer patients 
(Natarajan et al., 2018, FDA, 2018). Cediranib and nintedanib are other VEGF inhibitors which 
are currently in clinical use (Natarajan et al., 2018). 
Metformin is a potential chemotherapeutic drug for ovarian cancer, which is under phase II 
clinical trials. It is currently used for the treatment of type 2 diabetes (Buckanovich et al., 
2017). Both preclinical and epidemiological studies have shown antitumor effects of 
metformin on breast, endometrial and gynaecological cancers. The clinical studies have 
shown that metformin regulates tumour growth by activating AMPK, which involves in 
inhibition of mTOR pathway. However, detailed mechanism of the drug action still to be 
elucidated (Irie et al., 2016)   
VAL-083 is another drug which in clinical trials for ovarian cancer treatment. Preclinical results 




Figure 1-7. Current molecular target drugs (approved or under clinical investigation) based on hallmarks of ovarian cancer 
(Petrillo et al., 2016) 
1.4 Cannabinoids 
Cannabis has been used as a medicinal plant for many centuries by Asian and African countries 
for diseases such as malaria, rheumatic pains, constipation, diseases related to female 
reproductive organs, and also as an anaesthetic (Alexander et al., 2009) (Dariš et al., 2018). 
An example of the use of Marijuana in traditional therapy can be seen in Ayurvedic medicine 
in India, where it was used for neurological, respiratory, gastrointestinal, and infectious 
diseases (Dariš et al., 2018).  However, lack of pharmacological investigations on toxicity 
meant that it did not become a mainstream medicine in the western world until the 19th 
century(Alexander et al., 2009, ASHTON, 1999).  In the mid-19th century, the analgesic, 
antiemetic and antispasmodic effects of cannabis extracts were reported for the first time in 
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Europe (Shevyrin. and Morzherin., 2015, Dariš et al., 2018). In 1851, the cannabis extracts, 
and resin glands from the plant were accepted as a medicine by the US Pharmacopoeia. 
However, due to increased use of cannabis for recreational purposes, lack of consistency in 
the preparation of the extracts, poor investigation in isolating medically active compounds 
from the cannabis, and extensive research in alternative forms of medicine, the progression 
of cannabis as a mainstream medicine was aborted (Dariš et al., 2018). Studies conducted in 
the late 20th century on cannabis lead to the identification, and extraction of the 
pharmacologically active components, named cannabinoids (ASHTON, 1999). The 
identification of significant medical cannabinoids and recent legislative changes have 
improved the possibility of drugs derived from cannabis been approved for use by regulatory 
bodies (Dariš et al., 2018). 
Cannabinoids are the unique family of chemically active components derived from resin 
glands of Cannabis plant. There are over 100 cannabinoids, which have been identified in 
Cannabis sativa (Reekie et al., 2017). Cannabinoids are classified into three main subtypes, i) 
phytocannabinoids, which are produced in plants, ii) synthetic cannabinoids which are 
chemically related analogues, and activate similar primary targets of phytocannabinoids,  and 
iii) endogenous cannabinoids, which are naturally produced in humans and animals, and are 
a derivate of arachidonic acid  (Alexander et al., 2009, Caffarel et al., 2012, Sarfaraz et al., 
2008)  
 Endocannabinoids  
Endocannabinoids are structural analogues of THC produced biologically in mammalians. 
Endocannabinoids are endogenous ligands that often binds to cannabinoid receptors (Hanuš 
et al., 2016). Endocannabinoids are structurally saturated or unsaturated amides found in 
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mammalians. Anandamide and 2- arachidonoylglycerol are the major endocannabinoids, 
which are widely studied.  
 The biosynthesis, transportation, biological activity, and degradation of endocannabinoids 
collectively referred to as the endocannabinoid system (Pertwee, 2006, Shevyrin. and 
Morzherin., 2015). ECS consists of endogenous ligands, cannabinoid receptors, and the 
enzymes involve in the metabolism of the ligands. Fatty acid amide hydrolyse (FAAH), and 
monoacylglyceride lipase (MAGL) are the metabolic enzymes known to degrade the AEA and 
2- AG respectively (Izzo et al., 2009, Dariš et al., 2018). The endocannabinoids function by 
binding and activating cannabinoid receptors of the t central nervous system as a retrograde 
messenger and involve in inhibition of neurotransmitter. Most of the endocannabinoids 
discovered act as agonist for cannabinoid receptors. However, virdhamine has shown 
antagonistic effects on CB1 receptors (Pertwee, 2006) 
The regulation of food intake, emotional homeostasis, inflammatory and stress related 
responses, immune system are other functions performed by ECS. ECS also reported engaging 
in cancer cell signalling. ECS gained the attention of pharmacologists as a potential 
therapeutic target due to the ability to regulate many biological functions.  Targeting the 
cannabinoid receptors and inhibiting the enzymes involved in degradation of 
endocannabinoids are viable strategies for ECS based therapies for neuropsychiatric 
conditions (Pertwee, 2006, Dariš et al., 2018, Shi et al., 2017). 
Most of the endocannabinoids discovered act as agonist for cannabinoid receptors. However, 
virdhamine has shown antagonistic effects on CB1 receptors (Pertwee, 2006) 
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 Cannabinoid Receptors: 
The pharmacological activity of cannabinoids can be defined by their ability to activate 
receptors and its action depends on concentration, duration of exposure and type of the cells 
and their ligands (Cridge and Rosengren, 2013)  
The lipophilic nature of cannabinoids made researchers to assume that the biophysical 
activity of cannabinoids exerted by direct interaction with lipid bilayer membrane of targeted 
cells. In 1990, an orphan G- coupled protein receptor named SKR6 (obtained from rat cerebral 
cortex cDNA library) was found to be a receptor for ∆9-tetrahydrocannabinol (∆9 -THC) 
pharmacological activity. This discovery of first cannabinoid receptor SKR6 was later named 
CB1. Three years later another G- coupled protein receptor named CX5 (later renamed CB2) 
was identified as cannabinoid receptor in human promyelocytic leukemic cell line HL60 
(Pertwee et al., 2010, Pertwee, 2006).  
CB1 receptors are mainly expressed in the central nervous system at high levels in basal 
ganglia, cerebellum, hippocampus and cerebral cortex.  The activation of CB1 can affect the 
process of cognition and memory, induce analgesia and controls the motor function. It is also 
found in peripheral nervous system and extra- neural tissues include spleen, eyes, testis and 
uterus, adipocytes and ileum where its activation also mediates the psychotropic properties 
(Bifulco et al., 2006). 
CB2 receptors are mainly expressed in cells and organs of immune system includes spleen 
marginal zone, lymph node cortex, secondary follicles in tonsils. The activation of CB2 
receptors involved in differentiation and migration of immune cells and cytokines suggesting 
its role in immune responses. CB2 receptors are unrelated to psychotropic properties of 
cannabinoid agonists (Bifulco et al., 2006; Pertwee et al., 2010). Both receptors act on 
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secondary messenger system of cells by regulating Ca+ and K+ ion channels and involves in 
formation of cAMP (ASHTON, 1999).   
Cannabinoid agonists were found to exert pharmacological activities beyond CB1 and CB2 
receptors suggested the possibility of other receptors. However, IUPHAR committee 
proposed a set of guidelines to classify a receptor as a cannabinoid receptor. The five essential 
criteria for nomenclature of a new cannabinoid receptor include: i) the receptor should be 
activated by established CB1/ CB2 ligand at its orthosteic site, ii) the receptor should be show 
sequence amino acid homology with CB1 or CB2 receptors if it is a GPCR, iii) an established 
CB1/ CB2 agonist should activate the receptor at a physiological concentration, iv) it should 
not be an established non CB receptor, and it should not show higher potency and intrinsic 
affinity to a non-cannabinoid receptor compared to endocannabinoid, and V) it should be 
expressed in mammalian cells that express active endogenous ligands (Console-Bram et al., 
2012, Pertwee et al., 2010) 
GPR55 is potential cannabinoid receptors from G- coupled protein receptor (GPR) family. It 
has larger evidence as a cannabinoid receptor because of its ability to mediate the 
pharmacological responses of many phytocannabinoids, synthetic cannabinoids and 
endocannabinoid ligands. GPR55 receptors are highly abundant in posterior root ganglion of 
neurons, involves in upregulation of intracellular calcium upon activation by various 
cannabinoids (Leyva-Illades and DeMorrow, 2013, Lauckner et al., 2008). In vivo studies have 
shown that GPR55 mediates the  anxiolytic effects in mice by down regulating the glutamate 
receptors GluA1 and GluN2A expression (Shi et al., 2017). GPR55 associated with various 
physiological activities, and the dysfunction can lead to several diseases. GPR55  involve in 
regulation of vasculature, regulation of motility in gastrointestinal tract, anti- inflammatory 
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responses in acute pancreatitis and pro-inflammatory in colitis. GPR55 upregulates insulin 
secretion and regulate glucose tolerance in pancreases. The physiological function of GPR55 
was reported in various cancers including ovarian, breast, prostate, glioblastoma and 
cholangiocarcinoma (Figure 1-8) (Leyva-Illades and DeMorrow, 2013). Studies have shown 
that autocrine release of endocannabinoid L-α-lipophosphotidylionsitol (LPI) mediates 
tumour invasion and metastasis to mediate cancer proliferation and angiogenesis in ovarian 
cancer through putative cannabinoid receptor GPR55 in ovarian cancer cells (Leyva-Illades 
and DeMorrow, 2013).   
Although GPR55 lack CB binding packet, and insufficient amino acid sequence homology with 
both CB1 (13.5%) and CB2 (14.4%) receptors, cannabinoids still able to activate the receptor 
and mediates physiological functions makes GPR55 an atypical cannabinoid receptor 
(Pertwee et al., 2010).  
GPR18 and GPR119 are G-coupled receptors reported to activate by cannabinoids, however, 
lack of sufficient evidences robust to rename them as cannabinoid receptor isoforms. 
Transient receptor potential cation channel V family member 1 (TRPV 1) discovered as 
another potent cannabinoid receptor activated by endogenous cannabinoids AEA 
(Anandamide) and NADA (N- Archidonoyl dopamine) (Cridge and Rosengren, 2013). 
The involvement of ECS in cancer progression is not illustrated completely (Javid et al., 2016). 
However, both the upregulation of endocannabinoids and cannabinoid receptors, and the 
down regulation by activating endocannabinoid degrading enzymes were observed in various 
tumours pathogenesis. Pre-clinical studies on anti- cancer properties of cannabinoids have 
shown that cannabinoids induce apoptosis by activating cannabinoid receptors in many 




Figure 1-8. The known physiological role of GPR55 in cancer. Adapted from (Leyva-Illades and DeMorrow, 2013) 
 
 Phytocannabinoids: 
Phytocannabinoids are a group of C21 terpenophenolic compounds derived from cannabis 
plant that exert the pharmacological effects by binding to the cannabinoid receptors. Among 
the phytocannabinoids discovered so far, ∆9 – tetrahydrocannabinol (THC), and CBD are the 
most abundant phytocannabinoids, followed by cannabinol (CBN), cannabichromene (CBC), 
∆8 – tetrahydrocannabinol (THC),  cannabidiolic acid (CBDA) , cannabidivarin (CBDV), and 
cannabigerol (CBG) (Dariš et al., 2018, Reekie et al., 2017).  
THC exerts many neuropathological functions through cannabinoid receptors, which includes 
the modulation of neuro transmitter release, regulation of pain perception, and many 
gastrointestinal, cardiovascular activities. The anti- cancer properties of THC also been 
reported in human breast, prostate and glioma cells (Dariš et al., 2018). Although, THC has 
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shown many medicinal properties, it was limited to clinic use due to its well-known 
psychotropic activities. CBD is a structural analogue to THC however; it does not have any 
psychotropic activities. Both the compounds have been widely studied for their medicinal 
properties. The combination of THC and CBD has shown analgesic efficacy related to 
neuropathic pain.  It currently used as an oral spray to treat spasticity and pain resulting from  
multiple sclerosis under commercial name Sativex  (Reekie et al., 2017, Alexander et al., 2009, 
Caffarel et al., 2012, Sarfaraz et al., 2008, Portenoy et al., 2012).  
 Synthetic cannabinoids  
 Synthetic cannabinoids gained the attention of pharmaceutical companies in the late 1970s. 
In 1979, Pfizer synthesised a THC analogous called CP47497 as a potential analgesic drug. The 
clinical studies showed that CP47497 as an effective analgesic compound. However, later 
studies have shown the higher narcotic effects of CP47497. The same company synthesised 
another THC analogue (CP55940). However, this compound exhibited even higher narcotic 
activities. Although CP55940 was failed to use as an analgesic drug, the research on this 
compound later lead to the finding of the cannabinoid receptor 1 (CB1). Besides the above 
compounds, nabilone was another synthetic THC analogue, which was used as an antiemetic 
drug under chemotherapy for cancer treatment, despite its narcotic effects (Shevyrin. and 
Morzherin., 2015). HU- 210 is another synthetic cannabinoid tested as an analgesic drug that 
had failed in clinical trials due to psychoactive nature, later a stereoisomer was developed 
from HU-210 called HU- 211, which has no affinity for CB1 receptor meaning no psychoactive 
properties. This drug is currently under clinical trials  (Shevyrin. and Morzherin., 2015). 
Despite the attempts to use synthetic cannabinoids in medical pharmacology, it has gained 
popularity for the drug abuse in Europe, Russia, and North America. In early 2000, synthetic 
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drugs CP47497, and JWH- 018 were sold as online herbal smoking blends under the 
commercial name ‘k2’ or ‘spice’. Over the years, many countries including Germany and 
Russia tried to implement legal restrictions to control misuse of synthetic cannabinoids. 
However, it did not wholly restrict the illegal drug trade. Therefore, identification and 
development of medically significant synthetic cannabinoids with less psychoactive effects 
remain challenging (Shevyrin. and Morzherin., 2015, Tai and Fantegrossi, 2014). 
 Cannabinoids and their anti- cancer activity: 
Cannabinoids have been used in cancer therapy to reduce the side effects include nausea, 
alleviate pain, and lack of appetite. However, pre- clinical studies have shown anti- cancer 
properties of cannabinoids for many cancers in mammalian cells and biological models (Dariš 
et al., 2018). 
Cannabinoids have been attracting a great deal of interest as a source of anti- cancer drugs 
since the early 1970s because of their ability to regulate cell growth, invasion, and cell death 
(Guzmán et al., 2001, Dariš et al., 2018). The anti- tumour ability of cannabinoids was first 
reported by Munson et al. in 1975 where cannabinoids were found to be involved in the 
inhibition of tumours and prolonged life of mice bearing Lewis lung adenocarcinoma. The 
involvement of cannabinoid receptors in antitumor genic effect of cannabinoids was 
described by Galve- Ropreh in 2000, subsequently many independent studies have reported 
anti- tumour activity in vitro on different cancer cell lines including lung, glioma, pancreas, 
lymphoma, prostate, uterus and breast carcinoma cells (Alexander et al., 2009).  
Cannabinoids have to be shown to be involved in  inhibiting tumour cells by altering the cell 
signalling receptors further inducing apoptosis or inhibiting angiogenesis of tumour cell 
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(Velasco et al., 2007), it also has been reported that cannabinoids inhibits the tumour 
metastasis and induce growth arrest (Blázquez et al., 2008).  
  Non-psychotropic cannabinoids as potential anticancer drugs: 
Psychotropic cannabinoids such as ∆9- tetrahydrocannabinol (THC) have shown a wide range 
of medicinal properties including antiemetic effects and tumour inhibition (Alexander et al, 
2009). However, the psychoactive properties, and the possible risk of the emergence of 
dependency and tolerance challenge its practical use in cancer treatment. Other than 
psychoactive properties, there were no significant side effects with cannabinoids has been 
observed, so far the general side effects seen include dry mouth, tiredness, and dizziness. 
However, tolerance to the common side effects is observed within a short period. This gives 
hope for non-psychotropic cannabinoids as a potential therapeutic approach for cancer 
treatment (Ostadhadi et al., 2015, Dariš et al., 2018).  




 Cannabidiol (CBD) 
CBD (CBD) is one of the major non-psychotropic phytocannabinoids, highly abundant in 
cannabis plant with no psychotomimetic properties. It was first isolated by Adam and 
colleagues in 1940.  In 1963, Mechulam and Shvo determined the stereo chemical structure 
of CBD (Figure 1-9).  The research carried out in 1970s showed CBD to have the antiepileptic 
action. However, clinical trials were not progressed further as the preliminary screening 
results showed uncertain efficacy even with a large dose. The strong antioxidant effect and 
Ca+2 homeostasis nature of CBD has many proven pharmacological effects include anti-
inflammatory, analgesic, neuroprotective, anxiolytic, antipsychotic and anti-ischemic effects 
(Figure 1-11) (Izzo et al., 2009, Zuardi, 2008). 
Unlike many cannabinoids, CBD has low affinity for CB1 and CB2 receptors. The studies have 
shown CBD acts as an antagonist towards the CB1, and inverse agonist towards CB2. CBD has 
been shown to have multiple molecular targets. The ability of CBD to regulate 
endocannabinoid system has gained the attention as a therapeutically potential compound. 
CBD has shown biphasic effects on oxidative stress, immune system, which indeed 
demonstrated the anti- tumour and neuroprotective nature of the compound. Regulation of 
Ca+2 levels, induction of ROS, regulating ATP and proton leak suggest that the involvement of 
mitochondria is CBD cellular mechanism (Dariš et al., 2018, Kosgodage et al., 2018b). 
The anticancer properties of CBD were first examined in 2000 on glioma cells, which later 
extended to human meroblastic leukaemia cells (Blázquez et al., 2008, Caffarel et al., 2012). 
CBD has shown to induce cytotoxicity in human leukaemia cells by a caspase-dependant 
apoptosis pathway. It was also involved in oxidative stress by enhancing NOX4 (NADPH 
oxidase) and p22phox proteins levels in cytoplasm (Blázquez et al., 2008, Izzo et al., 2009) 
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Among 8 non-psychotropic phytocannabinoids tested, CBD has shown higher anti-
proliferative/ pro-apoptotic properties, and highest potency with IC50 values between 6 µM 
and 10.6 µM on MCF7 breast cancer cells. CBD exerted concentration dependant autophagy, 
and apoptosis induction in breast cancer cells. The inhibition of breast tumour metastasis by 
regulating the Id1 genes was also observed (Izzo et al., 2009, Shrivastava et al., 2011, Ligresti  
et al., 2006, Caffarel et al., 2012)  
CBD has shown anti- cancer effects in prostate cancer cell lines at a concentration where it 
has shown significantly less cytotoxicity to non-cancer cells. Further investigation of CBD 
cytotoxic mechanism on prostate cancer cells has shown the down regulation of CB1, and CB2 
receptors. The down regulation of pro- inflammatory interleukins (IL-6& IL-8), vascular 
endothelial growth factor (VEGF) and prostate specific antigens were observed (Kosgodage 
et al., 2018a, Sharma et al., 2014, Dariš et al., 2018). 
 CBD has shown to regulate Exosomes and macrovesicles (EMV). EMVs are extracellular 
vesicles, which involve in various physiological and pathological pathways including cell 
migration, and angiogenesis. CBD has shown anti- cancer activity on prostate, breast and 
hepatocellular cancer cells by inhibiting the EMV (Kosgodage et al., 2018a).  Although CBD 
exerted cytotoxicity towards cancer cells in multiple pathways, the molecular mechanisms 
responsible for CBD selective cytotoxity on different tumour cells has yet to be discovered 




Figure 1-9. Chemical structure of Cannabidiol (CBD) 
 Cannabigerol (CBG) 
CBG is a non-psychotropic phytocannabinoids. It was isolated by Goani and Mechulam in 1964 
when they separated hexane extract of hashish on florisil (Figure 1-10). Similar to CBD, CBG 
does not exert any psychoactive properties (Figure 1-11). CBG was shown to use antibacterial 
and antiglaucoma properties (Figure 1-11) (Borrelli et al., 2013). CBG has shown to antagonise 
the antiemetic effects of CBD (Rock et al., 2011). CBG has weak affinity for cannabinoid 
receptors CB1 and CB2. CBG believed to exert its mechanism of action through TRP receptors 
channels. It has shown weak agonistic effects to TRPV1 and TRPV2, a potent agonist to TRPA1 
and antagonist to 5-HTA1 and TRPM8 receptors (Borrelli et al., 2014).  
CBG exerted beneficial effects on Inflammatory Bowel Disease (IBD) in vivo.  The mechanistic 
studies of such effects showed that CBG possibly is involved in the reduction of oxidative 
stress in the intestinal mucosa. The destruction of intestinal mucosa through oxidative stress 
has been shown to be a significant factor in the cause of  IBD  (Borrelli et al., 2013). In vivo 
studies on a mouse model reported the neuroprotection nature of CBG in Huntington disease. 
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CBG reduced the aggregation of mutant Huntington in an in vivo model by up-regulating 
peroxisome proliferator-activated receptor and brain-derived neurotrophic factor (BDNF) 
(Valdeolivas et al., 2015) 
The cytotoxic effect of CBG is also reported in breast cancer cells with better IC50 values next 
to CBD. Recent studies have shown that CBG also inhibits colon carcinogenesis by acting as 
TRPM8 antagonists. The mechanistic studies of cytotoxicity of CBG on colorectal cells have 
shown ROS production, ER stress-related caspase-dependent apoptosis (Nishitoh, 2012, 
Borrelli et al., 2014, Ligresti  et al., 2006). Although CBG was identified and extracted around 
same time as other cannabinoids, the pharmacological activity of CBG is poorly investigated 
compared to CBD, and THC. However recent advancement in the identification of CBG 
pharmacological activities have been gained the attention of the scientific community 
(Borrelli et al., 2014, Ligresti  et al., 2006, Navarro et al., 2018) 
Non-psychoactive nature, ability to regulate endocannabinoids, induction of ROS, apoptosis 
and potentially targeting the transient receptor channels TRP channels indicates that CBG is 
one the potential cannabinoid for cancer treatment, which requires further investigation.   
 
Figure 1-10. Chemical structure of Cannabigerol (CBG) 
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Figure 1-11 pharmacological effects of CBD& CBG, and their proposed mechanism of action. Adapted from (Izzo 
et al., 2009). ↑indicates increase levels, ↓ indicates decrease in levels, + indicates activation of the receptor. 
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1.5 Mechanisms associated with anticancer activity of cannabinoids 
Evading apoptosis and alterations in cell cycle are critical hallmarks in tumour progression. 
The mechanism studies of anti-cancer activity of the cannabinoids have reported the 
induction of apoptosis, oxidative stress and inhibition of cell proliferation by cell cycle arrest 
(Dariš et al., 2018, Xu et al., 2015) 
 Apoptosis 
Apoptosis is a highly conserved mechanism where a cell intentionally undergoes programmed 
death. It has a vital role in various physiological processes including embryonic development, 
regulation of the immune system, and cell turnover. Apoptosis generally functions to 
maintain homeostasis of the cell population in a tissue; it also works as a defensive 
mechanism when irreversible damage has occurred to cell by diseases or the noxious agents. 
The imbalance in apoptosis can lead to many diseases including neurodegenerative diseases, 
ischemic damage, and autoimmune disorder where uncontrolled apoptosis occurs- Too little 
or no apoptosis would lead to cancer (Elmore., 2007) 
Morphological changes involved in apoptosis are cell shrinkage, where cell reduces in size 
with dense cytoplasm, pyknosis (irreversible condensation of chromatin) followed by 
membrane blebbing. Membrane blebbing associated with a process called budding which is 
involved in karryohexis (disruption of nuclear membrane) followed by distribution of cell 
fragments to apoptotic bodies. Later these apoptotic bodies are subsequently engulfed by 
tingled body macrophages, parenchymal cells and neoplastic cells and digested by 
phagolysosomes. Unlike necrosis, where cells undergo energy independent sudden death, 
apoptosis does not induce any inflammatory reactions. Apoptotic bodies are quickly engulfed 
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by phagolysosomes avoids secondary necrosis and lysosomes avoid activation of 
inflammatory cytokines (Elmore., 2007, Hengartner., 2000) 
Apoptosis is a highly sophisticated mechanism, which is mainly classified in to two types: 
extrinsic or death receptor pathway and intrinsic or mitochondrial pathway. Both involve in 
activation of a set of cysteine proteases called caspases. Caspases are pro- apoptotic enzymes; 
possessing cysteine active site that target Asp- xxx substrate in a protein. Caspases target 
cytoskeletal proteins and disrupt cell integration thus inactivating the biological activity 
leading to cell death. Later studies have shown apoptosis follows another pathway 
independent of caspases called T- cell mediated cytotoxicity and perforin- granzyme 
mediated cell death. All the pathways lead to same terminal called execution pathway, which 
is mediated by caspase 3, 6, and 7 activation (Hengartner., 2000, Elmore., 2007)  
1.5.1.1 Extrinsic/ Death receptor pathway 
The extrinsic pathway of apoptosis is involved in trans-membrane death receptor mediated 
interactions. Extrinsic pathway events are initiated by the binding of clustering receptors with 
homologous ligands. Fas ligand bind to the Fas receptor which further binds to adopter 
protein containing death receptor domain FADD,  TNF ligand bind to the TNF receptor which 
further binds to adopter protein containing death receptor domain TRADD. They further 
associate with procaspase- 8 to form the death receptor signalling complex (DISC), resulting 
in formation of caspase-8 by autocatalytic activation of procaspase 8. The activated caspase 
8 triggers the execution pathway. C-FLIP and Toso are the proteins, which regulates extrinsic 
apoptotic pathway (Elmore., 2007, Locksley et al., 2001).  
60 
 
1.5.1.2 Intrinsic/ Mitochondrial pathway 
The mitochondrial pathway is a non-receptor based mechanism based on intracellular signals. 
These signals can be either positive or negative. Negative signals include lack of growth 
factors, cytokines or hormones whereas positive signals include hypoxia, hyperthermia, 
toxicity and radiations, infections and free radicals. 
The intracellular signals initiate the pathway by depolarising the mitochondrial membrane, 
this forms mitochondrial membrane permeable transition (MPT) pores. MPT pores result in 
the release of two sets of proteins into cytosol, which results in apoptosis. The first set of 
proteins include cytochrome c, smac/ DIABLO and a serine protease H2rA2/omi (Saelens et 
al., 2004). Cytochrome c binds and activates apaf-1 and procasape 9 forms apoptosome, 
which leads to activation of caspase 9. Caspase 9 further triggers the execution pathway. 
smac/ DIABLO and H2rA2/omi  inhibits the IAP (inhibitor of apoptotic proteins) and promotes 
apoptosis(Elmore., 2007) 
The second set of pro- apoptotic proteins includes endonuclease G, CAD and AIF, which are 
released only after caspase-9 activation. AIF released from mitochondrial membrane 
translocated to the nucleus, results in DNA fragmentation and condensation of chromatin. 
Chromatin is further cleaved into oligonucleosomal DNA fragments by endonuclease G. The 
oligonucleosomal G is further cleaved into small DNA fragments by CAD proteins (Elmore., 
2007, Susin et al., 2000). 
The mitochondrial apoptotic pathway is regulated by proteins belong to the BC-2 family. Bcl-
2 family contain both pro-apoptotic and anti- apoptotic proteins. Tumour suppressor protein 
p53 involves in regulation of Bcl-2 family proteins(Elmore., 2007). 
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1.5.1.3 Execution pathway 
The execution pathway is the terminal phase of both the intrinsic and extrinsic pathways. 
Caspase-3, 6 and 7 are activated during the execution phase and acts as effector or 
executioner proteins. They cleave various substrates include poly (ADP- ribose) polymerase 
(PARP), cytokeratins, cytoskeletal (fordrin and gelsolin) and nuclear (NuMA) proteins by 
activating endonuclease proteins which results in degradation of nucleus and cytoskeleton 
(Slee et al., 2000). 
 
Figure 1-12 schematic representation of Apoptosis. Adopted from (Robinson., 2016) 
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Ovarian cancer survive apoptosis by multiple mechanisms of actions. p53 mutations exerted 
by 70% of EOC leads to dysregulation of proapoptotic proteins results in cancer survival. Over 
30% ovarian cancers exhibit PETN mutations, which results in alteration of PI3-kinase/Akt 
pathway. The alteration involves in inhibition of PIP3 dephosphorylation, which leads to 
evasion of apoptosis. Over 80% ovarian cancers overcome apoptosis by enhancing the 
immortality of cells (Saad. et al., 2010) 
 Cell cycle  
 The cell cycle in a conserved mechanism involved in duplication of cells by transferring 
genetic information from one generation to the next. Cell cycle machinery helps to maintain 
tissue homeostasis. The transformation of genetic information requires replication of the cell 
genome, which occurs in s-phase (synthesis phase), once s-phase is completely finished, the 
cell enters a division phase called M-phase (mitotic phase) where cell undergo division to form 
identical duplicates. The gap between s-phase and M- phase is called G2-phase, and M- phase 
to S-phase is called G1- phase. A cell enters from G1 to G0 phase, which is a quiescent state 
when it undergoes differentiation (Elmore., 2007, Pucci et al., 2000). 
Cell cycle is regulated by checkpoints that occur during G1/ S phase transition, in s-phase and 
during G2/M phase. The checkpoints are generally enabled for cell proliferation by growth 
factors. DNA damage and misalignment of chromosomes during mitotic spindle formation 
can also involve in activation of checkpoints results in growth arrest. During growth arrest, 
checkpoints allow cell to repair the damage and resume cell cycle if the damage is irreversible 
cell undergoes apoptosis(Pucci et al., 2000).  
The progression of cell cycle is dependent on activity of cdks (cyclin dependant kinases), which 
activated by cyclin subunits. Cdks are mainly regulated by pRb and p53. pRB is a 
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retinoblastoma tumour suppressor protein, which acts as a negative regulator for cell growth. 
Phosphorylation of pRb is required for a cell to transit from G1 to s-phase. It is mutated or 
deleted in many cancers such as retinoblastoma carcinoma of lung, prostate, breast, and 
bladder. P53 is a nuclear binding phosphoprotein, which regulates cell division by 
predominantly influencing G1 phase of cell cycle.  DNA damage by UV radiation, hypoxia or 
chemotherapeutic drugs can activate p53. As a result, p53 expresses p21 which inhibits cdks 
to phosphorylate pRb results in cell cycle arrest at G1 phase(Schneider et al., 1998, Pucci et 
al., 2000). 
 Reactive oxygen species (ROS) inducing apoptosis 
Reactive oxygen species is the collective term for radicals, ions, or molecules, which have 
unpaired electrons in its outermost shell. They are products of normal cellular metabolism or 
xenobiotic exposure; based on the concentrations it can be beneficial or harmful to cells. The 
low physiological levels of ROS can acts as a messenger for intracellular signalling and 
regulation. The excess levels of ROS create oxidative stress on cellular macromolecules and 
leads to dysfunction of proteins and results in cell cycle arrest, senescence and apoptosis 
(Circu and Aw., 2010, Liou and Storz., 2010). 
ROS are over expressed in most of the cancers. The high levels of ROS in cancer cells may be 
due to increased metabolism, increased cellular signalling, mitochondrial dysfunction, 
peroxisome activity or oncogene activity (Liou and Storz., 2010, Storz., 2005). During 
ovulation, the increased levels ROS can trigger the biochemical events, which involves in 
remodelling of follicle or OSE cells thus results in ovulation impairment. This can further leads 
to ovarian carcinogenesis. ROS has shown to contribute tumour proliferation and chemo 
resistance in ovarian cancer (Calaf et al., 2018, Kim et al., 2017) 
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The superoxide form of ROS is produced in mitochondrial membrane as an inevitable by-
product of oxidative phosphorylation. Superoxide is released into the cytosol through 
mitochondrial membrane permeable transition pore (MPTP) of outer mitochondrial 
membrane. The superoxide is generally dismutated to H2O2 either in cytosol or in 
mitochondrial matrix. But the loss of mitochondrial membrane potential results in increase 
leakage of superoxide into cytosol results in apoptosis by DNA fragmentation (Liou and Storz., 
2010, Wen et al., 2013). 
1.6 Rationale and aims of the project 
The heterogeneity amongst the ovarian cancer types and acquired resistance to the current 
chemotherapy drugs indicate the importance of new approaches for the treatment of ovarian 
cancer. Pre-clinical studies have shown the antitumor activities of cannabinoids in different 
cancer cells. Endocannabinoid system play important role in ovulation process. The autocrine 
release of endocannabinoid L-α-lipophosphotidylionsitol (LPI) mediates tumour invasion and 
metastasis to mediate cancer proliferation and angiogenesis in ovarian cancer through 
putative cannabinoid receptor GPR55 in ovarian cancer cells (Leyva-Illades and DeMorrow, 
2013). Besides, the upregulation of cannabinoid receptors CB1, CB2 and GPR55 has been 
observed in human ovarian cancer cells, and associated with regulation of tumour 
proliferation (Afaq et al., 2006a, Natarajan et al., 2018, Bast et al., 2009). As cannabinoids can 
potentially target CB receptors, this raises the possibility of cannabinoids as potential 
anticancer drugs for ovarian cancer treatment. Among the cannabinoids, non-psychotropic 
cannabinoids have gained interest amongst the scientific community due to their 
pharmacological activities without psychoactive effects. In vitro studies have demonstrated 
the anticancer properties of CBD and CBG in various cancer cells (Dariš et al., 2018, Borrelli et 
al., 2013, Kosgodage et al., 2018a).  
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The aims of this project are to evaluate potential dose-dependent and time-dependant 
cytotoxic effects of CBD and CBG on human ovarian cancer cells, in vitro. This project will 
investigate the cytotoxic effects the cannabinoids on cisplatin sensitive and cisplatin resistant 
ovarian cancer cells, and the selective cytotoxicity towards ovarian cancer cells will be 
determined by comparing the cytotoxic effects towards non- cancer cells. The combination 
effects of CBD or CBG in combination with current chemotherapeutic drugs will also be 
evaluated, and the combination effect will be determined by the calculation of the 
combination index. The potential mechanism of actions of CBD and CBG on ovarian cancer 
cells will be investigated, alongside investigations into the involvement of cannabinoid 
receptor GPR55 activity in CBD and CBG cytotoxicity on ovarian cancer cells. 
1.7 Hypothesis 
Based on studies of CBD and CBG in other cancer cell types and involvement of CB receptors  
in promoting cancer cell survival, it was hypothesised that CBD and CBG may show anti-cancer 
effects in ovarian cancer as CB receptors have been overexpressed in different ovarian cancer 
types. In particular, given identification of GPR55 as a putative CB receptor in ovarian cancer, 
it was hypothesised that CBD and CBG might mediate their effects through GPRR55 or one of 




CHAPTER 2: Materials and Methods 
2.1 Materials 
All the materials supplied by Sigma Aldrich, UK unless otherwise stated 






 Primary antibodies for western blot 
 
 
 SiRNA for RNAi mediated transfection 
 
 





2.2 Cell culture methods: 
Human ovarian cancer cells include A2780 (Sigma Aldrich, UK), A2780 cis (CP70)(Allison et al., 
2017) OVCAR3(Hamilton et al., 1983) and IGROV-1 (Erba et al., 2000); a colorectal cancer cell 
line HCT116 p53++;  non-cancerous cells include PNT2 (normal prostate epithelial cell line) 
(Sigma Aldrich, UK), and ARPE19 (human retinal pigment cell line) (Dunn et al., 1996) were 
maintained according to the ATCC guidelines. 
 
All the cells were grown in an incubator, which was maintained with 5 % CO2 at 37°C under 
humidified conditions. The cells were sub- cultured when reached 70% confluence. 
2.3 Sub- culturing of cells by trypsinisation 
Sub- culturing was carried out either to set up an experiment or to maintain the cells for future 
use.  The media was removed and, washed with 8mL of 1x PBS supplemented with 1 %( v/v) 
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EDTA.  2mL of trypsin (0.05%) - EDTA (0.02%) (Sigma Aldrich, UK) solution was used to detach 
cells from flask.  After 2 minutes of incubation, complete media was added to inactivate 
trypsin. Cells were transferred to 50mL conical flasks and centrifuged at 1200 rpm for 5 
minutes. Following centrifugation, the supernatant was removed, and cells were suspended 
in complete media. Cells were added according to a recommended ratio, to a fresh, labelled 
T75 flask and transferred to incubator. 
 Cell counting by haemocytometer: 
The cells were counted using haemocytometer (sigma Aldrich, UK). Trypan blue was used to 
distinguish the viable cells from dead. The total number of viable cells were calculated 
according to Equation 1 
                                 T = (N ÷ S) × D ×104                                                                         (Eq.1) 
T= Total number of viable cells/ mL 
N= Total number of viable cells counted 
S= Total number of squares (1mm2) counted  




Figure 2-1. General representation of haemocytometer grid with a square highlighted 
2.4 Cryo-preservation of cells: 
The cells were detached from flasks as described in section 2.3. Cells were suspended in 
complete media supplemented with 10% DMSO (dimethyl sulfoxide) and 20% FBS. These 
were aliquoted to cryovials (3 to 4 vials per T75), and placed in a cryopreservation box 
(Nalgene® “Mr. Frosty®”) containing isopropanol. Cryopreservation box avoids ice crystal 
formation of cells by allowing it to cool down 1° per min.  The box was immediately 
transferred to -20°C freezer, and then transferred to -80°C. After overnight storage, the vials 
were transferred liquid nitrogen storage (-196°C) for long term storage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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2.5  Chemo sensitivity assay  
 Preparation of MTT solution:  
MTT (sigma Aldrich, UK) was dissolved in ultra-pure water with 5% (w/v) final concentration. 
The solution was sterile filtered and stored at 4°C (protected from light).  The final 
concentration of 0.5 % MTT (w/v) solution was added to each well in a 96 well plate. 
 Drug addition 
All drugs or compounds were dissolved in ethanol (1% final concentration), DMSO (0.1% final 
concentration) or ultrapure water. All the concentrations mentioned in experiments were the 
final concentrations.  Repetman pipette (Gilson, UK) was used for the addition of drugs. 
 MTT assay: 
The cells were detached from flasks as described in section 2.3. Cells were seeded at a density 
of 1500 cells per well for A2780 and A2780 CP70, 2000 cells per well for ARPE19 19 and 
3000cells per well for OVCAR3 and PNT2 in 96 well plates.  The final volume in each was kept 
constant (200 µL media per well), and cells were incubated for 24 h before drug treatment. 
After 24 h, 2 µL of drug (1 nM – 100 µM) or vehicle was added to wells, and incubated for a 
further 24 h, 48 h, 72 h or 96 h. After the allocated contact time had elapsed, the media was 
removed and 0.5 % (w/v) MTT solution diluted in complete media (200 µL) was added to each 
well. Following a 4 h incubation, the supernatants were removed, and the formazan crystals 
were dissolved in dimethylsulfoxide (150µL). The absorbance was read at 540 nm on a Tecan 
Infinite 50 plate UV reader. 
 Chemo sensitivity assay with drug washout 
The seeding of cells and addition of drugs in 96 well plates were performed as described in 
section 2.5.3. After the allocated contact time had elapsed, the media was removed, washed 
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with PBS. 200 µL of complete media was added to each well to allow the cells to recover. At 
96 h time point (since the drug added) MTT assay was performed as described in section 2.5.3.  
 
 IC50 determination: 
Cytotoxicity was expressed as a relative percentage of the absorbance measured at 540 nm 
din the control and drug-treated cells. Data were presented as the mean ± standard error of 
the mean. At least 3 independent experiments were carried out to determine the IC50 (n ≥ 3).  
 Selectivity Index: 
Preferential cytotoxicity of CBD and CBG towards cancer cells were determined by selective 
index. The Selective index (SI) is the ratio of mean IC50 values on non-cancer cells to cancer 
cells.  If SI > 1, this means drug shows preferential cytotoxicity towards cancer cells, if S1= 1, 
means it is equally toxic to both cancer and non- cancer cells. If S1<1,  this means it is more 





SI= N ÷ C                                                      (Eq.2) 
SI = Selectivity Index 
N= Mean IC50 on non- cancer cells 
C= Mean IC50 on cancer cells                                                                            
 Combination Index: 
The combination Index (CI) for drug A (CBD or CBG), when they were combined with drug B 
(Carboplatin or Paclitaxel) was calculated by the ratio of the applied concentration of drug A 
(100 nM) in the combination to the IC50 of A when it was applied individually, the ratio of the 
applied concentration of drug B in the combination (combination IC50 – concentration of drug 
A), to IC50 of B on the cells (Liang Zhao, 2004)    
CIA+B= (CA ÷ IC50 A) + (CB ÷ IC50 B)                      (Eq.3) 
CIA+B =   Combination index of A and B  
CA =   Concentration of A applied in the combination  
CB =   Concentration of B applied in the combination  
IC50 A =   IC50 of drug A when it was applied individually to the cells  
IC50 B =   IC50 of drug B when it was applied individually to the cells 
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Table 2-1. Indication of combination effects relative to combination index values. Adopted from (Bijnsdorp et al., 
2011) 
 
2.6 Viability Assay: 
Viability of cells were determined by NucleoCounter NC-3000 image cytometry using Via1 
cassettes (Chemometec, Denmark). Via1 cassettes are preloaded with acridine orange and 
DAPI. Acridine orange stains all the cells whereas DAPI differentiate dead cells from viable by 
staining DNA of dead cells. Following the preparation of cell suspension in 1X PBS, cells were 
drawn into cassettes by inserting the tip of cassette into cell suspension and pressing the 
piston. The cassettes were immediately paced on NC3000 for analysis. Cell density should be 
in between 5× 104 cells/mL -- 5× 106 cells/mL for ideal results. 
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2.7 Mitochondrial membrane potential assay: 
The mitochondrial membrane potential assay was performed to detect the loss in 
mitochondrial potential (de-polarisation), which is a vital step in apoptosis. Cells were seeded 
in T25 flasks at 4×105 cells per flask, and were incubated for 48 h. the incubation time was 
sufficient for the flasks to reach ideal confluency to carry out the assay. After incubation time 
elapsed. Drug concentrations 10 µM, 30 µM and 50 µM were added to the flasks, and further 
incubated for 24 h. Following incubation, cells were harvested and suspended in PBS. Cell 
viability and number were determined by the cell viability assay using via1 cassettes on NC 
3000 system. The samples were diluted in PBS to 1×106 cells/mL. 2.5 µg/mL of JC-1 
(Chemometec, Denmark) was added to each sample. JC-1 is a negatively charged dye, which 
stains as a fluorescent red as it aggregates in the mitochondrial matrix. In the absence of 
mitochondrial membrane potential, JC-1 localises in the cytosol in its fluorescent green form. 
Following the addition of JC-1 the cells were incubated for 10-30 minutes at 37°C.  After the 
incubation, cells were washed twice with 1x PBS without disturbing the pellet, and the pellet 
was re-suspended in 0.25mL of 1µg/mL DAPI (Chemometec, Denmark). DAPI stains as 
florescent blue in late apoptotic and necrotic cells by binding to the DNA. 12.5µL of samples 
were loaded on to an A-8 slide (Chemometec, Denmark) ensuring that no air bubbles formed. 
The samples were analysed immediately using the NC-3000 image cytometry. The degree of 
apoptosis (in proportional to loss in mitochondrial membrane potential) was measured using 
a scatter plot of JC-1 red fluorescence vs JC-1 green fluorescence. 
2.8 Annexin- V assay 
The Annexin- V assay was performed to differentiate healthy cells from early and late 
apoptotic cells.  Cells were seeded in T25 flasks at 2.75x 105 cells per flask and were incubated 
for 24 h. Drugs were added as described in section 2.7. Cells were suspended in PBS at a 
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density of 4x105 cells/mL, followed by centrifugation at 400 g for 5 minutes. The supernatant 
was removed and replaced with 100 µL of Annexin V mix (94 µL of Roche buffer (BD 
Bioscience), 2 µL of Annexin V-CF488A (Santa Cruz Biotechnology, UK), 2 µL of 10 µg/mL of 
Propodium Iodide (PI) (Chemometec, Denmark), and 2 µL of Hoechst 33342 buffer (Thermo-
Scientific, UK)). Hoechst 33342 buffer in the Annexin V mix binds to all the nuclei in the sample 
and fluoresces violet. The early apoptotic cells are stained with Annexin V-CF488A, which 
fluoresces, green. The non- viable cells are stained by PI, and the late apoptotic cells are 
stained by both PI and Annexin V-CF488A, which fluoresces red, and green respectively. 
Following the addition of Annexin V mix, samples were incubated at 37°C for 20mins in the 
dark with regular mixing to keep the cells in suspension. After the incubation time elapsed, 
40 µL of samples were loaded on to an A-2 slide (Chemometec, Denmark) ensuring that no 
air bubbles formed. The samples were analysed immediately using the NC 3000 system. The 
scatter plot of the fluorescence intensity of Annexin V-CF488A vs the fluorescence intensity 
of PI was used as a representation of cells in different stages of apoptosis. 
2.9 Cell cycle analysis 
Cells were seeded, and drugs were added to the flasks as described in section 2.7. Cells were 
suspended in PBS with density closer to 1x106cells mL-1. The cells were washed twice with 1x 
PBS before the addition of 250 µl of lysis buffer (solution 10, Chemometec) supplemented 
with 10 µg/mL DAPI (solution 12, Chemometec) was added to the samples and incubated for 
5 minutes at 37ºC. After incubation, 250 µl of stabilisation buffer (solution 11, Chemometec) 
was added. 12.5 µL of Samples were loaded on to an A-8 slide ensuring that no air bubbles 
formed. The samples were analysed immediately using the NC 3000 system. 
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2.10 Caspase 3/7 assay 
Caspase 3/7 assay was carried out to determine the involvement of caspase in execution of 
apoptosis induced by CBD and CBG on ovarian cancer cells. 
  Sensolyte homogenous caspase 3/7 assay: 
Sensolyte homogenous caspase 3/7 assay kit (Anaspec, UK) was used to determine the 
caspase activity in ovarian cancer cells when treated with CBG. Cells were seeded in 96 well 
plate at 6×103 cells per well, and were incubated for 24 h. CBG was added in concentrations 
of 10 µM, 20 µM, 30  µM and 50 µM and incubated for 24 h. After the incubation time elapsed, 
the media was removed and replaced with 150 µL/well of fresh complete media. Caspase 3/7 
solution was prepared by diluting the caspase substrate 1:100 with DTT- containing assay 
buffer. 50µL/well caspase substrate was added to the plates, and the cells were incubated for 
30 mins. Ac-DEVD-AMC serves as the fluorogenic indicator for assaying caspase-3/7 activities. 
AcDEVD-AMC generates the AMC fluorophore, in the presence of caspase 3/7, which 
produces bright blue fluorescence. The fluorescence was measured by the FLOUstar OPTIMA 
plate reader with the excitation at 354nm and emission at 442nm. 
  ApoTox-Glo™ Triplex Assay (caspase 3/7 activity)  
Cells were seeded and drugs were added as described in section 2.10.1. After 24 h incubation, 
caspase 3/7 reagent was prepared by mixing caspase buffer and substrate (Promega, UK) and 
100 µL of reagent was added to each well for 30 minutes incubation at room temperature. 
The pro luminescent substrate DEVD- Aminoluciferin would be activated in presence of 
caspase3/7 enzyme. The luminescence was measured by the FLOUstar OPTIMA plate reader. 
78 
 
2.11 H2DCFDA- ROS assay 
Cells were seeded in 96 well plate at 6000 cells per well and were incubated for 24 h. Drugs 
were dissolved in ethanol, and added in concentrations ranging 10 µM, 30 µM and 50 µM 
(two rows for each concentration) 100 µM hydrogen peroxide was used as positive control 
incubated for 2 h, 3 h and 6 h time points. At each time point, media was removed from 96 
well plates and replaced with 100µL of PBS. 10 µM DCFDA (2′, 7′-dichlorodihydrofluorescein 
diacetate) reagent was added to one row each concentration and incubated for 30 minutes. 
After incubation PBS containing H2DCFDA reagent was removed and replaced with fresh 
100µL of PBS. Fluorescence was observed at maximum excitation 492nm and emission 520nm 
spectra using FLUOstar OPTIMA micro plate reader. 
 
Figure 2-2 Schematic representation of the concept of H2DCFDA- ROS assay 
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2.12 Western Blot analysis 
Cells were seeded and drugs were added as described in section 2.7. Following the drug 
incubation, cells were harvested by trypsinisation. Cells were washed twice with 5mL of 1X 
PBS. The cell pellets were homogenised in RIPA lysis buffer (100 µL) containing protease 
inhibitors (2% v/v) and incubated for 30 minutes on wet ice with occasional sonication. Cell 
homogenates were centrifuged at 13500 rpm and 4°C for 15 minutes to remove cell debris. 
The cell lysate supernatants were collected and stored at -80°C.  
Bradford assay was used to determine the concentration of proteins. Cell lysates were diluted 
using ultra-pure water.  Protein standards ranging from 250 µg/ µL - 1500 µg/ µL (Thermo 
fisher scientific, UK), and diluted lysate samples were added to 96 well plates. 250 µL Bradford 
Reagent (Life Technologies, Paisley, UK) and incubated at room temperature for 5mins. The 
absorbance was read on a Tecan Infinite 50 plate UV reader at 595 nm. 
Protein concentration was calculated, and 20 µg of protein sample was supplemented with 1 
M DTT (2 µL), LDS sample buffer (5 µl) and ultra-pure water to bring the total volume up to 
20 µL. The samples were then heated for 5 minutes at 95°C. 
The samples were resolved on polyacrylamide pre-cast gels (4-12 % tris-bis) (Thermo fisher 
scientific, UK) using Running Buffer (1X) (Thermo fisher scientific, UK) at 180 V, 400 mA for 
50mins. The gels were then, electro transferred to nitrocellulose membranes at 25 V, 400 mA 
for 2 h on wet ice using transfer buffer (1X) (Thermo fisher scientific, UK). The membranes 
were blocked in 5 % Skimmed Milk in TBST for 1 hour at room temperature. After incubation, 
the primary (1°) antibody (diluted in 5 % Skimmed Milk/ TBST) was added. The blots were 
then, incubated at 4°C on slow rotor overnight. The unbound primary antibody was washed 
by TBST (3 times with 5 minutes wash each time). The appropriate 2° antibody (1:5000 
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dilution) was added to blots and incubated for 1 hour at room temperature (in the dark).  The 
blots were washed again with TBST (3 X). A Li-cor Odyssey infrared imaging system was used 
to analyse the blots.  The contrast wavelength was chosen according to the fluorescent dye 
conjugated to secondary antibody (700nm/ 800nm). The image quality of blots were 
optimised by adjusting the intensity, brightness and contrast.  
2.13 ELISA Pathscan® Apoptosis and Stress assay 
Cells were seeded, and drugs were added to the flasks as described in section 2.7. Following 
the drug incubation, cells were harvested and cell lysates were collected using RIPA lysis 
buffer (100 µL) containing protease inhibitors (2 % v/v) as described in section 2.12 
Bradford assay was used to determine the concentration of proteins. Pathscan® stress and 
apoptosis signalling antibody array kit (Cell Signalling, USA) (Error! Reference source not 
found.) was assembled according to the manufacturer instructions. Before the addition of 
lysates to the wells, the blocking buffer (100 µL/well) was added to block non- specific binding, 
and the wells were incubated for 15 mins at 22.5°C using orbital shaking at 50 rpm. After the 
incubation, the blocking buffer was decanted, and 75 µL of lysates (500 µg/mL) were added 
to the wells, and incubated for 18 h at 4°C, 50 rpm on an orbital shaker.  Following the 
incubation time elapsed, the lysates were decanted, and the wells were washed using 1x array 
wash buffer (5 x 100 µL, 5 minutes, and 22.5 °C). Followed by the washing steps, 1 x DyLight™ 
detection antibody cocktail was added to the wells, and incubated 1 hour at 22.5 °C.  After 
the incubation, the wells were washed using 1x array wash buffer (5 x 100 µL, 5 minutes at 
22.5 °C). Followed by the washing steps, 1 x DyLight™ 680-linked Streptavidin solution was 
added, and incubated for 30 minutes at 22.5°C in darkness. After the incubation, the wells 
were washed using 1x array wash buffer (5 x 100 µL, 5 minutes, and 22.5 °C). The multi- well 
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gasket slide was removed from the pads, and the slide was washed with 10 mL ultra-pure 
water. The slide was allowed to dry. The Images were captured using LI-COR® Biosciences 
Odyssey® infrared imaging system. 
 
Figure 2-3 The plan of Pathscan® stress and apoptosis signalling antibody array kit(Cell Signaling Technology, 
2015) 
 
2.14 siRNA mediated RNAi transfection 
Low passage cells were used for siRNA transfection. A2780 cells were seeded with a density 
of 2.5*105 cells per T25 flask where as HCT116 p53+/+ cells were seeded at a density of 
2.75*105 cells/ flask. The cells were incubated for 24 h. Before transfection, siRNA was diluted 
(200nM) with OPTIMEM (Thermo fisher scientific, UK), mixed with Oligofectamine (Thermo 
fisher scientific, UK) for a liposomal siRNA formation. The flasks were washed two times with 
3mL of OPTIMEM, followed by the addition of 2mL of OPTIMEM to each flask with dispenser. 
0.5mL of siRNA and mix was added to each flask drop by drop. The flask was moved zigzag 
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manner (keeping it flat) to increase the efficiency of transfection. The flasks were incubated 
for 5 h. After the incubation time elapsed, 2.5mL of feed media (2X complete media) was 
added to flask using dispenser (final volume of media in flask was 5mL) and incubated further 
for 48 h and 72 h. 
After the incubation time elapsed, the cells were harvested using trypsin, and the cells were 
washed twice with ice cold PBS. The PBS was carefully removed and cell pellets were stored 
at -80oC. 
2.15 mRNA extraction 
Total mRNA was extracted from the cell pellets using a RNeasy mini kit (Qiagen, UK). The cells 
were disrupted by adding 600 µL of RLT buffer (0.1% beta mercaptoethanol). Lysates were 
transferred onto QIAshredders (Qiagen, UK), centrifuged for 2min at 16000g for 
homogenisation. 600 µL of 70% ethanol was added to lysates. 700 µL sample was transferred 
into RNeasy column placed in a 2mL collection tube. It was spun down at 9000g for 15s. The 
flow through was discorded. 350 µL of RW1 was added to spin column and centrifuged for 
15s at 9000g. The flow through was discorded. Each sample was treated with 10 µL DNAase 
in 70 µL of RDD buffer solution to digest the residues of cellular DNA, and incubated at room 
temperature for 30 mins. The columns were treated with 350 µL of RW1 and centrifuged for 
15s at 9000g. 500 µL of RPE buffer was added to RNeasy column and, centrifuged at 9000g 
for 15s. Column was washed again with RPE buffer and centrifuged for 2mins. The flow 
through was discorded. RNeasy column was placed in a new 2mL collection tube and 
centrifuged at 16000g for 2mins. RNeasy column was placed in a new 2mL collection tube, 
followed by addition of 50 µL of RNase- free water. RNeasy column was centrifuged for 1 min 
at 9000g.  RNA from collection tube was carefully transferred into new 1.5mL centrifuge tube. 
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mRNA was quantified by using the nanodrop2000 (Thermo fisher scientific, UK), a sample 
retention spectrophotometer. 
2.16 Reverse transcription (cDNA synthesis): 
cDNA was synthesised from the mRNA using a Precision nanoScript2 reverse transcription Kit 
(Primer Design, UK). 2µg of RNA template was used for reverse transcription. The dilutions 
were made with DNase/ RNase free water to make the final volume of 8µL. 1µL of oligo-dT 
primers and 1µL of random nanoprimers were added to each of the samples. Samples (10µL) 
were then transferred to the thermocycler, and incubated at 65°C for 5 mins. This step is 
called the annealing step, in which the RT primers are annealed to the denatured RNA 
.Following the annealing step, samples were immediately transferred onto wet ice to avoid 
RNA degradation. 10µL of reverse transcription mix containing 5µL of 4x nanoscript buffer, 
3µl of RNase- free water, 1µL of 10mM dNTP mix, and 1µL nanoscript enzyme was added to 
each sample. The samples (20µL) were then transferred to thermocycler for ‘extension step’. 
During the extension step, samples were incubated at 25oC for 5 min, followed by the 
incubation at 42oC for 20mins. The reaction was heat inactivated by incubating samples at 
72oC for 10 mins. cDNA samples were collected, and stored at -20oC. 
2.17 Real-Time qPCR 
A Precision FAST qPCR Master Mix was used for the real-time qPCR. 50ng of cDNA was used 
as a template for the reaction.  DNase/ RNase free water was used as a control, and mRNA 
with no RT (reverse transcription) was used as a negative control. 5 µL of cDNA (diluted using 
DNase/ RNase free water) was added to each well in a 96 well plate. 15 µL of  master mix 
containing 10 µL of precision FAST mix, 4 µL of DNase/ RNase free water and 1 µL of 20X 
TaqMan probe (GAPDH/ GUSB/GPR55/ CB1/ CB2) was added to each well.  The Step one real 
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time qPCR system was used for amplification. Plate design was edited according to the 
experimental plan. The steps involved in the amplification protocol were activation of the 
enzyme by hot start for 2min at 95°C, denaturation step at 95°C for 5sec followed by annealing 
and extension steps at 60°C for 20 sec, where the data was collected after each cycle. The 
final data was collected after 40 cycles, and it was analysed using a Stepone v2.3 software and 
Microsoft excel. 
2.18 Statistical Analysis 
Statistical analysis were carried out using Graph pad 7, one-way ANOVA with Dennett’s multi 
comparison test. P values of <0.05 were considered to be statistically significant compared to 
control values.   
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CHAPTER 3: Evaluation of CBD and CBG cytotoxicity towards ovarian 
cancer cells in vitro 
3.1 Introduction 
CBD and CBG have been shown to exert in vitro anticancer activity on breast, prostate and 
colon cancer cell lines (Dariš et al., 2018). The purpose of this chapter is to evaluate the 
activity against ovarian cancer cells A2780, cisplatin resistant A2780/CP70 cells, and OVCAR-
3 cells. Selective cytotoxicity of CBD and CBG towards ovarian cancer is determined by 
comparing their cytotoxicity towards non- cancer cells ARPE19 and PNT2. Cytotoxicity and 
selectivity is compared to that of the palatinate carboplatin, which is in use for treatment of 
ovarian cancer. 
3.2 Results 
  Solvent/ Vehicle effect on A2780 viability: 
Cannabinoids are highly soluble in ethanol so it was used as a solvent to dissolve CBD and 
CBG. Whilst a solvent control was used in all experiments, it was important to determine the 
toxicity of ethanol at different concentration to identify non- toxic concentrations on ovarian 
cancer cells.  
A2780 cells were seeded at 1500 cells per well (7500cells mL-1), and incubated for 24 h. After 
incubation time elapsed, ethanol (1%, 0.1% and 0.01%) or media were added to the 
corresponding wells. The plates were then incubated for a further 24 h, 48 h, and 72 h. After 
the allocated contact time had elapsed, MTT assays were carried out as described in section 





Figure 3-1 Solvent or vehicle effect on A2780 cell viability:  Viability of A2780 Cells treated with 0.01%, 0.1% and 
1% ethanol compared to control cells (cells with complete media) at 24 h, 48 h and 72 h. Data represents the mean 
± standard error of mean of n=3, n is the number of independent biological experiments. 
The viability of A2780 cells were unaffected by ethanol up to a concentration of 1% (Figure 
3-1). The effect of ethanol concentration above 1% on ovarian cancer cells was not tested, as 
it was the maximum concentration of solvent control required which was added to the cells.  
3.2.1.1 Effect of vehicle/ solvent concentration on CBD cytotoxicity: 
The solubility of CBD in ethanol and its cytotoxic effect when it was dissolved in pure ethanol 
and 10% ethanol was tested on A2780 cells.  A2780 cells were seeded at 1500 cells per well 
(7500cells mL-1) and, incubated for 24 h. After 24 h, CBD was serial diluted separately in 
absolute and 10% ethanol (90% complete media) to prepare a concentration range from 100 
nM to 10 mM. 2 µL of different concentrations of CBD (1nM to 100 µM final concentrations) 
diluted in absolute and 10% ethanol were added to corresponding wells in each plate. The 
87 
 
plates were incubated further for 24 h, 48 h, 72 h and 96 h. After the allocated contact time 
had elapsed, MTT assay was carried out to determine the viability of cells 
CBD diluted in absolute ethanol had shown the IC50 values ranged from 3.46 µM to12.3 µM 
whereas CBD diluted in 10% ethanol was ranged from 9.09±0.83 µM to 18.88± 0.7 µM. 
Despite the fact that CBD diluted in both absolute and 10% ethanol did not form any detected 
precipitation, the above results had shown that CBD has more potency when pure ethanol is 
used as a vehicle. This could be due to undetected precipitation or the instability of compound 
when dissolved in 10% ethanol compared to absolute ethanol. Based on the results obtained 
(Figure 3-1, Table 3-1), 1% ethanol was used as vehicle for further experiments. 
Table 3-1. The mean IC50 values of CBD on A2780 cells with 0.1% and 1% ethanol respectively 
 
 
 In vitro anticancer activity of CBD: 
The effects of CBD were investigated on ovarian cancer cell lines (A2780, A2780 CP70, IGROV 
and OVCAR 3) and non- cancer cells include PNT2 (prostate cells) and ARPE19 (retinal 
epithelial cells). A2780 and A2780/CP70 cells were seeded at density of 1500 cells per well, 
IGROV and ARPE19 were seeded at density of 2000 cells per well whereas OVCAR-3 and PNT2 
were seeded at 3000 cells per well. After 24 h incubation, different concentrations of CBD or 
vehicle were added to corresponding wells. The plates were further incubated for 24 h, 48 h, 





Figure 3-2. In vitro cytotoxicity of CBD. The effect of CBD (1 nM to 100 µM) on ovarian cancer cells A2780, 
A2780/CP70 and non- cancer cells ARPE19 (retinal epithelial) and  at 24 h (a), 48 h(b), and 72 h (c), and 96 (d) 
hour time points. The effect of CBD on cell viability as indicated by absorbance at 540 from dissolved formazan 
crystals compared to vehicle control. Data represents the mean ± standard error of n=4, n is the number of 
independent biological experiments. 
CBD (1 nM- 100 µM) induced dose-dependent cytotoxicity in the ovarian cancer cells. CBD 
exerted cytotoxic effects evidently from 1 µM on all the cell lines tested (Figure 3-2). The 
dose-response curves to CBD on ovarian cancer cells (A2780, A2780 CP70) compared ARPE19 
and PNT2 cells after 24 h, 48 h, 72 h and 96 h exposure indicated increase in activity towards 
the cancer cells. CBD was shown to be more potent in inducing cytotoxicity in A2780 cells 
compared cisplatin resistant A2780/CP70 cells at all the time points tested. 
Table 3-2 IC50 values for CBD induced cytotoxicity on ovarian cancer A2780, A2780/CP70, OVACAR-3 cells and 





Figure 3-3 The IC50 values of CBD. IC50 values of CBD on A2780, A2780/CP70, ARPE19 and PNT2 cells at 24 h, 48 
h, and 72 h, and 96 h time points. Data represents the mean ± standard error of mean of n=4. n is the number of 
independent biological experiments. **P<0.01 and ***P<0.001 (AREPE19), ###P<0.001 (PNT2). 
The cytotoxicity of CBD increased with exposure time on all the cell lines tested. Amongst the 
cell lines tested, CBD was shown the highest potency on A2780 ovarian cells with lower IC50 
values (12.3 ± 0.7 µM, 6.84± 1.07 µM, 4.47± 0.15 µM and 3.46± 0.17 µM). Furthermore, CBD 
was shown lower IC50 values in ovarian cancer A2780 and A2780/CP70 cells to non-cancer 
cells at all the time points tested.  At 96 h contact time, the IC50 values were significantly lower 
on ovarian cancer cells compared to PNT2 non- cancer cells. 
3.2.2.1 Preferential Cytotoxicity of CBD: 
Any preferential cytotoxicity of CBD cancer cells was compared to non-cancer cells by 
calculation of the selectivity index. Mean IC50 values (n=4) on each ovarian cell lines were 
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compared with non- cancer cells ARPE19 and PNT2 separately for 24 h, 48 h, 72 h and 96 h 
time points. 
SI= N ÷ C                                                     (Section 2.5.6) 
SI = Selectivity Index 
N= Mean IC50 on non- cancer cells 
C= Mean IC50 on cancer cells            
If SI > 1, this means the drug shows preferential cytotoxicity towards cancer cells, if S1= 1, it 
means it is equally toxic to both cancer and non- cancer cells. If S1<1,  this means it is more 
toxic to non- cancer cells than cancer cells (Allison et al., 2018) 
 
Figure 3-4. The selective index of CBD against ARPE19 and PNT2. The selectivity index values of CBD on ovarian 
cancer cells A2780, A2780 CP70, OVCAR 3 (based on mean IC50 values) against non- cancerous cells ARPE19 and 
PNT2 after 24 h, 48 h, 72 h, and 96 h time points. Data represents the mean of n=4, n is the number of 
independent biological experiments. 
CBD was shown to induce the preferential cytotoxicity in ovarian cancer cells A2780 and 
A2780/CP70 cells compared to ARPE19 and PNT2 at all the time points tested. The cancer 
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selectivity of CBD increased with increasing exposure time. CBD was shown selectivity 
towards OVACAR-3 only after 96 h exposure.  
 In vitro anticancer activity of CBG: 
Similar experiments were performed to evaluate the activity of CBG on ovarian cancer and 
non-cancer cells as described in section 3.2.2 IC50 values were achieved from dose response 
of CBG (1 nM- 100 µM) on the cell lines. The results are summarised (Figure 3-5, Figure 3-6, 







Figure 3-5. In vitro cytotoxicity of CBG. The effect of CBG (1 nM to 100 µM) on ovarian cancer cells A2780, 
A2780/CP70 and non- cancer cells ARPE19 (retinal epithelial) and  at 24 h (a), 48 h(b), and 72 h (c), and 96 (d) 
hour time points. The effect of CBG on cell viability as indicated by absorbance at 540 from dissolved formazan 
crystals compared to vehicle control. Data represents the mean ± standard error of n=4, n is the number of 
independent biological experiments. 
CBG has induced cytotoxicity in a dose-dependent manner in all cells. The cytotoxicity effects 
of CBG increases with drug exposure time (Figure 3-5). The pattern of CBG cytotoxicity 
towards all the cells tested was also similar to CBD, where A2780 cells were the most 
sensitivity followed by A2780/CP70, OVCAR-3 cells were the least sensitive ovarian cancer 
cells when treated with CBG (Figure 3-5).  
 





Figure 3-6 The IC50 values of CBG. IC50 values of CBG on A2780, A2780 CP70, ARPE19 and PNT2 cells at 24 h, 48 
h, and 72 h, and 96 hour time point (a& b). It represents the mean ± standard error of n=4, n is the number of 
independent biological experiments. **P<0.01 and ***P<0.001 (AREPE19). ##P<0.01 and ###P<0.001 (PNT2) 
 The IC50 values of CBG are lower in ovarian cancer cells A2780 and A2780/ CP70 cells 
compared to non- cancerous cells except for OVCAR-3 cells where IC50 values are close to both 
ARPE19 and PNT2 cells at all the time points tested (Figure 3-6). 
3.2.3.1 Preferential Cytotoxicity of CBG:  
Any preferential cytotoxicity exerted by CBG towards ovarian cancer cells when compared to 
non-cancer cells was determined by calculation of the selective index. 




Figure 3-7. The selective index of CBG against ARPE19 and PNT2. The selectivity index values CBG on ovarian 
cancer cells A2780, A2780 CP70, OVCAR 3 (based on mean IC50 values) against non- cancerous cells ARPE19 and 
PNT2, after 24 h, 48 h and 72 and 96 h time points. Data represents the mean of n=4, n is the number of 
independent biological experiments 
Similar to CBD, CBG was shown the preferential cytotoxicity towards ovarian cancer cells 
A2780 and A2780/CP70 compared to ARPE19 and PNT2 at all the time points tested. After 96 
h exposure, CBG was equally toxic to OVCAR-3 and non-cancer cells with selective index value 
closer to 1. 
In comparing the cytotoxicity of CBD and CBG, CBD induced greater cytotoxicity with lower 
IC50 values towards the ovarian cancer cells tested compared to CBG. CBD and CBG both were 
shown their preferential cytotoxicity towards ovarian cancer cells A2780 and A2780/CP70 
compared to ARPE19 and PNT2. Among all the time points tested, CBD and CBG were shown 
their highest selectivity towards cancer cells after 96 h exposure. However, OVACAR 3 seemed 
to be resistant to both cannabinoids. There was not any significant difference in preferential 
cytotoxicity between CBD and CBG. However, CBD is appeared to be preferable because of its 
lower IC50 values and slightly better selective indices. 
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 Cytotoxicity of CBD and CBG with drug washout experiments: 
It was important to investigate whether the anticancer activities of CBD or CBG are due to 
rapid toxicity or anti-proliferative effects, which for example growth arrest of cells. So further 
investigations were carried out where both A2780 and A2780/CP70 cells were treated with 
CBD and CBG, and cells were allowed to recover from drug exposure after each time point by 




Figure 3-8 Comparison of cytotoxic effects of CBD in normal vs drug washout MTT assays. MTT assays were 
used to compare the cytotoxic effects induced by CBG after each time point and the cytotoxic effects of CBD when 
the cells were allowed to recover from drug exposure; the time points assayed were 24, 48 and 72 h. Graph a& 
d represents the 24 h exposure of CBD whereas b& e represents 48 h and, c& f represents 72 h on A2780 and 
A2780 CP70 cells respectively (n=4) 
Table 3-4. The comparison between the IC50 values of CBD on A2780 cells, when cells were allowed to recover 
after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure. 
 
Table 3-5. The comparison between the IC50 values of CBD on A2780/CP70 cells, when cells  were allowed to 
recover after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure 
 
There was no significant difference observed in dose-responses of CBD between the MTT 
assay performed after each time point to the drug washout experiments, where the cells were 
allowed to recover from drug exposure, on both ovarian cancer cells at all the time points 
tested (Figure 3-8, Table 3-4,& Table 3-5) 
Similar experiments were carried out with CBG on A2780 and A2780/CP70 cells. Results are 





Figure 3-9 Comparison of cytotoxic effects of CBG in normal vs drug washout MTT assays. MTT assays were 
used to compare the cytotoxic effects induced by CBG after each time point and the cytotoxic effects of CBG when 
the cells were allowed to recover from drug exposure; the time points assayed were 24, 48 and 72 h. Graph a& 
d represents the 24 h exposure of CBG whereas b& e represents 48 h and, c& f represents 72 h on A2780 and 
A2780/CP70 cells respectively (n=4) 
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Table 3-6 The comparison between the IC50 values of CBG on A2780 cells, when cells were allowed to recover 
after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure. 
 
Table 3-7. The comparison between the IC50 values of CBG on A2780/CP70 cells, when cells were allowed to 
recover after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure. 
 
Similar to CBD, the IC50 values achieved by CBG with the instant MTT assays, and the cell 
recovery chemo sensitive assays were not significantly different from each other at 24 h, 48 
h and 72 h exposure on both A2780 and A2780 CP70 (Table 3-6 and Table 3-7).  
There was no significant difference in the dose-responses data generated by the drug 
washout chemo sensitive assays and the instant MTT assays with CBD and CBG treatment. 
These results indicate that both cannabinoids exert irreversible cytotoxic effects on ovarian 
cancer cells. 
 Cytotoxicity of Carboplatin: 
Carboplatin is one of the currently using chemotherapeutic drugs for ovarian cancer 
treatment. It was important to compare the effects of carboplatin with CBD and CBG on 
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ovarian cancer cells. The cytotoxic effects of carboplatin were investigated with different drug 
exposure times (24 h, 48 h, 72 h and 96 h) on A2780 and A2780/CP70 cells. Both normal MTT 
assays (section 2.5.3), and drug washout assays (section 2.5.4) were carried to investigate the 
difference in dose responses of carboplatin. 
Carboplatin did not induce cytotoxicity when MTT assay was performed immediately after 24 
h exposure in both the cell lines tested. However, the drug washout experiments where 
carboplatin was removed after 24 h, and cells were left in fresh complete media, and MTT 
was carried out after 72 h showed the greater cytotoxicity at concentrations higher than 1 
µM. The maximum viability occurred around 5% at the highest concentration of 100 µM.  
Similar profile of response was observed when carboplatin was intact for 48 h. However, there 
was no significant difference between cytotoxicity induced by carboplatin at all the 
concentrations tested when cells were exposed to 72 h in both the conditions, and 
cytotoxicity response curves of carboplatin were superimposable after 72 h exposure (Figure 




Figure 3-10 . Chemosensitive dose-response curves of A2780 and A2780/CP70 to carboplatin. The difference in 
cytotoxic effects of carboplatin (1 nM to 100 µM) on A2780 and A2780 CP70 when MTTs were performed 
normally after each time point to drug washout experiments. Graph a& d represents the 24 h exposure of 





Table 3-8 The comparison between the IC50 values of carboplatin on A2780 cells, when cells were allowed to 
recover after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure. 
 
Table 3-9. The comparison between the IC50 values of carboplatin on A2780 CP70 cells, when cells were allowed 
to recover after each time point, and instant MTT viability assay after 24 h, 48 h and 72 h drug exposure. 
 
Chemo sensitivity assays carried out immediately after each time point showed that the IC50 
values of carboplatin were higher than 100 µM on both A2780 and A2780/CP70 cells after 24 
h and 48 h. However, after similar exposure times where the cells were allowed to recover, 
carboplatin exerted cytotoxicity on A2780 with IC50 values 7.95±0.51 µM and 4.79±0.24 µM, 
on A2780/CP70 cells with 66.5 ±0.35 µM and 48.7 ±0.4 µM respectively with drug washout 
chemo sensitivity assay. This might be because of the mechanism of action of carboplatin, 
which will be analysed further in discussion (Table 3-8 and Table 3-9). 
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 Comparison of carboplatin selectivity towards ovarian cancer cells 
compared to CBD and CBG: 
 The preferential cytotoxicity of carboplatin towards ovarian cancer cells against ARPE19 cells 
were investigated. The results were compared against CBD and CBG. Figure 3-11, Figure 
3-12& Figure 3-13 
 
Figure 3-11. The comparison of chemosensitivity of carboplatin against CBD and CBG on ARPE19 cells. The 
difference in dose-response curves of carboplatin on ARPE19 cells after 96 h exposure was compared with dose 
responses of CBD and CBG against ARPE19 cells. Each point represents mean± s.e mean of n=4. 
The cytotoxicity effects of carboplatin on ARPE19 cells exerted an IC50 value of 83.62 ±0.4 µM 
after 96 h exposure. This was higher to the IC50 value exerted by carboplatin on A2780 (2.57 
±0.3 µM) and A2780/ CP70 cells (44.9±3.5 µM). 
The preferential selectivity of carboplatin towards ovarian cancer cells against ARPE19 was 





Figure 3-12 Comparison of Selectivity Index. The selectivity index of carboplatin on A2780 (left) and A2780/CP70 
(right) cells against ARPE19 cells were compared with selectivity index of CBD and CBG after 96 h exposure.  
Carboplatin was shown better preferential cytotoxicity towards A2780 cells when compared 
to CBD and CBG. However, CBD and CBG were shown better selectivity index towards cisplatin 
resistant A2780/ CP70 cells compared to carboplatin after 96 h exposure (Figure 3-12).  
 Comparison of carboplatin resistance factor with CBD and CBG in ovarian 
cancer cells 
The resistant factor values for carboplatin, CBD and CBG were calculated by using the ratio of 
the mean IC50 values of the compounds on cisplatin resistant A2780/ CP70 cells to the mean 
IC50 values of the compounds on cisplatin sensitive A2780 cells. The cross resistance towards 
cisplatin resistance cells was determined by resistance factor calculation (McDermott et al., 
2014) 
RF = R ÷S                          (Eq. 4) 
RF= Resistant factor 
S= Mean IC50 values of the compounds on sensitive cell line 





Figure 3-13. Comparison of Resistant factor. The difference between the resistance factor values of carboplatin, 
CBD and CBG after 24 h, 48 h, 72 h and 96 h contact times. Each value represents the mean ± s.e mean of n=4. 
The resistant factor values for carboplatin, CBD and CBG indicated that all the compounds 
were less sensitive towards cisplatin resistant cells. CBD and CBG exerted RF values <2 at all 
the time points tested. However, carboplatin was shown much higher RF values with 
maximum up to 17.83 (Figure 3-13).  Even though carboplatin seemed to be more potent on 
A2780 cells with higher selectivity index, CBD and CBG exerted almost similar cytotoxic effects 
on both cisplatin-sensitive and cisplatin resistant cells. 
3.3 Discussion 
The results from chemosensitivity experiments indicated that both CBD and CBG have 
micromolar potency towards all three human ovarian cancer cell lines tested which included 
the cisplatin- and carboplatin- resistant line A2780/CP70. The IC50 values of CBD and CBG on 
A2780, A2780/CP70, and OVACAR 3 ovarian cancer cells are consistent with other published 
reports of activity against breast and prostate cancer cells at similar doses (Izzo et al., 2009, 
Ligresti  et al., 2006) 
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IC50 values for CBD were slightly lower than for CBG for the three ovarian cancer cell lines 
tested at all the time points indicating that CBD is more potent compared to CBG against 
A2780, A2780/CP70, and OVACAR-3. This is similar to studies in MCF-7 and breast cancer cell 
lines, which also indicated CBD to be the more potent cannabinoid (Ligresti  et al., 2006). CBG 
induced selective cytotoxicity towards oestrogen receptor positive MCF-7 (9.8± 3.4 µM) cells 
compared to oestrogen negative cells, MDA-MB-231 (16.2± 2.1 µM)  whereas CBD induced 
similar cytotoxicity in both MCF-7 (8.2± 0.3 µM) and MDA-MB-231 (10.6± 1.8 µM) cell lines. 
This suggests CBG can be a potential anti-cancer compound for oestrogen positive ovarian 
carcinoma (Ligresti  et al., 2006).  
CBD and CBG on ovarian cancer cells showed their highest selectivity towards cancer cells 
after 96 h exposure, suggesting the cancer selective cytotoxic effects of CBD and CBG 
increased with exposure that is more prolonged. However, both cannabinoids were much less 
active against OVACAR-3 cancer cells with IC50 values similar to those of CBD and CBG towards 
the two non-cancer cell lines tested. OVCAR-3 cells were developed from malignant ascites of 
a patient with progressive adenocarcinoma of the ovary, which was refractory to the 
combination of Adriamycin, melphalan and cisplatin  chemotherapy drugs used as treatment, 
so the cross-resistance could be a possible reason for the lower potency of the cannabinoids 
towards OVCAR-3 cells (Hamilton et al., 1983). 
MTT assay is considered the gold standard cell sensitivity assay by many researchers. Since 
mitochondrial dysfunction considered as a common indicator for many cellular pathological 
processes. MTT assay rely on intracellular NAD (P) dependant oxidoreductases, which are 
produced by functional mitochondria. The production of NAD (P) dependant oxidoreductases 
also affected in a viable cell with reduced mitochondrial activity (Jaszczyszyn and 
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Gasiorowski., 2008, Surin. et al., 2017). However, microscopic observation of ovarian cancer 
cells treated with CBD/CBG in well plates developed for MTT, were shown 50% of growth 
inhibition at a concentration range similar to the IC50 values obtained by MTT assay. 
The drug washout chemosensitivity assays showed that both CBD and CBG exerted similar 
IC50 values to the values generated by normal MTT assay after the corresponding time points. 
This indicates that the effects of CBD and CBG did not change with the cell recovery time, 
suggesting irreversible cytotoxic effects of the cannabinoids on the ovarian cancer cells. 
IC50 values exerted by carboplatin by drug washout chemosensitivity assay were significantly 
lower than the values generated by conventional MTT assay at 24 h and 48 h: this could be 
because of carboplatin mechanism of action. The cytotoxicity mechanism of carboplatin 
involves its binding to DNA thus inhibiting transcription and replication as well as the 
generation of DNA damage which may result in cell cycle arrest or if the damage is not 
repaired cell death by apoptosis or other mechanisms. This complex mechanism would take 
a longer time to effect on mitochondrial function (Sousa et al., 2014). 
The selectivity index of carboplatin towards the A2780 ovarian cancer cell line compared to 
the non-cancer ARPE19 cells indicates that carboplatin is more cancer cell selective in its 
cytotoxicity than CBD or CBG. However, when the relative cytotoxic effects of the drugs on 
cisplatin resistant A2780/CP70 cells and the parental cisplatin sensitive A2780 cells were 
tested the resistance factor values of carboplatin, CBD and CBG indicated that carboplatin 
had a greater than 9 fold resistance factor compared to CBD and CBG.  This could be due to 
the cross-resistance mechanism of cisplatin resistant ovarian cancer cells towards carboplatin 
(Gore et al., 1989). 
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The lower resistance factors (< 2) of both CBD and CBG indicate that they exerted similar 
cytotoxic effects on both cisplatin sensitive and cisplatin resistant cells. Based on these data, 
further investigations were carried out to determine whether CBD or CBG when combined 
with current ovarian cancer chemotherapy drugs could increase their efficacy towards 
ovarian cancer cells.  
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CHAPTER 4: Evaluation of the combination effects of CBD/ CBG with 
the chemotherapeutic drugs, In Vitro 
4.1 Introduction 
The development of a malignant tumour is associated with a series of complex genetic 
mutations and alteration of multiple pathways, which makes cancer a difficult disease to 
treat. The fact that ovarian cancer associated with a diversity of mutations and histological 
types, it is difficult to get the desired therapeutic effect with a single drug (Natarajan et al., 
2018, Kashif et al., 2015, Humphrey et al., 2011).  The combination of drugs that exert 
different or non-overlapping mechanisms of action could improve the therapeutic effect. The 
different mechanisms of action also helps to overcome the drug resistance, which is a 
significant challenge in cancer treatment. Drug combinations can also sometimes reduce the 
considerable side effects of drugs, as lower, less toxic concentrations are required in the 
combination compared to single drug treatments  (Kashif et al., 2015).  However, side effects 
such as hypersensitive reactions, and the accumulation of toxicities of current combination 
treatments highlight the need to investigate potential compounds for combination therapies 
to treat cancer (Kashif et al., 2015, Fotopoulou, 2014). 
This chapter will be focused on the combination effects of CBD with CBG, carboplatin, and 
paclitaxel (Taxol) to determine the most potent combination for ovarian cancer cells.  
Carboplatin and Taxol are both currently used for ovarian cancer chemotherapy (Fotopoulou, 
2014). 
4.2 Results 
 Combination effects of CBD with CBG 
CBD and CBG used in this combination experiments were supplied by the GW 
Pharmaceuticals, UK. The purity of the compounds was tested using LC-MS. The cytotoxic 
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effects of CBD and CBG were provided by GW Pharmaceuticals, UK was compared against CBD 
and CBG purchased from Tocris, UK. 
 
Figure 4-1. Dose- response curves of CBD and CBD after 72 h. The Representative comparison of dose-response 
curves of CBD, and CBG supplied by GW pharmaceuticals and Tocris on A2780 (a& c) and A2780/CP70 (b& d) 
cells after 72 h. The effect of CBD on cell viability as indicated by absorbance at 540 from dissolved formazan 
crystals compared to vehicle control. Data represents the mean ± standard error of mean of n=4, n is the number 
of independent biological experiments. 
As shown in Figure 4-1, the dose-response curves of CBD and CBG supplied by Tocris and GW 
pharmaceutical were overlapping at 72 h contact times tested. Similar results were observed 
at 24 h, and 48 h indicates that the there is no difference in the compounds supplied by both 
the companies. Therefore, the experiments conducted using CBD and CBG provided by GW 
pharmaceuticals are comparable to the other experiments where the compounds were 
purchased from Tocris, UK. 
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The combination effect of CBD and CBG was investigated on A2780 and A2780/CP70. The cells 
were seeded in 96 well plates and incubated for 24 h. After incubation, different 
concentrations of CBD and CBG drugs were prepared at different ratios (1:1, 1:5 and 5:1) of 
concentration- response curves were constructed for each ratio from 1 nM to 100 µM. 2 µL 
of combination mix was added to corresponding wells. The plates were further incubated for 
24 h, 48 h and 72 h. When the allocated time elapsed, MTT assay was performed. IC50 values 




Figure 4-2 CBD in combination with CBG. The representative comparison of dose-responses of CBD alone to CBG 
alone and CBD and CBG in 1:1 combination on A2780 and A2780/CP70 cells after 24 h(a& d), 48 h (b& e) and 72 
h (c& f) contact times. Graph a& d represents the 24 h exposure whereas b& e represents 48 h and, c& f represents 
72 h on A2780 and A2780 CP70 cells respectively (n=4) 
CBD alone on A2780, A2780/CP70 cells was more effective than CBG alone and CBD in 
combination with CBG (1:1) (Figure 4-2). Amongst the combinations tested, CBD: CBG 5:1 
showed better cytotoxic effects followed by CBD: CBG 1:1 and 1:5 respectively on both the 
cell lines. 
Table 4-1 The IC50 ( µM) values of CBD alone, CBG alone and, CBD:CBG (1:1, 1:5, 5:1) on both A2780 and 
A2780/CP70 cells after 24 after 24 h, 48 h and 72 h contact time 
 
The IC50 values demonstrated by CBD alone on A2780, and A2780/CP70 cells were lower than 
CBG alone and all the combinations of the compounds tested. Among the cannabinoid 
combinations, IC50 values of CBD in combination with CBG 5:1 were closer to the IC50 values 
of CBD alone, followed by CBD/CBG 1:1 and 1:5 respectively. Based on the results (Figure 4-2 
& Table 4-1) it was observed that the combination of CBD and CBG did not increase the 
potency of CBD. 
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 Carboplatin in Combination with CBD or CBG:     
4.2.2.1  Carboplatin in Combination with CBD or CBG on A2780 cells: 
The combination effects of CBD or CBG on ovarian cancer cells were investigated when 
combined with carboplatin. The sub-lethal concentrations (100 nM) of CBD or CBG on ovarian 
cancer cells were taken as a constant in combination to carboplatin (1nM- 100 µM). The cells 
were seeded in 96 well plates and incubated for 24 h. The following day the plates were 
treated with 100 nM CBD or CBG, and incubated for 30 minutes. After the incubation time 
elapsed, the plates were treated with carboplatin with the dose ranges from 1 nM to 100 µM 
to the corresponding wells. The plates were further incubated for 24 h, 48 h, 72 h and 96 h 
contact times. After each time point (24 h, 48 h and 72 h), the media was removed from 96 
well plates, and were washed with PBS to remove any remaining drug. The wells were 
replaced with 200 µl of complete media. Cells were allowed to recover up to 96 h from initial 








Figure 4-3 Carboplatin in combination with 100 nM CBD or 100 nM CBG on A2780 cells. Comparison between 
carboplatin alone to carboplatin in combination with 100 nM CBD and carboplatin in combination with 100 nM 
CBG. 1% ultrapure water was used as a solvent control for carboplatin alone whereas 100 nM CBD and 100 nM 
CBG were used as a control for combination. Graph a) represents 24 h, b) represents 48 h, c &d represents 72 h 
and 96 h respectively. The viability of A2780 cells with 1% ethanol (control) were compared to the viability with 
100 nM CBD and 100 nM CBG at 24 h (e), 48 h (f), 72 h (g), and 96 h (h). **P<0.01 and ***P<0.001.  (n=4) 
As can be seen in Figure 4-3 , when carboplatin was used in combination with 100 nM CBD 
the cytotoxic effect of carboplatin was improved at all the time points tested. The 
combination of 100 nM CBG plus carboplatin induced superimposable concentration 
response curves. The results indicate that CBD, when used at non- toxic concentrations, in 
combination with carboplatin induces greater cytotoxicity compared to the effects of 
carboplatin alone on both the ovarian cancer cells. 
 
Figure 4-4 IC50 values of carboplatin alone, and in combination with CBD or CBG in A2780 cells. The comparison 
of IC50 values of Carboplatin alone, and carboplatin when combined with 100 nM CBD or 100 nM CBG on A2780 
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cells at 24 h, 48 h, 72 h, and 96 h. It represents the mean ± standard error of mean of n=4, **P<0.01 and 
***P<0.001 
That carboplatin in combination with 100 nM CBD shown significantly (P< 0.001) lower the 
IC50 values (2.91± 1.62 µM, 0.82± 0.62 µM, 0.82± 0.13 µM and 0.23± 0.13 µM) compared to 
carboplatin alone (7.9± 0.5 µM, 4.7± 0.2 µM, 2.6± 0.5 µM and 2.5± 0.3 µM). Carboplatin in 
combination with 100 nM CBG showed the IC50 value 1.46± 0.5 µM significantly (p<0.01) lower 
than carboplatin alone treatment at 96 h exposure (Figure 4-4)  
In order to investigate CBD or CBG induce additive or synergistic effects when combined with 
carboplatin, the combination Index was calculated. It has accepted that If CI between 0.90 
and 1.10 indicates additivity; CI below this range indicates synergism and above this range 
indicates antagonism (Liang Zhao, 2004). The combination Index (CI) for CBD or CBG when 
combined with drug Carboplatin was calculated by the ratio of the applied concentration of 
CBD or CBG (100 nM) in the combination to the IC50 of CBD or CBG when it was applied 
individually, the ratio of the applied concentration of carboplatin in the combination 
(combination IC50 – 100 nM), to IC50 of B on the cells. 
 
CI = (100 nM ÷ the IC50 of CBD or CBG) + (carboplatin concentration in combination IC50 ÷ the 
IC50 of CBD or CBG) 
For e.g.   The CI of carboplatin in combination with CBD at 24 h contact time on A2780 cells 
Concentration of CBD in the IC50 of the combination = 100 nM (0.1 µM) 
Concentration of carboplatin in the IC50 of the combination= 2.91 µM – 0.1 µM = 2.8 µM 
The IC50 of CBD on A2780 cells at 24 h = 12.3 µM 
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The IC50 of Carboplatin on A2780 cells at 24 h = 7.9 µM 
So, 
CI [CBD + CARBOPLATIN] = (0.1 ÷ 12.3) + (2.8 ÷ 7.9) = 0.36 
The CI values of carboplatin in combination with CBD at 24 h (0.36), 48 h (0.17), 72 h (0.15), 
and 96 h (0.096) suggested the strong synergism effect. Whilst CBG has shown synergism with 
carboplatin only after 96 h exposure (CI = 0.55). 
4.2.2.2 Carboplatin in Combination with CBD / CBG on A2780/ CP70 cells: 
Similar experiments to A2780 cells were carried out on A2780/ CP70 cells.  The results were 






Figure 4-5 Carboplatin in combination with 100 nM CBD or 100 nM CBG on A2780/CP70 cells. The comparison 
between carboplatin alone to carboplatin in combination with 100 nM CBD and carboplatin in combination with 
100 nM CBG. 1% ultrapure water was used as a solvent control for carboplatin alone whereas 100 nM CBD and 
100 nM CBG were used as a control for combination. Graph a) represents 24 h, b) represents 48 h, c &d represents 
72 h and 96 h respectively. The viability of A2780/CP70 cells with 1% ethanol (control) were compared to the 
viability with 100 nM CBD and 100 nM CBG at 24 h (e), 48 h (f), 72 h (g), and 96 h (h). *P<0.05, **P<0.01 and 
***P<0.001. (n=4) 
Carboplatin had shown better cytotoxic effects when combined with CBD and CBG at 48 h, 72 
h and 96 h on A2780/CP70 cells.  CBD and CBG had shown similar dose-response effects when 
combined with carboplatin at all-time points except 24 h, where CBD in combination with 
carboplatin seemed to be more effective. 
 
Figure 4-6 IC50 values of carboplatin alone, and in combination with CBD or CBG A2780/CP70 cells. The 
comparison of IC50 values of Carboplatin alone, and carboplatin when combined with 100 nM CBD or 100 nM 
CBG on A2780/CP70 at 24 h, 48 h, 72 h, and 96 h. It represents the mean ± standard error of mean of n=4, n 
represents the number of experiments. **P<0.01 and ***P<0.001 (n=4). 
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Carboplatin in combination with 100 nM CBD determined significantly (P<0.001) lower IC50 
values (56.7± 2.6 µM, 37.5± 1.2 µM, 36.1± 1.1 µM and 23.6± 0.7 µM) compared to carboplatin 
alone (66.5± 3.3 µM, 48.7± 0.4 µM, 45.6± 0.5 µM and 44.9± 3.2 µM). Carboplatin in 
combination with 100 nM CBG achieved significantly lower (P<0.001)  IC50 values of 36.5± 3.2 
µM, 32.1± 2.7 µM, and 29.5± 0.5 µM at 48 h, 72 h and 96 h respectively (Figure 4-6). 
Carboplatin when combined with CBD has demonstrated slightly synergistic effects with CI 
values 0.85, 0.78, 0.8 and 0.57 after 24 h, 48 h, 72 h, and 96 h respectively. Carboplatin in 
combination with CBG exerted similar effects at 48 h (0.78), 72 h (0.71), and 96 h (0.65). 
Both the cannabinoids demonstrated synergistic effects when combined with carboplatin on 
A2780, and cisplatin resistant A2780/ CP70 cells. Further combination experiments were 
carried out on ARPE19 cells to determine whether the synergetic effects demonstrated by the 
cannabinoids in combination with carboplatin were cancer selective as seen in Figure 4-7. 
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Figure 4-7. Carboplatin in combination with 100 nM CBD or 100 nM CBG on ARPE19 cells. The comparison 
between carboplatin alone to carboplatin in combination with 100 nM CBD and carboplatin in combination with 
100 nM CBG. 1% ultrapure water was used as a solvent control for carboplatin alone whereas 100 nM CBD was 
used as a control for combination. Graph a) represents 24 h, b) represents 48 h, c &d represents 72 h and 96 h 
respectively. (n=4). 
Unlike in the ovarian cancer cells, CBD or CBG did not show any significant difference in 
carboplatin cytotoxicity on ARPE19 cells when used in the combination. The results suggested 
that synergetic effects of the cannabinoids in combination with carboplatin were cancer 
selective (Figure 4-7). 
 Paclitaxel (Taxol) in combination with CBD or CBG 
4.2.3.1 Taxol in combination with CBD or CBG on A2780 cells 
Paclitaxel, commonly known as Taxol, is a standard drug used in combination with carboplatin 
in the treatment of ovarian cancer. Therefore, the combination effects of the cannabinoids 
CBD or CBG with Taxol was investigated on A2780 and A2780/CP70 cells. The sub-lethal 
concentrations (100 nM) of CBD or CBG on ovarian cancer cells were taken as a constant in 







Figure 4-8. Taxol in combination with 100 nM CBD/ 100 nM CBG on A2780 cells. The comparison between Taxol 
alone to Taxol in combination with 100 nM CBD, and Taxol in combination with 100 nM CBG. 0.1% DMSO was 
used as a solvent control for Taxol alone whereas 100 nM CBD or 100 nM CBG were used as a control for 
combination. Graph a) represents 24 h, b) represents 48 h, c &d represents 72 h and 96 h respectively. *P<0.05, 
**P<0.01 and ***P<0.001.  (n=4) 
Taxol (10 pM- 100 nM) induced a greater cytotoxicity when cells were pre-treated with 100 
nM CBD following 72 h and 96 h contact times. However, pre-treated with CBG was shown a 
very little effects on the dose response curves of Taxol on A2780 cells at all the time points 
tested as shown in Figure 4-8 
 
 
Figure 4-9. IC50 values of Taxol alone, and in combination with CBD or CBG in A2780 cells. The comparison of IC50 
values of Taxol alone, and Taxol when combined with 100 nM CBD or 100 nM CBG on A2780 cells at 24 h, 48 h, 72 h, and 96 




Taxol in combination with 100 nM CBD afforded lower IC50 values (19.12± 2.3 nM, 18.75± 0.8 
nM, 8.94± 0.5 nM and 8.32± 1.3 nM) compared when Taxol was used in combination with 100 
nM CBG (19.25± 1.6 nM, 18.8± 0.3 nM, 16.86± 0.8 nM and 14.01± 2.3 nM) and Taxol alone 
(23.5± 1.2nM, 18.87± 0.8 nM, 14.33± 0.7 nM and 13.23± 0.5 nM). The results were significant 
only after 72 h exposure (Figure 4-9). 
The CI values of CBD in combination with Taxol at 72 h (0.54) and 96 h (0.6) demonstrated a 
synergistic effect on A2780 cells. 
4.2.3.2 Taxol in combination with CBD or CBG on A2780/CP70 cells 







Figure 4-10. Taxol in combination with 100 nM CBD or 100 nM CBG on A2780/CP70 cells. The comparison 
between Taxol alone to Taxol in combination with 100 nM CBD and 100 nM CBG on A2780/CP70 cells. 0.1% 
DMSO was used as a solvent control for Taxol alone whereas 100 nM CBD and 100 nM CBG were used as a control 
for combination. Graph a) represents 24 h, b) represents 48 h, c &d represents 72 h and 96 h respectively. 
*P<0.05, **P<0.01 and ***P<0.001. (n=4) 
Pre-treatment of CBD or CBG in combination with Taxol induced the difference in the dose –
response curves compared to Taxol alone at 24 h, 48 h and 72 h contact times on cisplatin 
resistant A2780/ CP70 cells. There was a difference observed at 96 h at 30 nM concentration, 
where combination of Taxol with CBD, and CBG showed significant (p< 0.01) dose- responses 
compared to Taxol alone (Figure 4-10) 
 
Figure 4-11. IC50 values of Taxol alone, and in combination with CBD or CBG in A2780/CP70 cells. The 
comparison of IC50 values of Taxol alone, and Taxol when combined with CBD or CBG on cisplatin resistant A2780/ 
CP70 cells at 24 h, 48 h, 72 h, and 96 h. Data represents the mean ± standard error of n=4, n represents the 
number of experiments. *P<0.05, **P<0.01 and ***P<0.001 
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Taxol in combination with 100 nM CBD significantly induced the cytotoxicity with lower IC50 
values (27.35± 0.8 nM, and 22.75± 0.9 nM) compared to Taxol in combination with 100 nM 
CBG (39.88± 2.3 nM and 23.75± 1 nM), and Taxol alone (41.26± 2.3 nM, 25.74± 0.6 nM, and 
22.89± 0.6 nM) at 48 h (P<0.001),  72 h (P<0.05) and 96 h (P<0.05)  on A2780/ CP70 cells. 
Taxol in combination with 100 nM CBG demonstrated significantly lower IC50 values (18.73± 
0.6nM) (*P<0.05) compared Taxol alone (22.89± 0.6nM) at 96 h contact time. The 
combination index was calculated for the above time points to determine the combination 
effects of CBD or CBG when combined with Taxol (Figure 4-11).  
CI values of Taxol with CBD at 48 h (0.69), 72 h (0.88) and 96 h (0.87) demonstrated slightly 
synergistic effects of the combination on A2780/CP70. CBG in combination with Taxol also 
shown slight synergism with CI value 0.83 on A2780/CP70 at 96 h. 
CBD in combination with Taxol on A2780 cells showed synergism after 72 h exposure and 
whereas it was showed, slight synergistic on A2780/CP70 cells.  CBG in combination with Taxol 
showed additive effect on both A2780 and CP70 cells. Based on the combination results, Taxol 
seemed to be more effective when combined with CBD than CBG. Pre- treatment of CBD in 
combination with Taxol showed to be more effective in A2780 cells compared to cisplatin 
resistant A2780/ CP70 cells. 
4.3 Discussion 
There was no increase observed in the cytotoxicity towards ovarian cancer cells of CBD when 
combined with CBG (1:1,1:5 and 5:1).  The IC50 values of the combinations tested were in-
between the values generated by CBD and CBG. Amongst all of them, CBD generated the 
lowest IC50 values followed by 5:1, 1:1, 1:5 (CBD:CBG), and CBG alone. This is consistent with 
earlier results (Chapter 3) indicating that CBD is more potent than CBG against these cells. As 
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the proportion of CBD decreased, the IC50 values of the combinations increased. Indicates 
that CBD alone is more potent than when in combination with CBG. This could be due to them 
sharing the same receptor targets for their mechanism of action but having different receptor 
affinities or stability. , In prostate cancer cells (LnCaP) both CBD and CBG induced cytotoxicity 
effects by targeting the TRM8 receptor (De Petrocellis et al., 2013). The results in this study 
suggest that the combination of CBD and CBG does not improve cytotoxicity of CBD as a single 
agent. 
Carboplatin potency towards ovarian cancer cells was increased when combined with sub-
lethal doses of CBD and CBG. In A2780 cells, CBD has shown strong synergistic effects after 
24 h (CI 0.36), 48 h (CI 0.17), 72 h (CI 0.15), and 96 h (CI 0.096) contact time. However, 
carboplatin, when combined with CBG was only able to achieve a significant synergistic effect 
after 96 h (CI 0.55). In cisplatin resistant A2780/CP70 cells, CBD was shown similar effects; 
however, in this cell line, CBG demonstrated synergistic effects from 24 h although synergy 
overall was less pronounced. Overall, CBD is the preferable cannabinoid for carboplatin 
combination based on the synergism observed. CBD or CBG, when combined with 
carboplatin, did not show any synergistic effects on non- cancer ARPE19 cells, indicating that 
the synergistic effects of the cannabinoids with carboplatin are ovarian cancer selective.  
In A2780 cells, Taxol, when combined with CBD, was shown to have synergistic effects after 
72 h (CI 0.54), and 96 h (CI 0.6) contact times. However, CBG in combination with Taxol was 
shown to have no or a very little effect on the dose responses of Taxol at all the time points 
tested. In A2780/CP70 cells, the combination index analysis of Taxol when combined with 
CBD demonstrated slightly synergistic effects at 48 h (0.69), 72 h (0.88) and 96 h (0.87). Unlike 
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in A2780 cells, CBG in combination with Taxol also was shown to have slight synergism with 
CI value 0.83 on A2780/CP70 at 96 h. 
Both CBD and CBG has shown effects at sub-lethal concentrations when combined with 
carboplatin or paclitaxel.  This could be due to the effects of the cannabinoids on growth 
factor inhibition of cells that may not cause cell death as measure by the MTT assay. Overall, 
greater synergy was observed with CBD than with CBG whether in combination with 
carboplatin or Taxol. The synergistic effects were more pronounced with carboplatin than 
Taxol, which may relate to the different mechanisms of action of carboplatin and Taxol as well 
as that of the cannabinoids themselves. Importantly, CBD and CBG did not synergise with 
carboplatin in the non-cancer ARPE19 cells, however, this has yet to be tested for 
combinations with Taxol.   
132 
 
CHAPTER 5Mechanistic studies of CBD and CBG on ovarian cancer cells 
5.1 Introduction 
In vitro and in vivo pre-clinical studies  indicate that the anti- cancer mechanism of action of 
cannabinoids can differ depending on the type of cancer, and also that the effects are highly 
dependent on dose and the specific cannabinoid itself (Dariš et al., 2018). To better 
understand how cannabinoids might exert anti- tumour activity in context of ovarian cancer, 
it is essential to understand the effects of cannabinoids on important cellular processes that 
contribute to tumorigenesis (Dariš et al., 2018). At present, there are no reports in the 
literature testing CBD or CBG against human ovarian cancer cells either in vitro or in vivo. In 
this chapter, mode of action studies are carried out to assess possible effects of CBD or CBG 
on, a) the cell cycle and, b) apoptosis. Based on studies against other cancer tissue types, 
effects of CBD and CBG on levels of reactive oxygen species (ROS) in the ovarian cancer cells 
and their possible contribution to cytotoxicity are also investigated. Results of a protein array 
focused on cellular stress signalling proteins are also presented which indicate differences in 
the molecular response to CBD and CBG as well as differences between the cisplatin-resistant 
and cisplatin-sensitive ovarian cancer cells.   
5.2 Results  
 Cycle analysis of A2780 and A2780/CP70 cells following CBD or CBG 
treatment 
Experiments were carried out to investigate the effects of CBD and CBG on the cell cycle in 
cisplatin sensitive and parental A2780 cells. 
The experiments were carried out as described in section 2.9  The effects of CBD and CBG on 
the cell cycle were analysed by NC3000 image cytometry using DAPI, a fluorescent stain that 
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binds to DNA. The changes in DNA content at different stages of cell cycle was observed by 
variation in DAPI fluorescence.  
 
Figure 5-1 Cell cycle analysis of A2780 cells treated with CBD. Representative analysis of the DNA content in 
different stages of cell cycle when A2780 cells were treated with CBD for 48h. M2 represents G0/G1 Phase, M3 
represents S phase, M4 represents G2/M phase and M1 represents Sub G0 phase. a) A2780 cells treated with 
vehicle b) A2780 cells treated with 30 µM CBD c) A2780 cells treated with 50 µM CBD.  
The DNA content at each stage of the cell cycle was quantified using manual gating (Figure 
5-1). The control sample was gated according to the NC3000 cell cycle analysis protocol. Drug 
treated samples were applied similar gating systems to the control using the NC3000 
software. Three biological independent replicates were carried out and the mean with 




Figure 5-2. Cell cycle analysis of A2780 cells treated with CBD. The  Comparison of different stages of A2780 cell 
cycle when cells were exposed to CBD (10 µM, 30 µM and 50 µM) for 48 h. 1% ethanol treated cells were used as 
a control. The percentage of DNA content among CBD treated cells as a relative factor for different stages of cell 
cycle (left), the fold change compared to control (right). It represents the mean ± standard error of mean of n=3, 
*P<0.05 and **P<0.01  
A2780 cells when treated with CBD for 48h, there was increase in G0/G1 phase from control 
(76.4±2.5%) at 10 µM (81.4±1.3%) and 30 µM CBD (85±1.5%) is observed (Figure 5-2). The 
increase in the G0/G1 phase correlates with a decrease in the S phase population from control 
(13.3± 1.9) at 30 µM CBD (6 ±1.5%). The decrease in the G0/G1 at 50 µM CBD (61.6±1.4%) 
was explained by significant increase in subG1 phase (P<0.01) from control (1.6±0.4%) to 50 
µM CBD (11.1± 1.02%); this suggests that 50 µM was too high concentration and exerted the 
cytotoxic effect on cells leading to DNA fragmentation which further lead to induction of cell 
death. 
The increase in G0/G1 correlated by decrease in S phase when A2780 cells treated with CBD, 
indicates the possibility of G1 growth arrest however, the changes observed were not 
significant (Figure 5-2). 
 
Figure 5-3 Cell cycle analysis of A2780 cells treated with CBG. Comparison of different stages of A2780 cell cycle 
when cells were exposed to CBG (10 µM, 30 µM and 50 µM) for 48 h. 1% ethanol treated cells were used as a 
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control. The percentage of DNA content among CBG treated cells as a relative factor for different stages of cell 
cycle (left), the fold change compared to control (right). Data represents the mean ± standard error of n=3, N 
represents the number of experiments. *P<0.05, **P<0.01 and ***P<0.001 
Similar to CBD, when A2780 cells treated with CBG, the increase in G0/G1 phase from control 
(71.3±0.5%) to 10 µM (79.1±0.4%) and 30 µM CBG (80.2±1.3%) was observed. The increase in 
G0/G1 phase was correlated by decrease in S phase from control to 30µM CBG (Figure 5-3). 
The decrease in G0/G1 A2780 cells treated with of 50 µM CBG (67.6±1.1%) was explained by 
significant increase in subG1 phase (P<0.01) from control (2±1.2%) to 50 µM CBD (8.7±0.6); 
indicates DNA fragmentation. However at 50 µM CBD there was a significant increase (P<0.01) 
in S phase and a significant decrease (P<0.01)  in G2/M compared to the control; this suggests 
the possibility of growth arrest at S phase (Figure 5-3). 
 
Figure 5-4 Cell cycle analysis of A278/ CP70 cells treated with CBD. Comparison of different stages of A2780 
CP70cell cycle when cells were exposed to CBD (10 µM, 30 µM and 50 µM) for 48 h. 1% ethanol treated cells were 
used as a control. The percentage of DNA content among CBD treated cells as a relative factor for different stages 
of cell cycle (left), the fold change compared to control (right). It represents the mean ± standard error of n=3, n 
represents the number of experiments. **P<0.01  
CBD exerted similar effects on cisplatin resistant A2780/CP70 cells compared to parental 
A2780 cells.  The increase in G0/G1 phase from control (70.8±1.4%) at 10 µM (77.4±1.3%) and 
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30 µM CBD (85.1±1.1%) along with a decrease in the S phase were observed.  The decrease 
in G0/G1 of 50 µM CBD treated A2780 C70 cells (64.9±0.9%) was explained by significance 
increase in subG1 phase (P<0.01) from control (1.5±0.06%) at 50 µM CBD (6±0.9%) suggest 
that 50 µM was too high concentration and exerted cytotoxic effect on cells lead to DNA 
fragmentation (Figure 5-4). 
 
Figure 5-5 Cell cycle analysis of A278/ CP70 cells treated with CBG. Comparison of different stages of A2780 
CP70 cell cycle when cells were exposed to CBG (10 µM, 30 µM and 50 µM) for 48 h. 1% ethanol treated cells 
were used as a control. The percentage of DNA content among CBG treated cells as a relative factor for different 
stages of cell cycle (left), the fold change compared to control (right). It represents the mean ± standard error of 
mean of N=3, N represents the number of experiments. *P<0.05, **P<0.01 and ***P<0.001 
After 48 h, there was increase in G0/G1 from control (83.6±0.6%) to 10 µM (86.4±0.5%) and 
30 µM CBG (90.6±0.4%) was observed in A2780/CP70 cells. The decrease in S phase was 
observed from control (13.3±0.6%) to 30 µM CBG (5.6±0.6%) followed by the significant 
increase at 50 µM CBG. Similar to S phase, significant increase (P<0.01) in G2/M phase 
observed at 50 µM CBG (16.4+ 1.9). SubG1 phase increased (P<0.01) from control (1.9±0.14%) 




The results demonstrate that CBG at highest concentration tested (50 µM CBG) possibly 
induce partial growth arrest in S phase and G2/M phase in cisplatin resistant A2780/CP70 cells 
at 48 h time point (Figure 5-5). 
The cell cycle analysis of A2780 and A2780/CP70 when treated with CBD has shown the 
possibility of G0/G1 growth arrest.  The cell cycle analysis of A2780 treated with CBG 
demonstrated possible growth arrest at S phase whilst partial growth arrest in both S phase 
and G2/M phase was observed in cisplatin resistant A2780/CP70 cells. 
Having observed the cell cycle analysis of ovarian cancer cells when treated with CBD/ CBG, 
the cytotoxicity mechanism of both the cannabinoids were investigated to determine the 
involvement of apoptosis. This was assessed by two different methodologies: mitochondrial 
membrane potential assay and Annexin V assay. 
 Mechanistic investigation of CBD/ CBG cytotoxicity on ovarian cancer cells 
by mitochondrial membrane potential assay 
The disruption of mitochondrial membrane potential (Δψm) leads to mitochondrial 
dysfunction, which results in apoptosis. Mitochondrial membrane potential assay can be used 
to assess the early apoptosis in a cell (Ly et al., 2003). The assay was performed on the NC3000 
imaging analysis system using JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-
carbocyanine iodide). JC-1 is a lipophilic cation dye, which can penetrate through healthy 
mitochondrial membrane. At low concentrations, JC-1 exists as green florescent monomer 
whereas it forms red fluorescent aggregates in healthy mitochondrial membrane. The 
decrease in red to green fluorescent ratio indicates the disruption of mitochondrial 
membrane potential (Δψm)(Galluzzi et al., 2007).  DAPI (4’, 6- diamidino-2- phenylindole) stain 
was also used, which gives blue stain for late apoptotic and dead cells. 
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The percentage of healthy and early apoptotic cells were estimated by excluding DAPI stained 
dead cells using NC3000 image analysis software. 
The experiment was carried out as described in section 2.7. The results were summarised 
below.   
 
Figure 5-6  Mitochondrial membrane potential assay on A2780 cells treated with CBD. The percentage of 
apoptotic cells of non-treated to CBD treated with 10 µM, 20 µM, 30 µM and 50 µM on A2780 and A2780 CP70 
respectively after 24 h contact time. 1% ethanol treated cells were used as a control. It represents the mean ± 
standard error of mean of N=3, N represents the number of experiments. **P<0.01 and ***P<0.001 (relative to 
controls), and ###P<0.001 (relative to each other cell line at the concentration). 
 CBD induced an increase in the percentage of apoptotic cells in a dose-dependent manner in 
both the cell lines (Figure 5-6). Those achieved significance (p< 0.01, p<0.001) at 20 µM, 30 
µM, and 50 µM CBD.  Pre-treatment with 30 µM, and 50 µM CBD induced significantly 
(p<0.001) greater percentage of apoptotic cells in A2780 as compared to cisplatin resistant 
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A2780/CP70. This correlates with greater cytotoxic effects of CBD on cisplatin sensitive 
compared to cisplatin resistant ovarian cancer cells, which was previously observed. 
 
Figure 5-7 Mitochondrial membrane potential assay on A2780 and A2780/CP70 cells treated with CBG. The 
percentage of apoptotic cells of non-treated to CBG treated with 10 µM, 20 µM, 30 µM and 50 µM on A2780 and 
A2780/CP70 respectively after 24 h contact time. 1% ethanol treated cells were used as a control. It represents 
the mean ± standard error of mean of N=3, N represents the number of experiments. *P<0.05, **P<0.01 and 
***P<0.001 (relative to controls) #P<0.05, ##P<0.01 and ###P<0.001 (relative to each other cell line at the 
concentration). 
CBG induced an increase in the percentage of apoptotic cells in a dose-dependent manner in 
both the cell lines after 24 h (Figure 5-7). Those achieved significance (p< 0.01, p<0.001) at 30 
µM, and 50 µM CBG.  CBG at 50 µM induced significantly (p<0.001) greater percentage of 
apoptotic cells in A2780 as compared to cisplatin resistant A2780/CP70. This correlates with 
greater cytotoxic effects of CBG on cisplatin sensitive compared to cisplatin resistant ovarian 
cancer cells, which was previously observed.  
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The results indicated that both CBD and CBG affect mitochondrial membrane potential to 
induce apoptosis. CBD was shown to induce apoptosis at lower concentrations compared to 
CBG on both ovarian cancer cells correlates with the IC50 values demonstrated earlier.  
 Mechanistic investigation of CBD/ CBG induced apoptosis by Annexin V 
assay 
Annexin V is a cell impermeable protein, which has a high affinity for phosphatidylserine. 
Phosphatidylserine is located on the cytoplasmic surface of a cell membrane in a normal 
functioning cell. However, in apoptotic cells, it is translocated to the outer surface of the 
plasma membrane, which makes it available for Annexin v binding. In this experiment, 
Annexin v conjugated with a green fluorescent dye CF™488A was used. When Annexin V binds 
to Phosphatidylserine, it releases CF™488A (Ex/Em = 490/515 nm), which was analysed by 
NC3000 image cytometry.  
The experiments were carried out on ovarian cancer cells A2780 and A2780/CP70, and non-




Figure 5-8. Representation of Annexin V assay analysis. The representative results of Annexin V analysis in A2780 cells and 
ARPE19 cells treated with CBD for 24 h.  a, b & c represents A2780 cells treated with vehicle, 30 µM CBD and 50 µM CBD 
respectively, and d, e& f represents ARPE19 cells treated with vehicle, 30 µM CBD and 50 µM CBD respectively. 
The scatter plot of the fluorescence intensity of Annexin V-CF488A vs the fluorescence 
intensity of PI was used as a representation of cells in different stages of apoptosis. The 
percentage of cells were quantified using manual gating (Figure 5-8). The control sample was 
gated according to the NC3000 Annexin V protocol. Drug treated samples were applied similar 
gating systems to control using the NC3000 software. Three biological independent replicates 







Figure 5-9. CBD Annexin V assay at 24 h. The percentage of cells in early apoptosis (left) and late apoptosis 
(right) when A2780, A2780 CP70 and ARPE19 were treated with 10 µM, 20 µM 30 µM and 50 µM of CBD. 1% 
ethanol treated cells were used as a control.  It represents the mean ± standard error of mean of n=3, n represents 
the number of biological experiments. *P<0.05, **P<0.01 and ***P<0.001 (relative to ARPE19 cells) 
CBD at 10-30 µM induced early apoptosis in A2780 cells at 24 h. However, at 50 µM of CBD 
higher percentage of cells were in late apoptotic phase. Similar profile of action was observed 
in A2780/CP70 cells. Both ovarian cancer cells shown significantly (P<0.001) less percentage 
of apoptotic cells compared to non-cancer ARPE19 cells correlates with the selective 






Figure 5-10. CBG Annexin V assay at 24 h. The percentage of cells in early apoptosis (left) and late apoptosis 
(right) when A2780, A2780 CP70 and ARPE19 were treated with 10 µM, 20 µM 30 µM and 50 µM of CBG. 1% 
ethanol treated cells were used as a control.  It represents the mean ± standard error of mean of n=3, n represents 
the number of biological experiments. *P<0.05, **P<0.01 and ***P<0.001(relative to ARPE19 cells) 
Similar to CBD, The percentage of apoptotic cells in A2780 cells were higher than A2780/CP70 
and ARPE19 cells when treated with CBG for 24 h.  A2780 showed 20±6.4%, 90±8.3 % of cells 
in early apoptosis and late apoptosis whereas A2780 CP70 72±1.4%, 9±1.4 % and ARPE19 
54±2.1%, 5.6±1.8 when treated with 50 µM CBG (Figure 5-10). At 50 µM CBG, both ovarian 
cancer cells shown significantly (P<0.001) less percentage of cells in early apoptosis compared 
to non-cancer ARPE19 cells. CBG also shown selective induction of apoptosis in the ovarian 
cancer cells tested compared to non- cancer ARPE19 cells. 
When compared to CBD, more percentage of the ovarian cancer cells when treated with CBG 
were in early apoptosis than late apoptosis; it correlates with the earlier results where CBD 
has shown better cytotoxicity compared to CBG. 
The Annexin V assay results suggest that both CBD and CBG induce apoptosis selectively in 
ovarian cancer cells compared to non-cancer cells. Results showed that cells were in early 
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apoptosis when treated with 50 µM CBG whereas cells were in late apoptosis when treated 
with same concentration of CBD. 
Mitochondrial membrane potential assay and Annexin V assay demonstrated that CBD and 
CBG induce apoptosis in the ovarian cancer cells. So further investigations were carried out 
to understand better the pathways leading to apoptosis.  Caspase 3/7 assay was carried out 
to determine whether the apoptosis induced by CBD or CBG in ovarian cancer cells through a 
caspase-dependent mechanism. Caspase 3 and caspase 7 are involved in the execution of 
both intrinsic and extrinsic caspase-dependent pathways hence the quantification of caspase 
3/7 in ovarian cancer cells when treated with CBD/ CBG were investigated. 
 Investigation of Caspase 3/7 Activity in CBD and CBG induced apoptosis 
The protease activity of caspase 3/7 was quantified in the ovarian cancer cells in the presence 
of CBD or CBG. The experiments were carried out as described in section 2.10.2. The results 
are analysed and summarised below.  
 
Figure 5-11.  ApoTox-Glo™ Triplex assay of CBD treatment at 24 h. The fold change in caspase3/7 activity of A2780 
(left) and A2780 CP70 (right) when treated with CBD of 10 µM, 20 µM, 30 µM and 50 µM respectively.  It 




Figure 5-12. Sensolyte caspase 3/7 assay of CBG treatment 24 h. The fold change in caspase3/7 activity of A2780 
(left)  and A2780 CP70 (right) when  treated with CBG of 10 µM, 20  µM 30  µM and 50  µM respectively after 24 
h contact time. 1% ethanol treated cells were used as a negative control whereas 50 µM of cisplatin was used as 
Positive control. It represents the mean ± standard error of mean of N=3, N represents the number of biological 
experiments. *P<0.05, **P<0.01 and ***P<0.001 
As shown in Figure 5-11 & Figure 5-12, Both CBD and CBG increased the caspase 3/7 activity 
in both A2780 and A2780/CP70 cells in dose-dependent manner at 24 h time point. The 
significance difference in activity of caspases 3/7 was observed at concentrations higher than 
10 µM in both the cells lines treated with CBD or CBG. 
Based on the results obtained, both CBD and CBG induce cytotoxicity by caspase-dependant 
apoptosis in the ovarian cancer cells. 
 Investigation of reactive oxygen species (ROS) contribution towards CBD and 
CBG cytotoxicity 
Levels of intracellular reactive oxygen species was determined by dichlorodihydrofluorescein 
diacetate (H2DCF- DA). 2′,7′-dichlorodihydrofluorescein diacetate is a lipophilic, membrane 
permeable compound. Cellular esterase convert DCFDA to non-fluorescent DCFH, which 
further oxidised in the presence intracellular reactive oxygen species (H2O2) results in 
production of fluorescent 2′,7′-dichlorodihydrofluorescein (DCF) (Gomes et al., 2005) 
146 
 
The experiments were carried as described in section 2.10.  
 
Figure 5-13 DCF-DA reactive oxygen species (ROS) assay for CBD cytotoxicity. The fold change in fluorescence 
of 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF- DA) compound by CBD (10 µM, 30  µM and 50  µM) on 
ovarian cancer cells (A2780 CP70 and IGROV) and PNT2 (prostate non-cancer cells) at 2h, 3h and 6h contact 
points where 100 µM H2O2 used as positive control. (n=3) *P<0.05, **P<0.01 and ***P<0.001 
CBD did not show any significant increase in 2’7’-dichlorodihydrofluorescein production in 
PNT2 at any concentration (10uM, 30uM and 50uM) tested compared to control.  The highest 
concentration of CBD tested (50 µM) did not exert any change in the fluorescence at the time 
points 2h (0.79±0.23), 3h (1.18± 0.39), and 6h (0.97± 0.32) (Figure 5-13). 
CBD was shown the concentration-dependant 2’7’-dicholorodihydrofluorescein induced 
fluorescence in both A2780/CP70 and IGROV ovarian cancer cells. CBD shown to be 
significantly effective at 6-hour time point on A2780/CP70 where 10 µM, 30 µM and 50 µM 
showed 3.6, 3.5 and 4.4 fold changes respectively, similar trend was observed in IGROV at 10 
µM, 30 µM and 50 µM  with the fold changes 1.5, 4.03 and 4.5 respectively(Figure 5-13). The 




Similar experiments were carried out with CBG to determine the involvement of intracellular 
ROS production in the cytotoxicity exerted by CBG on the ovarian cancer cells. 
 
Figure 5-14. DCF-DA reactive oxygen species (ROS) assay for CBG cytotoxicity. The fold change in fluorescence 
of 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF- DA) compound by CBG (10 µM, 30  µM and 50  µM) on 
ovarian cancer cells (A2780 CP70 and IGROV) and PNT2 (prostate non-cancer cells) at 2h, 3h and 6h contact 
points. 1% ethanol treated cells were used as a negative control whereas 100 µM H2O2 used as positive control. 
*P<0.05, **P<0.01 and ***P<0.001 
Similar to CBD, CBG did not show any significant increase in 2’7’-dicholorodihydrofluorescein 
production in PNT2 at any given concentration (10 µM, 30 µM and 50 µM) compared to 
control.  The fold change in the fluorescence exerted by 50 µM CBG on PNT2 at 2h (0.82±0.32), 
3h (1.14± 0.3) and 6h (1.08± 0.19) were not different from the control (Figure 5-14). 
CBG has also shown the concentration dependant 2’7’-dicholorodihydrofluorescein induced 
fluorescence in both A2780 CP70 and IGROV ovarian cancer cells. At all the time points tested, 
CBG  was more effective at 6hour time point on A2780 CP70, and the fold change was directly 
proportional to the increase in CBG concentration; indicates the dose responsive production 
of ROS. However, CBG on IGROV was shown to be more effective at 3 h time point. The 
reduction in the fold change at the 6h time point might be due to the increased toxicity of 
CBG to IGROV with longer exposure time (Figure 5-14). 
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Both CBD and CBG had induced intracellular ROS in ovarian cancer cells whereas it did not 
show any effect on PNT2 cells. Cancer selective induction of ROS by CBD and CBG consistent 
with the he preferential cytotoxic nature of them on ovarian cancer cells compared to non-
cancer cells. However, the reason for this selective ROS require further investigation. 
Further investigations were performed to investigate the contribution of ROS in CBD induced 
cytotoxicity. 
 Rescue of CBD cytotoxicity on ovarian cancer cells by anti- oxidant: 
α-tocopherol also known as vitamin- E is an anti-oxidant and scavenger of Reactive Oxygen 
Species (ROS). Therefore, the cytotoxicity of CBD on the ovarian cancer in the presence of an 
anti- oxidant was tested to investigate the contribution of ROS in CBD induced cytotoxicity. 
Firstly, the cytotoxicity of α- tocopherol on A2780 and A2780/CP70 cells were investigated to 
by MTT assay.  
 
Figure 5-15 Toxicity of α- tocopherol on A2780 cells and A2780/CP70 cells. The cytotoxic effects of α- tocopherol 
at the concentration 1 µM, 5 µM, 25 µM, and 100 µM on A2780 (left), and A2780/CP70 (right) at 72h.  Data 
represents the mean ± standard error of mean of N=3, N represents the number of experiments. 
As shown in Figure 5-15, α- tocopherol at highest concentration tested (100 µM) did not 
induce cytotoxic effects on both A2780 and A2780/CP70 cells after 72 h exposure.  
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Further experiments were carried out where A2780 and A2780/CP70 cells were treated with 




Figure 5-16. The effect of 5 µM α-tocopherol on CBD cytotoxicity. The combination effect of 5  µM α-tocopherol 
with CBD comparted to CBD alone on A2780(left) and A2780 CP70 (right) after 24 hour exposure. 1% ethanol 
treated cells were used as a control for CBD alone whereas as 5 µM α-tocopherol treated cells were used as a 
control for combination. It represents the mean ± standard error of mean of N=4, N represents the number of 
experiments. *P<0.05, **P<0.01 and ***P<0.001 
As shown in Figure 5-16, in the presence of 5 µM α- tocopherol, the cytotoxic effects of CBD 
was reduced on both A2780 and A2780/CP70 cells. Further experiments were carried out in 
with 30 µM CBD in presence of α- tocopherol (1 µM- 100 µM). The cell viability was assessed 





Figure 5-17. The dose-dependent effect of α-tocopherol on CBD cytotoxicity. The cytotoxic effect of 30  µM CBD 
alone and in combination with tocopherol (1nM to 100  µM) on A2780 (top) and A2780 CP70 (bottom) cell line 
after 24 hour, 48 hour and 72 hour contact time. It represents the mean ± standard error of mean of N=4, N 
represents the number of experiments. *P<0.05, **P<0.01 and ***P<0.001 
The results (Figure 5-17) indicate that CBD cytotoxicity is reduced with increased 
concentrations of α-tocopherol on the ovarian cancer cells. After 24 h, 30 µM CBD combined 
with 100 µM of α-tocopherol did not induce any cytotoxicity whilst the same concentration 
of CBD alone induced over 90% cytotoxicity on both A2780 and A2780/CP70 cells. The above 
results strongly suggest the contribution of ROS in CBD induced cytotoxicity in A2780 and 
A2780/CP70 ovarian cancer cells. 
 Effects of CBD or CBG on expression of key proteins involved in apoptosis 
and stress signalling  
 ELISA Pathscan® Apoptosis and Stress assays (cell Signalling, US) were performed (as 
described in section 2.11), and the changes in the expression levels of some of the key 
proteins were summarised below. 
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5.2.7.1 Quantification of the expression cell cycle regulators (Chk 1& chk 2) 
Chk-1 and chk-2 are serine/ threonine kinases, which regulates the cell cycle. CHK- 1 is a stable 
protein throughout the cell cycle (predominantly in the G0/G1 phase) whereas chk- 2 is 
confined to S and G2/M phases. DNA damage is one of the factors involves inactivation chk-
1 and chk-2, which eventually leads to cell cycle arrest (Bartek and Lukas, 2003). 
The expression of Chk-1 and chk-2 in regards to increasing concentration of the CBD and CBG 
were quantified in A2780 and A2780/ CP70 cells.  
 
 
Figure 5-18. Fold change of Chk 1& 2 protein in A2780, and A2780/ CP70 cells. The change in the expression of 
phosphorylated Chk 1 (Ser345) & chk2 (Thr68) following with  CBD or CBG (10 µM or 30 µM) treatment  on A2780, 




As shown in Figure 5-18, a little increase in the fold change from control the expression of 
phosphorylated chk-1 (ser345) from control to 30 µM CBD on both A2780 cells (1.29), and 
A2780/ CP70 cells (1.53). Similar to CBD, there was not much difference in chk-1 was observed 
when A2780 cells treated with CBG. However, the cytotoxicity of CBG resulted in a 4-fold 
increase in chk-1 levels in the cisplatin-resistant A2780/ CP70 cells. The predominant increase 
in Chk-1 levels in regards to increased concentrations of CBG in the cisplatin-resistant ovarian 
cancer cells are consistent with the G2/M cell cycle arrest observed earlier (Figure 5-5). 
The approximately 2-fold increase in the expression of phosphorylated chk2 (Thr68) observed 
in A2780 cell treated with 30 µM CBD whilst CBG induced similar effects in A2780/CP70 cells 
(Figure 5-18). 
5.2.7.2 Quantification of the expression of caspase 3& caspase 7 
Caspase 3 and caspase 7 are involved in the execution of both intrinsic and extrinsic caspase-
dependent pathways hence the expression of cleaved caspases 3& 7 in ovarian cancer cells 





Figure 5-19 Fold change of caspase 3& caspase7 in A2780, and A2780/ CP70 cells. The fold change in the 
expression of cleaved caspase 3 (Asp 175) & caspase 7 (Asp 198) when A2780 and A2780 /CP70 cells treated with 
CBD or CBG (10 µM or 30 µM). CBD on A2780, and A2780/ CP70 cells (n=2); CBG on A2780, and A2780/ CP70 
cells (n=1) 
As shown in Figure 5-19, increase expression levels of caspase 3 (Asp 175) was observed in 
A2780 cells at 30 µM CBD (2.63) and 30 µM CBG (1.39). Similar results were exerted by CBD 
(1.89) and CBG (2.31) in the cisplatin-resistant A2780/CP70 cells. Similar to the caspase 3 
expression, there was a slight increase in caspase 7 (Asp 198) was also observed in both A2780 
cells and A2780/ CP70 cells at 30 µM CBD (1.49; 2.11) and 30 µM CBG (1.34; 2.31). The 
increase in cleaved caspase 3, caspase 7 consistent with the earlier assays where CBD and CBG 





5.2.7.3 Quantification of the expression of tumour suppressor gene (p53) 
P53 is a tumour suppressor gene, which involves in various biological processes including 
regulation of cell cycle. In response to DNA damage, p53 involves in the activation of pro-
apoptotic proteins (Ozaki and Nakagawara, 2011). By regulating both proapoptotic, and anti-
apoptotic proteins of BCl-2 family, p53 plays a crucial role in apoptosis. The expression of p53 
in both cell line in the presence of the CBD/ CBG was analysed and quantified as below. 
 
 
Figure 5-20. Fold change of phosphorylated p53 in A2780, and A2780/ CP70 cells. The fold change in the 
expression of phosphorylated p53 (serine 15) when A2780 and A2780 /CP70 cells treated with CBD or CBG (10 
µM and 30 µM). CBD on A2780, and A2780/ CP70 cells (n=2); CBG on A2780, and A2780/ CP70 cells (n=1) 
As shown in Figure 5-20, there was a 5 fold, and a 3 fold increase in the expression of 
phosphorylated p53 (ser15) was observed in A2780 andA2780/CP70 respectively when 
treated with 30 µM CBD. CBG at highest concentration did not alter the expression of p53 




5.2.7.4 Quantification of the expression of Bad and Survivin 
Bad is a proapoptotic protein of Bcl- 2 family. It promotes apoptosis by binding to anti-
apoptotic proteins. Survivin is an Inhibitory apoptotic protein (IAP) family protein. It involves 
in inhibition of apoptosis by binding to caspases. The expression of Bad and surviving was 
analysed and quantified as below. 
 
 
Figure 5-21 . Fold change of phosphorylated Bad and total survivin in A2780, and A2780/ CP70 cells. The fold 
change in the expression of Bad (serine 136) and total survivin when A2780 and A2780 /CP70 cells treated with 
CBD or CBG (10 µM and 30 µM). CBD on A2780, and A2780/ CP70 cells (n=2); CBG on A2780, and A2780/ CP70 
cells (n=1) 
As shown in Figure 5-21, although an effective increase in the expression of phosphorylated 
p53 (ser 15) in CBD treated A2780 and A270/CP70 cells, there was only a slight increase in the 
expression of Bad (ser136) was observed with the highest concentration of CBD tested (1.53; 
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1.68). At 30 µM, CBG there was a 3.86-fold increase in the survivin expression was observed 
in A2780/ CP70 cells. 
5.2.7.5 Quantification of the expression of Poly (ADP-ribose) polymerase (PARP) 
PARP are a family of proteins involves in various cellular functions including transcription, 
replication and DNA repair. In response to DNA damage, they involve in the regulation of 
apoptosis by activating Apoptosis-inducing factors (AIF). 
 
Figure 5-22. Fold change of PARP in A2780, and A2780/ CP70 cells. The fold change in the expression of cleaved 
PARP (Asp214) when A2780 and A2780 /CP70 cells treated with CBD or CBG (10 µM and 30 µM). CBD on A2780, 
and A2780/ CP70 cells (n=2); CBG on A2780, and A2780/ CP70 cells (n=1) 
A2780 cells have shown a 7-fold increase in the expression of cleaved PARP (Asp214) when 
treated with 30 µM of CBD (Figure 5-22), effective increase in the PARP (Asp214) levels in CBD 
treated A2780 cells correlates with the p53 increase observed earlier.  Compared to A2780 
cells, relatively less PARP activity was observed in A2780/CP70 cells (1.53 fold) when treated 
with 30 µM of CBD. In contrast to CBD, CBG at 30 µM (2.51) has shown an increase in PARP 




5.2.7.6 Expression of stress related proteins. 
HSP (heat shock protein) 27 is a stress-related protein. It involves cell survival processes under 
stress by inhibiting the activation of caspase 9. TAK 1is another protein involves in cell survival 
process by activating NFκB pathway. HSP27 and TAK1 proteins regulate the ROS induced 
apoptosis. Therefore, the expression levels of both the proteins with increased 
concentrations of CBD/ CBG on ovarian cancer cells were analysed. The results were 
summarised below. 
 
Figure 5-23 Fold change of phosphorylated HSP27 and TAK 1 in A2780, and A2780/ CP70 cells. The fold change 
in the expression of phosphorylated HSP27 (Ser82) and TAK 1 (ser412) when A2780 and A2780 /CP70 cells 
treated with CBD or CBG (10 µM and 30 µM). CBD on A2780, and A2780/ CP70 cells (n=2); CBG on A2780, and 
A2780/ CP70 cells (n=1) 
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AS shown in Figure 5-23, 30 µM CBD has shown 1.68 and 1.58 fold increase in the expression 
of HSP27 (Ser82) in A2780 and A2780/CP70 cells respectively. Similar to CBD, 30 µM CBG has 
shown a 1.48-fold increase on A2780 cells. However, at the same concentration of CBG, there 
was almost 4-fold (3.68) increase in HSP27 levels were in A2780/CP70 cells. CBD has shown a 
little increase TAK 1 levels at the 30µM concentration on A2780 cells (1.40), and A2780/CP70 
cells (1.29). Similar to HSP27, 30 µM CBG has shown a 3.36-fold increase on A2780/ CP70 
cells. 
5.3 Discussion 
The cell cycle analysis of A2780 cells and A2780/CP70 cells when treated with CBD (10 µM 
and 30 µM) have shown the possibility of G1 growth arrest at 48 h.  A small increase in Chk- 2 
phosphorylation levels (compared to control) when A2780 cells (2 fold), and A2780/CP70 (1.6 
fold) were treated with 30 µM CBD at 24 h supports the possibility of G1 growth arrest. The 
significant increase in DNA proportion of Sub G1 phase with increased doses of CBD in both 
the cell lines suggested the induction of cell death: this was later confirmed by several 
different apoptosis assays. 
 Cell cycle analysis of A2780 cells treated with CBG at 50 µM demonstrated the possible 
growth arrest at S phase whilst in the A2780/CP70 cells, increased doses of CBG suggested 
the partial growth arrest in the S phase and G2/M phase. A 4-fold increase in chk-1 levels was 
observed when A2780/CP70 cells were treated with 30 µM CBG supports cell cycle checkpoint 
activation.  
The cell cycle analysis was performed only at the 48 h time point. Therefore, the above results 
are only suggestive of possible cell cycle effects. Cell cycle analysis at later time points would 
indicate whether cells are accumulating in a particular phase of the cycle and time, indicating 
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arrest at that phase. The analysis of cell cycle progression with other techniques such as FACS 
with BrdU labelling would also help to confirm arrest in at particular phase of the cell cycle. 
The induction of apoptosis by CBD and CBG has been reported in cancer cells including 
prostate, breast and colon cancer cells (Dariš et al., 2018). Mitochondria can play a critical role 
in induction of apoptosis. Disruption in mitochondrial membrane potential (Δψm) increases 
the membrane permeability, resulting in release of pro-apoptotic factors, which activates 
induction of apoptosis (Fleury et al., 2002).  Quantifying the loss of Δψm is commonly used 
technique to assess the cellular apoptosis. Both CBD and CBG induced the loss of membrane 
potential in A2780 and A2780/CP70 cells in a dose-dependent manner suggesting the 
induction of apoptosis in both the cell lines. The possible induction of apoptosis by CBD and 
CBG in the ovarian cancer cells was confirmed by quantifying the Annexin V binding with 
extracellular exposed phosphatidylserine (PS) (Schutte et al., 1998). The Annexin V assay also 
demonstrated similar results to the mitochondrial membrane assay. 
There are several different mechanisms of apoptosis including the extrinsic and intrinsic 
apoptosis pathways, which are both caspase-dependent, and another mechanism is a 
caspase-independent mechanism (Elmore., 2007). 
CBD has demonstrated to induce caspase-dependent apoptosis in various cancers such as 
breast, prostate, leukaemia, and CBG has been shown to exert its cytotoxicity in prostate 
cancer cells by induction of intrinsic apoptotic pathway (Izzo et al., 2009, Dariš et al., 2018, 
Shrivastava et al., 2011).  Quantification of caspase 3/7 enzyme activity in the ovarian cancer 
cells with increased concentrations of CBD and CBG demonstrated the involvement caspases 
in apoptosis. The increase in the levels of cleaved caspases 3& 7, using an ELISA assay 
produced the similar results; the increase in the levels of cleaved PARP (Ser214) is also an 
160 
 
indication of caspase activity. As caspase 3 cleaves PARP to separate, the DNA binding site at 
amino terminal from catalytic domain, which leads to apoptosis(Nicholson et al., 1995, 
Lazebnik et al., 1994). The increased in the levels of cleaved PARP and multi fold increase of 
caspase activity observed in the ovarian cancer cells treated with CBD and CBG indicate that 
both CBD and CBG exert their cytotoxicity in ovarian cancer cells by caspase-dependant 
apoptosis. 
CBD is reported to be cytotoxic activity towards human glioma cells by induction of ROS 
whereas CBG induced ROS in colon cancer cells (Singer et al., 2015, Borrelli et al., 2014). Here 
it is shown that CBD and CBG both induced ROS production in the ovarian cancer cells. 
Importantly, the same concentration of CBD or CBG did not increase the ROS levels in non- 
cancer PNT2 cells.  The increased expression levels of phosphorylated HSP27 and TAK1 (stress 
related proteins) in the ovarian cancer cells treated with CBD and CBG also indicate the of ROS 
production (Omori et al., 2008, Liu et al., 2007). The selective oxidative stress observed in the 
ovarian cancer cells compared to non- cancer cells can be correlated with the neuroprotective 
and anticancer nature of the cannabinoids CBD and CBG (Valdeolivas et al., 2015, Dariš et al., 




CHAPTER 6 Investigation of cannabinoids receptors in CBD and CBG 
induced cytotoxicity on ovarian cancer cells. 
 
6.1 Introduction 
Cannabinoid receptors are involved in growth, metastasis and energy metabolism of various 
cancer types. Both the upregulation and downregulation cannabinoid receptors were 
observed in multiple tumours pathogenesis and anti-proliferative effects of cannabinoid in 
cancer cells are often associated with cannabinoid receptors (Chakravarti et al., 2014, Dariš 
et al., 2018). Since GPRR55 involves in regulation of inflammation, angiogenesis, and tumour 
invasion and metastases it was important to see whether the cannabinoids CBD and CBG exert 
their anticancer effects through GPR55 in ovarian cancer (Leyva-Illades and DeMorrow, 2013). 
In this chapter, the involvement of cannabinoid receptors CB1, CB2, and especially GPR55 in 
the anticancer activity of CBD and CBG in ovarian cancer cells will be investigated. 
6.2 Results 
 Investigation of expression levels of CB1, CB2 and GPR55 in hypoxia and 
normoxia conditions. 
The abnormality in oxygen tension commonly occurs in malignant tumours.  The rapid 
proliferative nature of tumour cells leads to the expansion of tumour tissue away from 
vasculature. The distance between vasculature and tumour cells results in a shortage of 
oxygen supply, which leads to the formation of a hypoxic environment in the tumour. The 
hypoxic environment advances tumour progression by enabling the tumour to upregulate 
angiogenesis, anaerobic glycolysis, cell mobility and metastasis. The hypoxic environment also 
induces the cell quiescence, which helps tumours to  increase their resistance to 
chemotherapy (Muz et al., 2015).  Therefore, the experiments were carried out to determine 
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the expression levels of cannabinoid receptors in the A2780 cells, A2780/CP70 cells, and 
ARPE19 cells in both normal and hypoxic conditions. 
The cells were seeded in T75 flasks as described in section 2.7.  A flask from each cell line was 
transferred to normoxia (normal incubator oxygen) and hypoxia condition (hypoxic chamber 
with 0.1% oxygen). After 6 hours, the media was replaced for the cells in hypoxic chamber 
with the complete media, which was incubated in hypoxic chamber 24 h prior to the seeding. 
Similarly, the cells in normal incubator was also replaced with normal complete media. After 
72 h (incubated to reach 70% cell confluence in the flasks), the RNA was extracted, cDNA was 
synthesised and qPCR was performed as described in section 2.15, 2.16, and 2.17.   
The expression levels of CB1, CB2 and GPR55 were quantified against GUSB.  In A2780 cells 
grown in hypoxia conditions, The A2780 cells did not show any difference in CB2 receptor and  
CB1 receptors was slightly over expressed (∆∆CT< 1) where as GPR55 over expressed with 
∆∆CT 2.69 compared to the A2780 cells grown in normal oxygen conditions. In cisplatin 
resistant A2780/CP70 cells, all the cannabinoid receptors tested CB1, CB2 and GPR55 were 
over expressed with ∆∆CT values 3.73, 5.48 and 3.97 respectively. In contrast to the ovarian 
cancer cells, in hypoxia conditions ARPE19 non-cancer cells under expressed CB1, CB2 and 
GPR55 receptors with ∆∆CT -0.89, -4.01 and -0.67 as shown in Figure 6-1 . The over expression 
of the cannabinoid receptors in the ovarian cancer cells, and under expression in non-cancer 
cells under hypoxic conditions is an interesting observation which could be possibly related 
to the upregulation of cannabinoid receptors in tumour progression. However, the 
investigation of cytotoxic effects of CBD and CBG and their affinity towards the cannabinoid 





Figure 6-1. The expression of CB1, CB2 and GPR55 receptors. ∆ CT values of CB1, CB2 and GPR55 compared to 
housekeeping gene GUSB in A2780, A2780/CP70 and ARPE19 cells under normoxia and hypoxia conditions. GUSB 









Figure 6-2. Fold change in the expression of CB1, CB2 and GPR55 receptors. The increased levels of CB1, CB2 
and GPR55 (the fold change in hypoxia conditions compared to normoxia in A2780, A2780/CP70 and ARPE19 
cells. GUSB was used as a housekeeping gene. Data represents n=1. 
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 Investigation of the involvement of GPR55 receptor in CBD and CBG induced 
cytotoxicity. 
The expression of GPR55 receptor in CBD and CBG treated A2780 and A2780/CP70 were 
determined by western blot analysis. The ovarian cancer cells were seeded, and vehicle or 
CBD (10 µM, 20 µM, 30 µM and 50 µM) were added as described in section 2.6. After 24 h 
incubation, the lysates were collected, and western blot analysis was carried out (as described 
in section 2.11). The expression of the GPR55 receptor in CBD/ CBG treated samples 
compared to the controls were quantifying against corresponding beta-actin levels. 
 
Figure 6-3. GpR55 protein levels in A2780 and A2780/CP70 cells treated with CBD. The levels of GpR55 protein 
in A2780 cells (left) and A2780/ CP70 cells (right) when treated with CBD (10 µM, 20 µM, 30 µM and 50 µM) were 
quantified against beta actin. Top left blots represent the protein expression of beta actin and GpR55 in A2780 
cells, and top right blots represent the protein expression of beta actin and GpR55 in A2780/ CP70 cells. 
Quantification by densitometry (n=1). 
As shown in Figure 6-3, GpR55 is expressed in both A2780 and CP70 cells raising the possibility 
that CBD/CBG might act via this receptor. A dose-dependent reduction of GpR55 receptor 
expression was observed in both A2780 and A2780/CP70 cells when treated with CBD.   At 50 
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µM CBD, the expression levels of the GpR55 receptor were reduced to 33% and 16% of basal 
expression levels in A2780 and A2780/CP70 cells respectively. The results indicate the 
possible involvement of the GpR55 receptor in CBD induced cytotoxicity. Similar experiments 
were carried out with CBG (10 µM, 30 µM and 50 µM)  
 
Figure 6-4. GpR55 protein levels in A2780 and A2780/CP70 cells treated with CBG. The levels of GpR55 protein 
in A2780 cells (left) and A2780/ CP70 cells (right) when treated with CBG (10 µM, 30 µM and 50 µM) were 
quantified against beta actin. Top left blots represent the protein expression of beta actin and GpR55 in A2780 
cells, and top right blots represent the protein expression of beta actin and GpR55 in A2780/ CP70 cells. 
Quantification by densitometry (n=1). 
A very small reduction of GpR55 receptor expression was observed in both A2780 and 
A2780/CP70 cells when treated with 50μM CBG but this was much less pronounced than the 
dose-dependent decrease with CBD treatment (Figure 6-4). At 50 µM CBG, expression levels 




Between the cells lines tested, CBD resulted in a greater reduction of GpR55 in cisplatin 
resistant A2780/ CP70 compared to A2780 cells. However, the experiment was performed 
once hence more biological repeats are required to determine whether this is a consistent 
and reproducible observation. 
Further investigations were carried out to investigate the cytotoxicity effects of both the 
cannabinoids in the presence of a GpR55 antagonist in A2780 and A2780/CP70 cells. 
 Investigation CBD and CBG cytotoxicity in the presence of GPR55 antagonist 
CID16020046. 
 
The involvement of the GpR55 receptor in CBD or CBG induced cytotoxicity was further 
investigated using CID16020046. CID16020046 is a selective antagonist for the GpR55 
receptor. Pre-treatment of the ovarian cancer cells with CID16020046 can potentially block 
the GpR55 receptor. The cytotoxicity of CBD or CBG on A2780 and A2780/CP70 in the 
presence of CID16020046 was tested to determine the involvement of the GpR55 receptor. 
A2780 and A2780/CP70 cells were seeded as described in section 3.2. After 24 h incubation, 
the cells were treated with 1 µM of CID16020046, and incubated for 1 h. After 1h, cells were 
treated with CBD or CBG (1nM to 100 µM) for 96h and MTT assays were then performed (as 




Figure 6-5. Cytotoxicity of CBD in the presence of GpR55 antagonist CID16020046. Comparison of the dose-response of CBD 
alone and CBD in combination with 1 µM CID16020046 on A2780 and A2780/CP70 cells after 96 h exposure. 1% ethanol was 
used as a solvent control for CBD alone. For combination experiments, % viability is expressed relative to that of 1 µM 
CID16020046 (a& b). Effect of 96h 1μM CID16020046 on cell viability as indicated by absorbance at 540 from dissolved 
formazan crystals compared to vehicle control (c& d). Data represents the mean ± standard error of mean of n=3, n is the 
number of independent biological experiments. 
As shown in Figure 6-5, the absorbance values of 1 µM of CID16020046 on A2780 (1.28± 0.1) 
and A2780/CP70 (1.55± 0.08) were similar to the absorbance values of 1% ethanol (vehicle) 
on A2780 (1.33± 0.1) and A2780/CP70 (1.61± 0.2) indicating that 1 µM of CID16020046 alone 
did not exert any cytotoxicity effects. The IC50 values exerted by CBD when combined with 
CID16020046 on A2780 (4.04± 0.35µM) was similar to the IC50 values exerted by CBD alone 
(3.46± 0.17 µM). CBD, when combined with CID16020046 on A2780/ CP70, has shown higher 
IC50 values (7.12± 1.17µM) compared to CBD alone (5.79± 0.82 µM) however, the difference 




Figure 6-6 cytotoxicity of CBG in the presence of GPR55 antagonist. Comparison of the dose-response of CBG alone and CBG 
in combination with 1 µM CID16020046 on A2780 and A2780/CP70 cells after 96 h exposure. 1% ethanol was used as a 
solvent control for CBG alone. For combination experiments, % viability is expressed relative to that of 1 µM CID16020046 
Data represents the mean ± standard error of mean of N=3, N is the number of independent biological experiments. 
Similar to CBD, The IC50 values of CBD when combined with CID16020046 were similar in 
A2780 cells compared to CBG alone. In A2780/CP70 cells the IC50 values of the combination 
(13.2± 2.8 µM) were significantly (P<0.05) higher than CBG alone (7.1± 0.7 µM) (Figure 6-6). 
170 
 
Previous pharmacological studies have shown significant GPR55 antagonistic effects of 
CID16020046 at 20 µM in ovarian cancer cells (Hofmann et al., 2015a). Further experiments 
were carried to determine the combination effects of CBD on CID16020046 induced 
cytotoxicity in A2780 cells 
The effects of 10 µM and 20 µM CID16020046 alone, and in combination with 10 µM CBD was 
investigated on A2780 cells were investigated after 48 h by performing Annexin V assay (as 




Figure 6-7 Annexin V analysis of CBD in combination with CID16020046 on A2780 cells. The comparison of the 
percentage apoptotic cells induced by the cytotoxicity of 10 µM and 20 µM CID16020046 alone, and in 
combination with 10 µM CBD in A2780 cell.  a) A2780 cells treated with 1% ethanol b) A2780 cells treated with 
10 µM CBD c& d A2780 cells treated with 10 µM CID16020046 alone, and 10 µM CID16020046 in combination 
with  10 µM CBD respectively whereas e& f A2780 cells treated with 20 µM CID16020046 alone, and 20 µM 
CID16020046 in combination with  10 µM CBD respectively. In each scatters plot, the bottom left quadrant 
represents the percentage of healthy cells, the bottom right quadrant represents the percentage of early 
apoptotic cells whereas top right represents the late apoptotic or necrotic cells. 
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As shown in Figure 6-7, the cytotoxicity effects of CBD on A2780 cells alone (61%) was rescued 
when combined with 10 µM CID16020046 (17%) and 20 µM CID16020046 alone (48%). The 
above results indicate that CID16020046 comprised the cytotoxic effects of CBD on A2780 
cells meaning the possible involvement of GPR55 receptor in the cytotoxic mechanism of CBD 
in the ovarian cancer cells. 
However, the results are the representation of one biological experiment, which requires 
further repeats.  
 GpR55 RNAi-mediated silencing in A2780 and A2780/ CP70 cells 
A2780 and A2780/CP70 cells were transfected with Negative Control siRNA and GPR55 siRNA 
as described in section 2.13. The flasks were incubated for 48 h and 72 h time points. After 






Figure 6-8. GPR55 RNA silencing in A2780 and A2780/CP70 cells. The bright field microscopic images of GPR55 
RNA silencing in A2780cells, and A2780/CP70 cells after 48 h and 72 h. a& b represents negative RNAi control, 
and GPR55 RNA silenced A2780 cells after 48 h; c& d represents negative RNAi control, and GPR55 RNA silenced 
A2780 cells after 72 h; e& f represents negative RNAi control, and GPR55 RNA silenced A2780/ CP70 cells after 
48 h; g& h represents negative RNAi control, and GPR55 RNA silenced A2780/ CP70 cells after 72 h. 
As shown in Figure 6-8, there were no morphological differences observed in A2780 cells. In 
A2780/CP70 cells, GPR55 RNA silenced cells looked slightly larger (Figure 6-8 f) compared to 
negative siRNA control cells (Figure 6-8 e). No significant difference in growth rate (the 
confluence of the cells in a flask) between the cells transfected with GPR55 siRNA and 
negative control cells was observed in both the ovarian cancer cells. 
Further investigation was carried out to determine the efficiency of the transfection. Western 
blot analysis was used to quantify the expression levels of GPR55 protein in transfected cells. 
 Analysis of GPR55 RNA silencing by western blot 
Western blot analysis was carried out for the transfected cells to determine the GPR55 
expression levels as described in section 2.12 .  
 
Figure 6-9. Western blot analysis of GPR55 transfection. Comparison of GPR55 protein expression GPR55 siRNA 
transfected samples to the controls. a& b represents the negative control and GPR55 siRNA samples of A2780 
cells after 48 h; c& d represents the negative control and GPR55 siRNA samples of A2780 cells after 72 h; c& d 
represents the negative control and GPR55 siRNA samples of A2780/CP70 cells after 72 h. 
As shown in Figure 6-9, the western blot results did not show the reduction of GPR55 in 
transfection samples. This could be due to low or no knockdown at mRNA levels Of 
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GPR55receptor. The stability or longer half-life of the GPR55 receptor in the cells, and the 
nonspecific binding of the GPR55 antibody could be other possibilities. 
 So further experiments were carried out to investigate the levels of target mRNA knockdown 
by the siRNA transfection of the GPR55 receptor. Based on the literature, HCT116 p53 +/+ cells 
were used as positive control for transfection, and preliminary experiments were carried out 
on A2780 cells. 
 Analysis of GpR55 RNAi-mediated silencing in A2780 cells by qPCR 
A2780 and HCT116 cells were transfected with Negative Control siRNA and GpR55 siRNA as 
described in section 2.13. The HCT116 cells were incubated for 48 h and 72 h time points 
following transfection whereas A2780 cells were incubated for 72 h. After incubation time 
elapsed, cells were harvested, and total mRNA was extracted as described in section 2.14. 
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Total mRNAs collected from samples were reverse transcribed, and qPCR was carried out as 
described in section 2.15& 2.16. 
 
Figure 6-10. Relative quantification of siRNA knockdown by qPCR. The levels of GPR55Mrna in GPR55 siRNA knockdown and 
negative siRNA knockdown A2780 cells and HCT116 cells were analysed by qPCR. (KD refers to GPR55 Knockdown samples). 
As shown in Figure 6-10, quantitative PCR results indicated the reduction in GPR55 levels in 
the siRNA transfected cells. After 72 h, The RQ values of A2780 GPR55 knockdown cells were 
0.53± 0.04, and the RQ values HCT116 p53++ GPR55 knockdown cells after 48 h and 72 h were 
0.67± 0.02 and 0.76± 0.10 respectively.  
Based on the results (Figure 6-10) indicating modest GPR55 mRNA knockdown by 
approximately 50%. Further experiments were carried out to determine the cytotoxicity 
effects of CBD and CBG in A2780 GpR55 knockdown cells although due to time constraints it 
has not been possible to validate reduction in GpR55 protein expression. It is possible that 
the ~50% reduction in GPR55 mRNA at 72h is not sufficient to cause a decrease in GPR55 
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protein as suggested by immunoblot analysis (Fig.  6-7). However, GPR55 antibody has also 
not validated with GPR55 wild type and knockout protein samples extracted from healthy 
ileum of mice. The results showed non-specific binding of GPR55 antibody in both wild and 
knockout samples (see appendix) 
 Evaluation of CBD and CBG cytotoxicity in GPR55 silenced A2780 cells. 
A2780 cells were transfected with GPR55 siRNA, and negative silencer RNA, and incubated 
for 48 h. After incubation time elapsed, 15 µM CBD or 15 µM CBG was added to GPR55 siRNA 
transfected cells, and control cells. The cells were further incubated for 24 h. After incubation 





Figure 6-11. CBD/ CBG cytotoxicity on GPR55 KD A2780 cells. Comparison of percentage of apoptotic cells in 
A2780 normal cells, negative siRNA silenced A2780 cells, and GPR55 siRNA A2780 cells, when cells were treated 
with 15 µM of CBG or CBD for 24 h. 
As shown in Figure 6-11, the total percentage of apoptotic cell in GPR55 KD A2780 cells with 
when treated with 15 µM CBD (34%) was lower than normal A2780 cells treated with 15 µM 
CBD (48%),  and negative siRNA transfected cells treated with 15 µM CBD (49%). Similar to 
CBD, GPR55 KD A2780 cells, when treated with CBG, has shown the lower percentage of 
apoptotic cells (32%) compared to CBG cytotoxicity on both normal A2780 treated cells (41%), 
and negative siRNA transfected cells (45%). The preliminary results suggest that both CBD and 
CBG cytotoxicity is compromised in the absence of GPR55, which is also consistent with the 
rescue of CBD cytotoxicity with GPR55 antagonist. However, the experiment was carried out 
only once. More biological repetitions, optimisation of GPR55 transfection incubation time, 
and using another independent siRNA would help to understand the affinity of the 
cannabinoids in the cytotoxic effects on the ovarian cancer cells. 
 In parallel to this study, the expression of GPR55 in different ovarian cancer patients was 
quantified.   
 GPR55 messenger RNA expression levels in ovarian cancer patients 
Dr Sandra Bell, a collaborator from the Leeds institute of medical and clinical sciences 
(LIBACS), UK has kindly provided RNA samples extracted from tissues or ascites of patients 
with ovarian cancer of different stages and grades. RNA samples were reverse transcribed, 




Figure 6-12 Expression of GPR55 in stage 1 ovarian carcinoma histotypes. The expression levels of GPR55 
compared to GUSB in different histological types of stage 1 ovarian cancer. Scatter plot shows the CT values of 
GPR55 and GUSB in each sample (top), detailed information of patients mentioned in the table (below). 
As shown in Figure 6-12, GPR55 was expressed in all stage 1 ovarian cancers tested. Among 
the histotypes, Granulosa carcinoma express higher levels of GPR55 (∆CT -2.88) followed by 
mucinous (∆CT 0.02) and endometrial cancers (2.27) compared to GUSB. The samples 
extracted from 3 patients diagnosed with 1c clear cell carcinoma expressed GPR55 with ∆CT 




Figure 6-13 Expression of GPR55 in stage 3 ovarian carcinoma histotypes. The expression levels of GPR55 
compared to GUSB in different histological types of stage 3 ovarian cancer. Scatter plot shows the CT values of 
GPR55 and GUSB in each sample (top), detailed information of patients mentioned in the table (below). 
As shown Figure 6-13, GPR55 gene was expressed in all stage 3 ovarian cancer patient samples 
analysed. CT values ranged from 25.44 cycles to 31.58 indicating substantial heterogeneity in 
levels of GPR55 expression. For the stage 1 ovarian cancer samples, CT values varied less, 
however, levels of GUSB expression as the housekeeper gene chosen were also more variable 
for the stage 3 samples. Most of the stage 3 ovarian cancer samples tested showed a lower 
181 
 
CT for GpR55 than for GUSB whereas this was not the case for the stage 1 samples suggesting 
higher expression of the receptor in the advanced stages. However, heterogeneity in GUSB 
expression also indicates the necessity of another housekeeping gene.  Among the patient 
samples tested, the adenocarcinomas showed amongst the highest levels of GpR55 with ∆CTs 
of -10.61 and -2.1 (patient samples 11 & 10).  A single low-grade serous ovarian cancer sample 
analysed showed a ∆CT value of -5.78 whereas the samples acquired from 3 different patients 
with high grade serous cancer showed much more variable levels of the receptor gene 
expression with ∆CT values  of -6.76, 0.35 and 6.8. Along with the ovarian tumour samples, a 
non-cancerous ovarian benign sample was also tested however; the tissue sample (50 ng 
input cDNA) did not express detectable GUSB mRNA up to 40 amplification cycles. Therefore, 
the sample was further analysed with another housekeeping gene, GAPDH.  The ovarian 
benign tumour sample expressed GpR55 (CT 31.07± 0.04) and GAPDH (CT 35.86) with ∆CT -
4.79. However, it was not possible to normalise GPR55 mRNA expression in ovarian tumour 
samples against the non-tumour sample as unexpectedly none of the carcinoma samples 
expressed GAPDH on analysis (50 ng input cDNA, 40 cycles). 
The preliminary analysis has shown the high-level expression of GPR55 in the ovarian tumour 
samples. Hence, for future studies, it would be ideal to continue further investigation to 
determine the role of GpR55 in CBD and CBG induced cytotoxicity in ovarian cancer. 
Preliminary experiments were also carried out using receptor antagonists to investigate the 
involvement of CB1, and CB2 receptors in CBD and CBG cytotoxicity in ovarian cancer cells.  
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 Investigation of the involvement of CB1 receptor in CBD/CBG induced 
cytotoxicity. 
The selectivity of CB1 receptor in CBD or CBG induced cytotoxicity was investigated using 
AM251. AM251 is a selective antagonist, pre-treatment of the ovarian cancer cells with 
AM251 potentially block the CB1 receptors.  The cytotoxicity of CBD or CBG on A2780 and 
A2780/CP70 in the presence of AM251 was tested to determine the involvement of CB1 
receptors. 
The cytotoxicity of AM251 alone on the ovarian cancer cells were tested by MTT assay (as 





Figure 6-14. Cytotoxicity of AM251 on A2780 and A2780/CP70 cells. The dose-response effects of AM251 on A2780 (a) and 
A2780/CP70 (b) after 96 h exposure. It represents the mean ± standard error of mean of n=3, n represents the 
number of biological experiments  
As shown in Figure 6-14, 1 µM of AM251 indicated sub- lethal effects on both A2780 and 
A2780/CP70 with viability 98±1.5% and 97±7% respectively. 1 µM of AM251 was used as 






Figure 6-15. Cytotoxicity of CBD or CBG in the presence of CB1 antagonist. The comparison of the dose-response effects CBD 
or CBG alone, and CBD/ CBG in combination with 1 µM of AM251 on A2780 (a&c ) and A2780/CP70 (b&d ) after 96 h 
exposure. 1% ethanol was used as a solvent control for CBD alone whereas 1 µM of AM251 was used as a control 
for the combination. It represents the mean ± standard error of mean of N=3, N represents the number of 
experiments. 
As shown in Figure 6-15, No significance difference was observed in the A2780 cells in the 
dose- response to CBD, and CBG in the presence or absence of CB1 antagonist AM251. The 
IC50 values achieved for CBD or CBG in combination with AM251 were similar to the IC50 values 
achieved of CBD or CBG alone on A2780 cells. However, a significant difference (P< 0.01) was 
observed in the IC50 value of CBG when combined with AM251 (13.35± 0.77µM) compared to 
CBG alone (7.12± 1.17µM) in A2780/CP70 cells suggest the possibility of CB1 involvement in 
CBG cytotoxicity on A2780/ CP70 cells. .  
  Investigation of the involvement of CB2 receptor in CBD or CBG induced 
cytotoxicity. 
The selectivity of the CB2 receptor in CBD or CBG induced cytotoxicity was investigated using 
AM630. AM630 is a selective antagonist for the CB2 receptor, pre-treatment of the ovarian 
cancer cells with AM630 can potentially block the receptor for CBD or CBG.  The cytotoxicity 
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of CBD or CBG on A2780 and A2780/CP70 in the presence of AM630 was tested to determine 
the involvement of CB2 receptors. 
Similar experiments were carried out to cytotoxicity of AM630 alone on the ovarian cancer 






Figure 6-16. Cytotoxicity of AM630 on A2780 and A2780/CP70 cells. The dose-response effects of AM630 on A2780 
(a) and A2780/CP70 (b) after 96 h exposure. It represents the mean ± standard error of mean of n=3, n represents 
the number of experiments 
As described in section 6.2.8, the cytotoxicity of CBD or CBG on A2780 and A2780/CP70 in the 
presence of 1 µM of CB2 antagonist AM630 (Jiang et al., 2007). The results were summarised 






Figure 6-17. Cytotoxicity of CBD or CBG in the presence of CB2 antagonist. The comparison of the dose-response effects CBD 
or CBG alone, and CBD/ CBG in combination with 1 µM of AM630 on A2780 and A2780/CP70 after 96 h exposure. 1% 
ethanol was used as a solvent control for CBD alone whereas 1 µM of AM630 was used as a control for the 
combination. It represents the mean ± standard error of mean of n=3, n represents the number of biological 
experiments. 
As shown in Figure 6-17, no significant difference in the dose-responses of the cannabinoids 
in the presence of CB2 antagonist was observed. The IC50 values achieved by CBD or CBG in 
combination with AM251 were similar to the IC50 values achieved CBD or CBG alone on both 
the A2780 and A2780/CP70 cells. This suggests that in contrast to the preliminary data for 
GpR55 (both the cell lines) and CB1 (A2780/CP70 cells), cytotoxicity of CBD or CBG may not 




The purpose of this chapter was to carry out initial investigations as to whether the 
cannabinoid receptors CB1, CB2 or GPR55 might be involved in mediating any of the observed 
cytotoxic effects of CBD or CBG. Several complementary approaches were taken including use 
of selective antagonists and RNAi-mediated receptor knockdown. 
CID16020046 is a reported selective antagonist for GPR55, shown to have antagonist 
properties towards GPR55 at concentrations from 40 nM to 20 µM (AlSuleimani and Hiley, 
2015, Hofmann et al., 2015b). Chemo sensitivity data showed that pre-treatment of the 
human ovarian cancer cells with 1 µM CID16020046 increased the IC50 values of CBD and CBG 
in the A2780 and A2780/CP70 ovarian cancer cells although effects were small and in the case 
of CBD were not significant.  Using a higher concentrations of antagonist in a different 
experiment assaying levels of apoptosis, the GPR55 antagonist at 10 µM completely rescued 
apoptosis in the A2780 cells (61%) induced by 10 µM CBD to (17%) apoptotic cells. Overall, 
this data suggests that the GPR55 receptor promotes or at least partially mediates some of 
the observed cytotoxicity of CBD and CBG. However, as selective antagonism of the GPR55 
receptor at the doses used has not been demonstrated here and similarly a reduction in 
GpR55 protein through RNAi mediated silencing had not been shown these results must be 
considered with caution and unconfirmed.  
The results (6.2.5) indicated modest GPR55 mRNA knockdown by approximately 50% in 
A2780 cells, which is consistent with published results where Kargl et al studies were able to 
achieve similar knockdown results in HCT116 cells (Kargl et al., 2016). However, this modest 
knockdown was not enough to see the difference in protein expression levels but due to time 
constraints, the cytotoxic effects of CBD and CBG analysed with the modest GPR55 
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knockdown cells. The results were shown both CBD and CBG cytotoxicity was inhibited in the 
GPR55 knockdown A2780 cells suggesting possibility of GPR55 involvement.  
The results (6.2.8) was shown that GPR55 upregulated in stage 1 and Stage 3 ovarian cancer 
patients. In stage 3 cancer patients, Gpr55 CT values ranged from 25.44 cycles to 31.58 
indicating substantial heterogeneity in levels of GPR55 expression. For the stage, 1 ovarian 
cancer samples were less varied compared to stage 3 cancer patients. Despite that fact that 
GUSB was reported as the stable reference gene, and consistent in both normal and malignant 
ovarian samples with CT values 26.7± 0.7 (Lv et al., 2017), GUSB was highly varied among 
stage 3 cancer patients. These results (6.2.8) indicate that GPR55 is clinically relevant as a 
potential target for ovarian cancer.  
At 1 µM concentration, AM251 and AM630 have been previously reported to have selective 
antagonistic effects on CB1 and CB2 receptors respectively (Jiang et al., 2007). The 
chemosensitivity results generated here show that in the presence of 1 µM AM251, the IC50 
values of CBG in A2780/CP70 Cells increases .This suggests that CBG cytotoxicity on A2780/ 
CP70 cells is partly mediated via CB1 . However, knockdown experiments to support this data 
have not yet been performed.  In contrast, there was no difference in cytotoxic effects of CBD 
and CBG in the presence of AM630 suggesting that their cytotoxic effects are not mediated 
via CB2 receptors in these ovarian cancer cells. This correlates with reports that anti- cancer 
properties of CBD are reported to be independent of CB2 receptors (Dariš et al., 2018) 
Expression of the cannabinoid receptors in the ovarian cancer cells was also assessed under 
conditions of hypoxia, as there is a critical need for new therapeutic approaches to target the 
hypoxic fraction of tumours. 
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Hypoxia generated in the context of tumour microenvironment associated with induction of 
angiogenesis, alterations in metabolism and increased tumour metastasis.  Over 60% of 
advanced tumours exhibit a hypoxia environment. The hypoxic environment reduces cell 
growth rate and can cause cells to enter a quiescent state, which increases tumours resistance 
to chemotherapy. The high rate resistance to chemotherapy by hypoxic tumours indicate the 
importance of understanding the alteration of molecular targets in hypoxic environment for 
new therapy strategies (Muz et al., 2015, Favaro et al., 2011).  Cannabinoid receptors are 
known for heterogeneity, and their expression levels are highly dependent on cancer 
histology and hormonal response (Dariš et al., 2018). Cannabinoid receptors CB1 and CB2 are 
reported to over express in ovarian cancer cells and in vitro studies showed that the activity 
of CB1 and CB2 were involved in proliferation of OVCAR-3 and SKOV- 3 ovarian cancer cells 
(Afaq et al., 2006b). GPR55 receptor was also shown to mediate proliferative effects in ovarian 
cancer cells (Pineiro et al., 2011).  Preliminary results showed (6.2.1) that cannabinoid 
receptors CB1, CB2 and GPR55 were over expressed in A2780 cells and A2780/CP70 cells 
under hypoxic conditions at the mRNA level in A2780 cells and A2780/CP70 cells under 
hypoxic conditions compared to normoxia. Whilst this suggests potential increased 
dependency on the cannabinoid receptors under these conditions, it remains to be 
demonstrated that these reporters are upregulated at the protein level and the functional 
significance of any upregulation. In glioblastoma cells, down regulation of CB1 receptor was 
reported under hypoxic conditions suggesting the differences in expression of cannabinoid 
receptors under hypoxia versus normoxia between different cancers (Sugimoto et al., 2017, 
Dariš et al., 2018).   
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CHAPTER 7 General Discussion& Future Work 
The significant side effects of established chemotherapeutic drugs and the high rate of cancer 
reoccurrence within short period of treatment indicate the importance of new approaches 
for the treatment of ovarian cancer (Mangal et al., 2013, Gubbels et al., 2010). The 
cannabinoids CBD and CBG have been to have no psychoactive side effects in comparison to 
psychotropic cannabinoids, whilst also showing promising potential activity against many 
diseases including cancer (Izzo et al, 2009). 
7.1 Potency and selectivity of CBD versus CBG towards human ovarian cancer cells 
Both CBD and CBG had demonstrated the dose-dependent and time dependant micromolar 
cytotoxic effects on ovarian cancer cells. CBD and CBG induced cytotoxicity on the ovarian 
cancer cells at a similar pharmacological concentration compared to the cytotoxicity exerted 
by them in breast and prostate cancer cells (Izzo et al., 2009, Ligresti  et al., 2006).  After 96 
h, the IC50 values of CBG in the ovarian cancer cells A2780, A2780/CP70 and OVACAR-3 cells 
were 1.64, 1.22, 1.33 folds higher than the IC50 values of CBD. This result suggests that CBD is 
slightly more potent than CBG towards the ovarian cancer cells tested. The further 
investigation in mechanistic studies of CBD and CBG also supported the statement. The 
mitochondrial membrane potential assay and Annexin V assay were showed that CBD induce 
apoptosis at lower concentration than CBG. Besides mechanistic studies, the combination of 
CBG with CBD did not induce a synergistic effect. However, it showed a dose-response 
cytotoxicity in proportion to the increased concentration of CBD in the mixture. The IC50 
values of the CBD and CBG combinations were lower than IC50 values of CBD alone suggest 
that CBD is a more potent cannabinoid than CBG in ovarian cancer cells. These results 
correlate with Shrivastava et al., findings where they demonstrated that CBD has higher 
potency than CBG in breast cancer cells (Shrivastava et al., 2011). 
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CBD and CBG showed cancer selective toxicity towards ovarian cancer cells A2780/CP70, and 
A2780/CP70 compared to non- cancer cells PNT2 and ARPE19. The cancer selective 
cytotoxicity of CBD and CBG was supported by the mechanistic studies of CBD and CBG on the 
ovarian cancer cells, and non-cancer ARPE19 cells. The Annexin V staining for apoptotic cells 
demonstrated that both CBD and CBG induced significantly lower percentage of apoptosis in 
ARPE19 cells compared to the ovarian cancer cells. The increase in ROS levels also suggested 
the selective induction of ROS by CBD and CBG in the ovarian cancer cells but not in non- 
cancer PNT2 cells suggesting CBD and CBG induced selective cytotoxicity towards ovarian 
cancer cells. This could be due to the selective induction of oxidative stress by the 
cannabinoids.  In support of casual role of ROS production in the selective cytotoxicity, the 
anti-oxidant, α-tocopherol was able to rescue CBD induced cytotoxicity in the ovarian cancer 
cells. 
Both CBD and CBG were reported to inhibit oxidative stress in as a part of neuroprotective 
mechanism, whilst simultaneously inducing apoptosis by ROS production in various cancers. 
The multiple mechanism of actions of the cannabinoid among different cells could be another 
reason for the selective cytotoxicity of CBD and CBG (Humphrey et al., 2011, Marsicano et al., 
2002, Gugliandolo et al., 2018, Dariš et al., 2018). 
One of the limitations of this work is that CBD and CBG have been screened against limited 
number of ovarian cancer cells. Whilst CBD and CBG encouragingly showed similar activity 
towards the A2780/CP70 cisplatin resistant line compared to the parental A2780 cell line 
indicating cross-resistance is not a problem however, the cannabinoids were less active 
towards OVCAR-3. This may relate to the genetic alterations in OVCAR3 compared to A2780 
and A2780/CP70. For example OVCAR-3 express mutant p53 whilst A2780 cells does not have 
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p53 mutations. However, the effects of CBD and CBG cytotoxicity in relation to the genetic 
variations in ovarian cancer has not been addressed (Hernandez et al., 2016). Another 
limitation is that the non-cancer cells are not tissue- matched, nevertheless the results 
provided some indication of selectivity prior to any possible progression towards in vivo 
studies. 
7.2 The combination of CBD or CBG with chemotherapeutic drugs 
The ovarian cancer associated with a diversity of mutations and histological types, it is difficult 
to get the desired therapeutic effect with a single drug (Natarajan et al., 2018, Kashif et al., 
2015, Humphrey et al., 2011). The preclinical studies have shown that cannabinoids increased 
cytotoxic effect of existing chemotherapeutic drugs when used in combination(Velasco et al., 
2012). Cannabinoids combination effects are widely tested in glioma cells. CBD in 
combination with THC induced shown anti- cancer activity glioma cells (Nabissi et al., 2016). 
CBD was also shown synergistic with bortezomib, a protease inhibitor on multiple myeloma 
cells (Morelli et al., 2014). Torres et al were shown that submaximal dose of THC (15mg/kg/d) 
in combination with temozolamide (5mg/kg/d) induce synergic effect on glioma xenografts 
(Torres et al., 2011). 
Carboplatin and paclitaxel (Taxol) are both currently used as clinical agents in ovarian cancer 
therapy. CBD was shown additive to synergistic effects in combination with Taxol in LN 231 
and 4T1 breast cancer cells (Ward et al., 2014). However, the combination of CBD with 
carboplatin and CBG with carboplatin or Taxol has not been tested on any cancer cells. 
CBD and CBG was shown to increase the efficacy of both carboplatin and Taxol on the ovarian 
cancer cells. CBD demonstrated better synergistic effects with both carboplatin and Taxol on 
A2780 cells compared to cisplatin resistant A2780/CP70 cells whereas CBG was shown to have 
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better combination effects on the cisplatin resistant cells compared to the cisplatin sensitive 
cells (chapter 4).  It is currently unclear as to the reasons of these differences in synergy but 
it indicates that CBD and CBG are acting differently, and the response will be different for 
different ovarian cancer cells. 
 The increase in efficacy of the chemotherapeutic drugs on the ovarian cancer cells could be 
due to the inhibition effects of the cannabinoids on ABCC1 receptor. Holland et al., 
demonstrated that plant cannabinoids inhibits ABCC1 in ovarian cancer cells, amongst the 
compounds tested CBD has shown the highest inhibition effects. ABCC1 is a multi-drug 
resistance transportation receptor (MRP1), which involves in efflux of anti-cancer drugs in 
phase II metabolism (Holland et al., 2008). By inhibiting ABCC1 receptor, cannabinoids could 
have possibly blocked the efflux of carboplatin or paclitaxel, which contributes their efficacy 
on the ovarian cancer cells.  However, this could be determined by directly measuring 
intracellular levels of carboplatin and paclitaxel when combined with CBD or CBG by mass 
spectrometry. Evaluating the combination effects of CBD or CBD with the clinical agents by 
inhibiting ABCC1 receptors in ovarian cancer cells would be another approach.  
Both CBD and CBG indicated synergistic effects when combined with carboplatin. This could 
be due to multiple mechanisms of action. As it was shown  that  the combination of drugs that 
exert different or non-overlapping mechanism of actions could improve the therapeutic effect 
(Kashif et al., 2015). The drug washout experiments (chapter 3) were shown that the 
cannabinoids and carboplatin showed the difference in cytotoxicity effects when compared 
to the conventional MTT assay also indicates the possibility of multiple mechanisms involved.   
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7.3 CBD and CBG mechanisms of action in ovarian cancer cells 
Pre-clinical studies (in vitro and in vivo) were shown that the anti- cancer mechanism of 
cannabinoids are largely varied among the cancer types, and the effect was highly dependent 
on dose and the cancer type (Dariš et al., 2018). Having observed activity of CBD and CBG 
against the human ovarian cancer cells tested, some mode of action studies were conducted. 
Differential effects on cell cycle, cell death by apoptosis, and cellular proteins involved in 
stress apoptotic signalling were found. 
The cell cycle analysis of the ovarian cancer treated with CBD was shown the possibility of G1 
growth arrest at 48 h. The increase in levels of phosphorylated chk 2 (thr68) and p53 (ser15) 
with CBD treatment also indicates that CBD might  induce G1 cell cycle arrest in the ovarian 
cancer cells by activating chk1 which further phosphorylates p53 at ser15 (Zhao et al., 2008). 
The activation of phosphorylated p53 at ser15 could be also related to the apoptotic 
mechanism of CBD on the ovarian cancer cells, as many studies shown that anti- cancer drugs 
such as irinotecan (Topoisomerase 1 inhibitor)  induced apoptosis in hepatocellular carcinoma 
by activating p53 (ser15) (Takeba et al., 2007). The above results correlates with the G1 growth 
arrest induced by CBD in breast cancer cells (Ligresti  et al., 2006) 
The cell cycle analysis of the ovarian cancer cells treated with CBG shown different results to 
CBD. CBG was shown to induce cell cycle arrest in S phase in A2780 cells and partial growth 
arrest at S phase and G2/M phase in cisplatin resistant A2780/CP70 cells. The increased in the 
expression levels of phosphorylated Chk1 (Ser 345) indicates that CBG  could induce chk1 
mediated G2/M phase cell cycle arrest in ovarian cancer cells (Leung-Pineda et al., 2006). It 
must be noted, however, that the protein expression changes indicated by protein array 
analysis here not yet been independently confirmed.  For example, Immunoblot analysis of 
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the individual proteins would help to understand the expression of above proteins in CBD or 
CBG treated ovarian cancer cells. As mentioned earlier (section 5.3), other assays like FACS 
with BrdU labelling also required to confirm the apparent suggested cell cycle effects. 
The anti- cancer activity of CBD and CBG mediated by apoptosis was reported in various 
cancers. In vitro studies reported the induction apoptosis by CBD in breast, prostate, glioma 
and colon cancers whereas CBG induced apoptosis was observed in prostate and colon 
cancers (Dariš et al., 2018, Borrelli et al., 2014, Caffarel et al., 2012) 
Mitochondria can play an important role in the apoptosis of a cell. Depolarisation of 
mitochondrial membrane potential will lead to mitochondrial dysfunction and release of 
apoptotic molecules cytochrome c and smac/DIA- BLO into the cytoplasm, which leads to 
caspase- dependent apoptosis. Shrivastava et al were able to shown that CBD induced 
mitochondrial membrane permeability based apoptosis in breast cancer cells. (Shrivastava et 
al., 2011). The mitochondrial membrane potential assay demonstrated that both CBD and 
CBG showed the depolarisation of mitochondrial membrane potential in both the A2780, 
A2780/CP70 ovarian cancer cells after 24 h exposure. The Annexin V assay also demonstrated 
similar results to mitochondrial membrane assay confirms the involvement of apoptosis in 
CBD and CBG induced cytotoxicity in the ovarian cancer cells. 
The quantification of caspase 3/7 enzyme activity in the ovarian cancer cells with increased 
concentrations of CBD and CBG demonstrated the involvement of caspases in apoptosis. The 
increase in the levels of cleaved caspases 3& 7, using ELISA technique demonstrated the 
similar results; the increase in the levels of cleaved PARP (Ser214) is also an indication of 
caspase activity (Nicholson et al., 1995, Lazebnik et al., 1994). These results are correlated 
with caspase-dependent cytotoxicity mechanism of CBD and CBG on prostate cancer cells. 
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Besides prostate cancer cells, CBD was also shown caspase-dependant apoptosis mechanism 
in breast and leukaemia cells   (Izzo et al., 2009, Dariš et al., 2018, Shrivastava et al., 2011). 
Mitochondrial dysfunction is one of the main reasons in production reactive oxygen species. 
Massi et al were the first group who suggested CBD induces production of ROS in glioma cells 
in 2006 (Massi et al., 2006). McAllister et al were able to show same results in MDA-MB- 231 
breast cancer cells. (McAllister et al., 2011). Borelli et al estimated the ROS production by CBG 
using 2′,7′-dichlorodihydrofluorescein diacetate reagent in colon cancer cells. In my study, 
2′,7′-dichlorodihydrofluorescein diacetate assay showed that both CBD and CBG induced the 
ROS production in the ovarian cancer cells. HSP27 is a small heat shock protein, known to 
promote neuronal survival. In vitro studies were shown that HSP27 regulates apoptosis 
induced by oxidative stress through Akt activation (Liu et al., 2007, Dokas et al., 2011). TAK 1 
is an intermediate of TNFα signalling cascade, regulates mitochondrial ROS mediated 
apoptosis (Wang et al., 2015, Omori et al., 2008). The increased expression levels of stress 
related proteins HSP27 (ser 82), and TAK1 (ser 482) expression in the ovarian cancer cells 
treated with CBD and CBG indicate the ROS mediated apoptosis. The rescue of CBD 
cytotoxicity by antioxidant α- tocopherol indicate that intracellular ROS production 
contributes the cytotoxicity of CBD in ovarian cancer cells.  These results consist with earlier 
studies where CBD cytotoxicity was compromised in glioma cells in the presence of α- 
tocopherol (Massi et al., 2013, Massi et al., 2006) 
DNA damage induced by anticancer drugs also promote the phosphorylation of p53 (Ser 15). 
The increased levels of p53 (Ser 15) in CBD treated A2780 cells, and A2780/CP70 cells could 
be related to DNA damage induced by CBD. Further investigation using DNA damage 
conformational assays such as comet assay and H2AX assay would help to understand the 
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involvement of DNA damage mediated cytotoxicity of CBD (Ivashkevich et al., 2012, Collins., 
2004). However, there was not enough evidence to support that CBD induces DNA damage 
mediated cytotoxicity in cancer cells. 
 Cannabinoid receptors in relation to CBD or CBG cytotoxicity in human 
ovarian cancer cells 
Cannabinoid receptors are reported to be involved in the regulation of tumour progression in 
many cancers, and preclinical studies in various cancer types have shown that cannabinoids 
exerted the anti-cancer effects through cannabinoid receptors (Soderstrom et al., 2017).  Afaq 
et al., and Pineiro et al., showed that involvement of cannabinoid receptors CB1, CB2 and 
GPR55 in promoting proliferation of ovaian cancer cells (Afaq et al., 2006b, Pineiro et al., 
2011).  
Both CBD and CBG were shown to have low affinity for CB1 and CB2 receptors. The studies 
have shown CBD acts as an antagonist towards the CB1, and inverse agonist towards CB2. In 
vitro studies were shown the antagonistic effects of CBD on GPR55 receptors (Dariš et al., 
2018, Kosgodage et al., 2018b). 
In the presence of GPR55 antagonist CID16020046, the cytotoxicity of CBD was rescued in the 
ovarian cancer cells. A similar profile of action was observed where the cytotoxicity of CBD 
was reduced in GRP55 knockdown A2780 cells. The reduction in cytotoxicity of CBG was also 
seen in GPR55 knockdown ovarian cancer cells. These preliminary results indicate that GPR55 
might involve in the cytotoxicity of CBD and CBG in the ovarian cancer cells.  In vivo studies 
showed the involvement of GPR55 in CBD cytotoxicity in pancreatic cancer cells supports the 
earlier statement (Ferro et al., 2018). However, due to time constraints, it has not been 
possible to determine the antagonistic concentration for the GPR55 receptor to validate the 
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effects of the cannabinoids on the ovarian cancer cells in the presence of antagonist, and the 
reduction in GpR55 protein expression needs to be validated. 
The preliminary results suggested that the possibility of CB1 receptor involvement in CBG 
cytotoxicity on cisplatin-resistant A2780/CP70 cells. However, this is based solely on the use 
of single CB1 antagonist. Future investigation with receptor knockdown is required. The 
preliminary antagonistic studies showed that CBD or CBG cytotoxicity might not be affected 
by CB2 receptor status in the ovarian cancer cells. 
The prliminay studies showed the CB1, CB2 and GPR55 in ovarian cancer cells A2780, 
A2780/CP70 were upregulated under hypoxia conditions whilst no changes were observed in 
non- cancer APRE19 cells. The results showed CBD and CBG may mediate cytotoxicity via 
GPR55 recptors, and CB1 receptors in ovarain canncer cells. importantly, GPR55 mRNA found 
to be over expressed in ovarian cancer tissue indicating a clinically relevant target for ovarain 
cancer therapy. However the expression of CB1, CB2 and GPR55 at protein level, and the 
variation in expression among different satges and grades of ovarain cancers remain to be 
studied.  
Furthermore, cisplatin senitive and cisplatin resistant A2780 cells showed similar expression 
levels of CB1 and GPR55 at mRNA level. This could be another possible reason for CBD and 
CBG similar activity towards cisplatin sensitive and cisplatin resistant cells besides distinctive 
mechanisms of action to platinum drugs. CB2 receptors were expressed more in cisplatin 
sensitive cells however, the preliminary results suggested the effects of CBD and CBG on 
human ovarian cancer cells to be independent of CB2. 
The effects of CBD and CBG on the expression levels of cannabinoid receptors (CB1/ 
CB2/GPR55) in ovarian cancer cells yet to be investigated. Future experiments should be 
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carried to investigate CB receptors expression levels in response to CBD or CBG treatment on 
OC cells. The effects CBD and CBG on serum starved OC cells to normal OC cells would help in 
understanding the relation between CB receptors expression levels to the anticancer effects 
of CBD and CBG. 
7.4 Future work- Development of CBD and CBG towards clinic 
CBD and CBG have shown preferential anticancer effects towards human ovarian cancer cells 
in vitro. However, one of the limitations of this work is that CBD and CBG have been screened 
against limited number of ovarian cancer cell lines. Future experiments should include a panel 
of ovarian cancer cells representing different histotypes to address the effects of CBD and 
CBG cytotoxicity in relation to the genetic variations and differences expression of CB 
receptors in ovarian cancer. Development of In vitro 3D cell culture models of ovarian cancer 
cells such as organoids would provide a more physiologically relevant model to test the effects 
of cannabinoids in addition to in parallel testing in in vivo models.  
The chemo resistance nature of metastasised ovarian carcinoma is one of the main causes for 
its high mortality. In order to develop CBD/CBG as potential anticancer drugs it is important 
to determine the effects of CBD and CBG on tumour invasion and metastasis. Future 
experiments involving such as wound/healing assay or Transwell/ modified boyden chamber 
assay will determine the effects of CBD/CBG on ovarian cancer cell metastasis (Pouliot et al., 
2013) 
This study was mainly focused on the effects of the cannabinoids on ovarian cancer, in vitro. 
However in order to develop CBD/CBG towards clinical trials, In vivo studies are essential.  In 
vivo models enable researchers to understand the effect of drugs on tumour growth, invasion 
and metastasis in living model organisms (Bobbs. et al., 2015). The pharmacokinetic 
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properties of CBD and CBG via different administration routes and exposure times are well 
studied in rat and mice in vivo models(Deiana. et al., 2012). Ovarian cancer xenografts are 
developed by administering OC cells by intraperitoneal (IP) or intrabursal (IB) into 
immunocompromised Nude (Foxnl), SCID (severe combined immune deficient) or Non-obese 
diabetic (NOD)/SCID mice models. A2780 cells have shown to be metastases in mice models, 
and widely used for chemo resistance studies in xenograft models (Bobbs. et al., 2015). Future 
experiments are required understanding the effects of administration of CBD and CBG alone 
or in combination with current chemotherapeutic drugs such as carboplatin and paclitaxel in 
xenograft models.  This involves in optimising in vitro doses and exposure times to xenograft 
models. 
The cannabinoid receptor levels were examined only at molecular level. Future experiments 
involving the determination of CB receptors at protein levels in various ovarian cancer cell 
types and the effects of CBD and CBG on those cell lines can possibly address the dependency 
of CBD and CBG effects on the expression of CB receptors in ovarian cancer. Further 
experiments involving in determination of expression of CBD/ CBG dependant CB receptors 
in different ovarian cancer histotypes by immunohistochemistry analysis helps to understand 
whether the target receptors are expressed in clinical settings.  
Future experiments involving in understanding the complete mechanism of action of CBD and 
CBG on ovarian cancer enables to identify a robust biomarker (eg: expression levels of GPR55 
in different ovarian cancer histotypes if the cannabinoids mediate their anticancer effects 
through GPR55), which can increases the sensitivity, and helps the compounds to develop 




CHAPTER 8 Conclusion 
The project was carried out to evaluate the effects of CBD and CBG on ovarian cancer cells. 
The results indicated that both CBD and CBG induce dose-dependent and time dependent 
cytotoxic effects on the ovarian cancer cells. The effects of cannabinoids were cancer 
selective, and CBD was shown to have higher potency compared to CBG. Amongst all the 
combinations tested, CBD in combination with carboplatin showed the strongest synergistic 
effect, and the synergism was ovarian cancer selective. The evaluation of CBD and CBG 
induced cytotoxicity on human ovarian cancer cells in vitro has provided evidence to justify 
conduction of in vivo studies in future and has flagged these compounds as potential 
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CHAPTER 9 Appendix 
 





Table 9-2 selective index values of CBG on ovarian cancer cells compared to non- cancer cells ARPE19 and PNT2 
 
 







Table 9-4 IC50 values of carboplatin alone, and in combination with CBD or CBG on A2780/CP70 cells 
 
Table 9-5 IC50 values of Taxol alone, and in combination with CBD or CBG on A2780 cells 
 
 

















Figure 9-1. Validation of GPR55 antibody for western blot analysis. GPR55 antibody was validated using mice 
healthy colon tissue samples expressing WT GPR55 receptor and knockout GPR55 samples. Samples a and b 
represent A2780 cells control and siRNA knockdown GpR55 cells after 48 h, samples c and d represent A2780 
cells control and siRNA knockdown GpR55 cells after 72 h, samples e and f represent A2780/CP70 cells control 
and siRNA knockdown GpR55 cells after 72 h, samples g and h represent WT and KO GPR55 mice healthy colon 
samples 
